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Abstract
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in the 
UK and other Westernised countries. High dietary intakes of whole grains have been 
associated with a reduced risk o f CVD and other associated morbidities including obesity 
and type II diabetes. The evidence, however, is predominantly observational, with very few 
randomised controlled dietary intervention studies, and thus can not be used to suggest a 
causative role for whole grains.
The aim of this research, therefore, was to investigate the effects of whole grains and 
their components and metabolites on markers of endothelial dysfunction and cardiovascular 
risk both in vivo and in vitro using a variety of approaches. It was hypothesised that an 
increase in whole grains and their constituents would reduce CVD risk as reflected in the 
markers investigated.
The Pilot Whole grain Intervention Study in England (Pilot WISE) trial was a 
randomised controlled parallel dietary intervention which investigated the effects of 48g 
whole grain per day on CVD risk markers and circulating metabolite profiles of men and 
women (aged 48.4 ±  11.7 years, BMI 28.8 ±  3.1 kg/m2) over eight weeks. The Fibre and 
Inulin Trial in Male Adults (FITMA) trial, a randomised controlled cross over designed 
dietary intervention trial researched the impacts on such CVD risk markers and metabolite 
profiles of 15g/day wheat fibre or inulin in high risk men (aged 39.8 ±  3.0 years, BMI 30.2 
±  1.0kg/m2, n= 10) over 28 days. The effects o f a range of physiologically relevant 
concentrations of the fermentation products of whole grains, the short chain fatty acids 
(SCFA), on cellular models of the vascular endothelium were also investigated to explore 
the potential mechanisms behind the proposed risk reduction.
Dietary interventions o f whole intact and whole milled grains, wheat fibre or inulin 
did not significantly impact on circulating levels o f inflammatory or haemostatic markers, 
lipid profiles or markers o f insulin sensitivity. Circulating levels of three species o f 
lysophosphatidylcholines, however, were significantly altered by the wheat fibre and inulin 
in the metabolic profile analyses. Treatment of endothelial cells with SCFA did not 
significantly alter levels o f secreted inflammatory or haemostatic mediators or o f cellular 
adhesion molecules.
In conclusion, no beneficial effects were observed as a consequence of the diets high 
in whole grains or their components and, as such, these data can not be used to support the 
dietary health messages associated with high whole grain intakes. Future work could benefit 
from involving higher numbers of participants or those with a higher CVD risk profile at 
baseline.
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Chapter 1
Introduction
Cardiovascular disease (CVD) encompasses multiple arterial diseases, both 
congenital and acquired, of the heart and blood vessels, including coronary heart disease 
(CHD), rheumatic heart disease, atherosclerosis and vascular inflammation. CVD is the 
largest single cause o f mortality and morbidity in the UK and several other Westernised 
countries (Truswell A  2002) accounting for over half the deaths in middle age and one 
third of all deaths in old age in most developed countries. CHD alone kills approximately
94,000 people in the UK per annum (BHF 2008). The pathology of CVD involves the 
inflammatory condition atherosclerosis, the build up of fatty plaques within the arteiy 
wall and the dysfunction of the cardiovascular endothelium with disruption of the control 
of vasodilation, thrombosis, haemostasis and tissue perfusion (Rush J 2005). CVD is 
often subclinical, remaining undiagnosed for decades without producing symptoms 
severe enough to prompt a diagnosis. Often the first symptom may be the narrowing of 
the coronary arteries, angina pectoris, characterised by pain in the chest on physical 
exertion due to the restriction of the arterial lumen by the atherosclerosis and subsequent 
reduction in blood flow to the myocardium.
During the inflammatory response associated with atherosclerosis, the expression 
of a range of adhesion molecules is transiently altered thus increasing the extravasation of 
white blood cells, platelets and other small molecules into the neointima, increasing the 
size and fragility o f the associated plaques. Levels of some cytokines, chemokines and 
haemostatic factors in the blood such as the acute phase reactant, C-reactive protein, can 
also be increased during inflammation due to the increased demands associated with
1.1 Cardiovascular disease
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repair, and can predict m ajor coronary events (Danesh J 1998; Ross R  1999; Danesh J 
2000).
The in itia l trigger o f these events is poorly understood, however, C V D  is 
associated w ith  elevated dietary saturated fats and cholesterol. I t  is, therefore, further 
associated w ith  circulating levels o f LD L-cholestero l, lipoprotein(a) and rem nant 
lipoproteins, in  association w ith  decreased levels o f H D L-cholesterol. These abnormal 
levels o f fats in the blood are known as dyslipidaem ia and contribute to a build up o f  
cholesterol w ith in  the smooth muscle cells o f the artery w all. Com m on co-m orbidities o f  
C V D  include hypertension, diabetes and obesity showing associated elevated levels o f 
risk markers such as hom ocysteine and to tal and LD L-cholesterol.
C V D  is a  m ultifactorial disease w ith  both m odifiable and non-m odifiable risk 
markers. N on-m odifiab le risk markers include age, sex, socio-econom ic status, genetic 
predisposition and ethnic background. M o d ifiab le  risk m arker include smoking status, 
exercise status, blood pressure, type I I  diabetes and diet, many o f w hich are interrelated, 
and w hich provide possible areas fo r interventions to reduce risk. Certain dietary patterns, 
fo r exam ple, are associated w ith  reduced risk o f cardiovascular disease. One o f these 
dietary patterns associated w ith  low er risk o f  C V D  is a diet high in w hole grains (Jacobs 
D  1998; L iu  S 1999; L iu  S 2000; L iu  S 2003; Steffen L  2003).
1.2 The endothelium — structure, function and indicators of vascular health
As C V D  is an inflam m atory disorder characterised by dysfunction o f the vascular 
endothelium , understanding the norm al physiology o f the vasculature is im portant. The
3
vascular endothelium  is a m onolayer o f approxim ately 1013 cells form ing the lining o f the 
blood vessels, situated between the intim a and the basal lam ina (a  thin layer o f collagen 
containing extracellular m atrix) w hich gives structure to the lining and separates it from  
the underlying tissue (figure 1.1). The endothelium  has an estimated mass o f 1.5kg and a 
surface area equivalent to a football pitch in adults (Anggard, 1994).
Loose fibrous 
connective tissue layer
Smooth muscle cell 
layer
Elastic lamina -----
containing collagen
Media
Endothelial cell layer 
Vessel lumen ----------
F igu re  1.1: R epresentation o f a blood vessel in  cross section. The loose fibrous 
connective tissue layer surrounds the inner smooth muscle, elastic lam ina, m edia and 
endothelial layers, w ith  the vessel lumen in the centre through which the blood flows.
This is a representative diagram  and is not to scale.
Endothelial cells themselves d iffe r in their properties at different anatomical sites 
w ithin the vascular tree (Thorin  and Sreeve 1988, V ercello tti 1988) w hich may be 
partia lly  explained by site specific variations in functional shear forces. These differences 
include variations in cytokine expression and cell/endothelial perm eability. W ith  the
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exception o f the specific region o f the blood-brain barrier, the endothelium  is a relatively  
perm eable membrane, form ing a m echanical barrier between the blood and the proxim al 
tissues and actively m anaging the passage o f cells, nutrients and other components 
between th em
The endothelium  plays an active role in  m aintaining haemostasis and regulates 
vascular tone v ia  a range o f m ediators, most o f w hich are dilatory, including n itric  oxide  
(N O ). M any other factors, including nitroglycerin, prostacyclin and acetylcholine, are 
also involved in the regulation o f vascular tone. Bleeding at any site in the vascular tree  
must be rapidly and effectively halted by the platelet and coagulation pathways. This  
response must also be very closely m onitored to prevent hyper-coagulation. Thus, the 
balance o f pro- and anti-coagulant mechanisms must be tigh tly  m aintained in the 
haemostatic system.
On damage to the vessel w a ll, vasoconstriction occurs to  reduce blood loss. 
C irculating platelets (produced in  bone m arrow  by the fragm entation o f the cytoplasm o f  
m egakaryocytes) adhere to  any exposed subendothelial m atrix proteins v ia  the interaction  
o f specific adhesive glycoproteins (G P Ib , G P IIb  and G P IIIa ) w ith  m atrix-coating von 
W illebrand Factor (v W F ). P latelets are activated which induces a change o f m orphology 
and initiates granule secretion. Collagen also binds to this aggregated p latelet-vW F  
com plex and this ligation activates G P IIb  and G P IIIa , resulting in further activation o f  
platelets and the production o f an unstable prim ary plug. Throm boxane A 2 then leads to  
further vasoconstriction and p latelet aggregation (figure 1.2). Vessel damage also releases 
tissue factor, in itiating the coagulation cascade, an am plification system in w hich
in itiation substances activate a cascade o f circulating precursor proteins, v ia  proteolysis, 
to their active protein form s, resulting in the generation o f throm bin. Throm bin then 
converts soluble plasma fibrinogen to fib rin , which enmeshes w ith the aggregated 
platelets to convert the prim ary plug into a firm , defin itive and stable haemostatic plug  
(Furie B 2005).
Figure 1.2: Endothelial cells form a barrier between the endothelial connected 
tissues and the contents of the lumen such as platelets and plasma clotting factors.
Endothelial cells produce substances that can in itiate coagulation, cause vasodilation, 
inhibit platelet aggregation or haemostasis, or activate fibrinolysis. Reproduced from  
(H offbrand A  2007).
The endothelium  lim its local thrombosis by production o f anticoagulant mediators 
including heparins, throm bom odulin and tissue plasminogen activator-1 (tP A -1 ) and
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prevents platelet aggregation v ia  the secretion o f N O . A t sites o f in jury the endothelium  
ceases secretion o f  these coagulation and aggregation inhibitors and instead secretes vW F  
and tissue throm boplastin. This aids coagulation and healing. N O  is released from  
macrophages and platelets as w e ll as endothelial cells. Its  activities include platelet 
activation and prom otion o f  vasodilation. Prostacyclin, also produced by the endothelial 
cells, enhances this inhibition o f  p latelet function and further promotes vasodilation. The 
adhesion m olecule platelet endothelial cell adhesion m olecule- 1 (P E C A M -1 ) further 
inhibits platelet activation. Hagem an factor, factor X U , circulates as an inactive plasm a 
protein. It  is the zym ogen form  o f  factor X lla , a serine protease class enzyme. A ctivation  
to  factor X lla  is triggered by collagen, platelets, o r exposed basement membranes and 
occurs v ia  conform ational change. A ctivated X lla  is able to activate the kinin system  
supporting inflam m atory processes including vasodilation, the fibrinolysis system (acting  
to oppose the coagulation system) and the coagulation system or clotting cascade.
Tissue plasminogen activator-1 (tP A -1 ) activates clot dissolution in the presence 
o f fib rin  by catalyzing the conversion o f plasm inogen to plasmin and cleaving cross- 
linked fib rin  to  fib rin  degradation products (including D -d im er). tP A -1 is used in clin ical 
m edicine to treat em bolic o r throm bolytic stroke and is a serine proteinase w hich  
m aintains a negative charge on the blood vessel surface (C ipollone F  2007). I t  is also 
critical in  the im m une response to  in jury and infection w ith in  the vasculature (K um ar V  
2003; M ajno G  2004). N orm al ranges o f circulating tP A -1 have been found to be 7 .77  +  
1.63ng/m l w ith  C H D  risk determ ined at 9 .67  ±  1.55ng/m l (G ram  J 2000). Another study 
associated angina pectoris and angiographically verified  coronary artery disease (C A D ) 
w ith  levels o f 9.3 +  3.9ng/m l. This level was raised to 10.9 +  3.5 in those w ith  angina and
C A D  who died w ith in  a seven year fo llo w  up (Jansson J 1993). H igh  plasm a levels o f  
tP A -1 have been shown to  precede a firs t acute m yocardial infarction in  both men and 
wom en (Thogersen A  1998).
Increased serum levels o f  tP A -1 antigen have been positively associated w ith  
incidence o f C H D  (Folsom  A  2001) in  the Atherosclerosis R isk in  Com m unities study. A  
further study showing significantly higher serum concentrations o f tP A -1 and C R P in  
individuals w ith  C H D  than in controls w ithout C H D  (G ram  J 2000) also concluded that 
tP A -1 is an independent risk m arker the evolution o f C H D , in  that it can be used to  
predict increased risk o f C H D  even when other markers are controlled for. Furtherm ore, 
tP A -1 and the tPA-1/plasm inogen activator inhibitor-1 com plex (tP A -l/P A I-1 ) have been 
associated w ith  increased risk o f firs t stroke (Johansson L  2000), an association w hich  
rem ained after adjustment fo r traditional risk markers, showing the tP A -l/P A I-1  com plex 
as an independent risk m arker fo r first stroke. This com plex was also determ ined as a risk 
m arker fo r recurrent m yocardial infarction in  both sexes (W im an B  2000).
Plasminogen activator in h ib ito r-1 (P A I-1 ) is the principal inh ib itor o f the serine 
tP A -1 and urokinase, the activators o f plasminogen and hence fibrinolysis. I t  is a serine 
protease inhib itor m ainly produced by the endothelium  but also secreted by other tissue 
types, such as adipose tissue. P A I-1  is present in increased levels in  various disease states 
including certain cancers and obesity. I t  has been linked to the increased occurrence o f  
thrombosis in  patients w ith  these conditions. In  inflam m atory conditions in  w hich fib rin  
is deposited in tissues, P A I-1  appears to play a significant role in the progression to
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fibrosis (pathological form ation o f connective tissue). Angiotensin I I  increases synthesis 
o f P A I-1  and so accelerates the developm ent o f atherosclerosis.
vW F , is a large (2 5 0 k D ) m ultim eric blood glycoprotein involved in  haemostasis 
w hich can be used as a m arker o f endothelial dysfunction. I t  is produced constitutively by 
the endothelium , in the W eibel-Palade bodies, and also by the sub-endothelial connective 
tissue (Sadler J 1998). vW F  plays a m ajor role in  blood coagulation w ith  deficiency or 
dysfunction (von W illebrand disease), therefore, leading to a bleeding tendency. v W F  is 
bound to factor V I I I  w h ile  inactive in  the circulation. Factors such as throm bin release 
v W F  from  factor V U I (w hich then rapidly degrades) leaving functional vW F.
Functional v W F  is know n to bind to many active particles involved in blood  
coagulation including several p latelet receptors providing a possible role fo r it in  
triggering thrombus form ation in the advancement o f C V D . vW F  binds to collagen on 
exposure, as in  the case o f in jury to  endothelial cells and appears to uncoil, decelerating  
and attracting passing platelets and binding to their receptors including G P Ib  (Sadler J 
1998) thus propagating any developing atherosclerosis. Prospective evidence suggests a 
relationship between increased v W F  levels and increased risk o f vascular disease in 
individuals w ith  type I I  diabetes (Jager A  2001). H igher than population average levels o f  
vW F  are more common among people who have had a single incidence o f ischaemic 
stroke (Bongers T  2006) w ith  v W F  antigen levels significantly higher in cases (1 .47  ±  
0 .6 6 IU /m l) compared w ith  controls at (1 .23 +  0 .50 IU /m ). O ther studies have determ ined 
healthy levels o f  vW F  as 1.19 ±  0 .4 2 IU /m l w ith  increased levels o f 1.28 ±  0 .44 IU /m l in  
those w ith  diagnosed ischaem ic heart disease (R um ley A  1998). vW F  is a considered an
established risk m arker fo r C H D  (M eade T  1994; Thompson S 1995) and an im portant 
risk m arker fo r recurrent m yocardial infarction (W im an B  2000) w ith  levels in healthy 
males and females at 1.34 ±  0 .5 4 IU /m l and 1.36 ±  0.48 lU /m l respectively, raised to 1.69 
+  0 .7 7 IU /m l and 1.66 +  0 .4 3 IU /m l respectively in counterparts who had suffered a 
m yocardial infarction.
N itric  oxide (N O ) was form erly referred to as ‘endothelium  derived relaxing  
factor’ and is known to be expressed by endothelial cells fo r the regulation o f vascular 
tone and blood homeostasis (B achetti T  2004). Endothelial n itric  oxide synthase (N O S ) is 
referred to as eNO S, ecNOS or N O S  in  and was discovered firs t in  endothelial cells 
(Forsterm ann U 1991; P ollock J 1991) and fo llow ed by other cells such as epithelial cells 
(Forsterm ann U  1995; Sakai M  1996). A lthough eNOS is constitutively expressed, its 
expression can be influenced by a num ber o f  factors including cytokines e.g. tum our 
necrosis factor-a  (T N F -a ), oxidised lipoproteins and oestrogens (Forsterm ann U  1995; 
Harrison D  1996).
Endothelial N O , released into the vessel lum en, is rapidly degraded to n itrate and 
nitrite , w hich further interchange w ith in  the circulation. Thus serum concentrations o f  
nitrate and n itrite  are often measured as surrogate markers o f N O  concentration. N O  is 
synthesized in biological systems by the constitutive, calcium - and calm odulin-dependent 
enzyme N O S  (M oncada and H iggs 1993), a highly com plex enzym e w hich acts on 
m olecular oxygen, arginine and N A D P H  to  produce picomols o f the short lived radical 
N O  (Nathan C  1994). Also produced in  this process are citru lline and N A D P +. This 
reaction requires the cofactors flav in  m ononucleotide, flav in  adenine dinucleotide,
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calm odulin and tetrahydrobiopterin, and the divalent cations calcium  and haem iron. 
Further to eNO S, tw o distinct isoform s o f N O S  have been identified: neuronal (n N O S ), 
inducible (iN O S ) (A ndrew  P  1999). B oth nN O S and eNOS are constitutively expressed 
but expression o f both is inducible to  a certain extent, w hile, iN O S  m ay be induced only  
under pathological conditions (M ich e l T  1997).
N O  produced in endothelial cells by eNO S is crucial fo r m aintaining norm al 
endothelial health and function (M onacada S 1991; Schmidt H  1994), is involved in  
blood pressure regulation (H uang P  1995) and is known to exert protective effects on the 
cardiovascular system (G ibbons G 1996). The iN O S  present in phagocytes is know n to be 
activated by IF N -y  alone, o r by T N F -a  and an accompanying signal (K aibo ri M  1999). 
N O  is secreted as a free radical and is toxic to bacteria v ia  mechanisms including D N A  
damage (W in k  D  1991).
Know n functions o f N O  include the inhibition o f platelet aggregation and 
adhesion, m odulation o f  smooth muscle cell proliferation , blood pressure regulation  
(Huang P  1995), attenuation o f endothelin generation and reduction o f leukocyte- 
endothelium  adhesion. I t  has protective effects on the endothelium  (G ibbons G 1996) 
w ith  decreased production levels o r im pairm ent o f  production pathways associated w ith  
pathophysiological conditions e.g. type I I  diabetes, atherosclerosis and hypertension 
(Dessy C  2004). The progression o f C V D  precedes the developm ent o f  type I I  diabetes, 
w ith  common features including NO -dependent endothelial dysfunction and im paired  
vascular responses to N O  donors (W illiam s S 1996). As N O  is associated w ith  good 
cardiovascular health, investigating methods o f increasing stim ulation are o f interest.
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1.3 The endothelium - response to injury or infection
1.3.1 Inflammation
The norm al response to in jury or infection is the in itiation  o f inflam m ation, a 
com plex series o f events involving soluble mediators and cells w orking synergistically to 
increase vascular perm eability, blood flo w  to the affected area and w hite blood cell 
m igration. The five  signs o f localized acute inflam m ation were first recognised tw o  
m illennia ago and are calour (heat), dolor (pain), rubor (redness), tum or (sw elling) and a 
reduction in function. Acute inflam m ation is generally associated w ith  a systemic 
reaction, the acute phase response, characterised by rapid alterations in  the levels o f 
plasm a proteins. The com plement cascade protein C3 cleaves to C 3a and C3b and 
stimulates the release o f  histam ine by mast cells, thus producing vasodilation and 
increasing blood flo w  to the area. Neutrophils are generally the firs t leukocytes to m igrate 
into tissues w ith in  the firs t six hours, w ith  an associated increase in  production w ith in  the 
bone m arrow  o f up to ten-fold. Extravasated neutrophils phagocytose invading pathogens 
and release further pro-inflam m atory mediators. This haemostasis phase usually leads to 
healing and repair, however, prolonged im m une activation can precipitate and encourage 
chronic inflam m atory disorders.
Acute inflam m ation can be triggered by resident macrophages and monocytes in  
tissues, mediators o f  inflam m ation and endothelial damage, v ia  leukotrienes, 
prostaglandins, bradykinin and histam ine. B radykinin is a vasoactive protein responsible 
fo r the induction o f vasodilation, increased perm eability, contraction o f smooth muscles 
and the induction o f pain. In terleukin -8 is responsible fo r the activation and 
chem oattraction o f  neutrophils to  the site o f inflam m ation. I t  also has a weak activating
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and chem oattractant effect on eosinophils and monocytes. In terleukin -6 is associated w ith  
adipose tissue production in  obesity (Bastard J 2000) and has been proposed as a 
m ediator in  obesity related insulin resistance. T N F -a  and IL -1  affect a variety o f cells to  
induce a range o f  inflam m atory reactions including the further production o f cytokines. 
Cytokines are also responsible fo r increased perm eability o f  the endothelium . Localised  
effects include leukocyte adherence, fever, activation o f fibroblasts and chemotaxis. 
System ic effects can include an increased heart rate and the loss o f appetite.
In flam m ation is also associated w ith  high circulating levels o f acute phase proteins (A P P ) 
w hich, although beneficial in acute inflam m ation, can be pathological in chronic 
inflam m ation. These APPs include C -reactive protein (C R P ), vasopressin, serum am yloid  
A  and serum am yloid P  and cover a range o f  sym ptom atic effects including increased 
blood pressure, loss o f  appetite, fever and malaise.
G row th factors including IL -6 , granulocyte-macrophage stim ulating factor (G M - 
C S F) and m onocyte colony stim ulating factor (M -C S F ) are involved in  the proliferation  
and m aturation o f granulocytes produced from  bone m arrow  progenitor cells. Such 
production is upregulated in  inflam m ation in  response to increased expression o f grow th  
factors from  the strom al cells and T  lym phocytes, on stim ulation by IL -1 , endotoxins or 
T N F . These cells then m igrate v ia  the blood stream to the site o f the inflam m ation.
CRP, the 25 ,106kD a mem ber o f the pentraxin fam ily  produced in  the liver, is an 
acute phase reactant and as such its circulating levels are increased in  inflam m ation by up 
to 1000 fold. CR P production is regulated by the cytokine IL -6 (Pepys M  2003). 
C irculating concentrations o f C R P have been determ ined as 1.68 ±  1.42m g/l w ith
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increased levels o f 3.35 ±  1.56m g/l in  subjects w ith  established C V D  (G lurich  1 2002) 
and epidem iological data have shown an independent association between increased 
levels o f CR P and risk o f coronary pathology (R idker P 1997; Tracy R  1997; R idker P  
1998). Hum an atherosclerotic lesions, coronary artery smooth muscle cells, aortic 
endothelial cells and adipocytes have a ll been shown to express CRP (Y asojim a K  2001; 
Carabro P  2003; Carabro P  2005). CRP has been shown to induce expression o f IC A M -1  
and V C A M -1  by endothelial cells suggesting a direct role in prom oting the inflam m ation  
associated w ith  atherosclerosis (Pasceri V  2000). Studies have identified  C R P as a 
possible risk m arker fo r C V D  in  wom en (R id ker P  2000) and C H D  in previously healthy 
but high risk men (K oenig  W  1999) and a m eta-analysis in  1998 determ ined raised CRP  
levels as a risk m arker fo r C H D  (Danesh J 1998). One study suggested that CRP may 
actively prom ote the form ation o f  atherosclerotic lesions by participation in the activation  
o f the com plement system and the form ation o f foam  cells (Torzew ski J 1998).
Individuals w ith  genetically increased levels o f  CR P have been shown not present w ith  
an increased risk o f C V D  (Zacho J 2008). M eta-analysis o f long term  prospective studies 
report the risk o f  C H D  is approxim ately 90%  (50%  -  130% ) increased in  individuals w ith  
m oderately raised circulating CR P when com paring those in  the highest th ird  o f  
concentration o f these factors w ith  those in  the bottom  th ird  (Danesh J 1998; Danesh J 
2000).
1.3.2 Cell migration
The movement o f circulating leukocytes into the subendothelial tissue has been 
w ell characterised. Tissue in filtra tio n  by leukocytes occurs in  the three distinct phases o f  
ro lling, attachment and extravasation w hich are largely regulated by the d iffe re n tia l.
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expression o f a range o f adhesion molecules. Leukocyte rolling w ith in  the lum en is 
m ediated by lo w  a ffin ity  bonds between leukocyte surface molecules and activated  
endothelial cells. This is predom inantly m ediated by E - and P-selectins (Tedder T  1995; 
M cE ver 2002), chemokines and addressins (Vestw eber D  2003) but can, alternatively, be 
mediated by the endothelial in tracellu lar adhesion m olecule-1 (IC A M -1 ) or vascular cell 
adhesion m olecule-1 (V C A M -1 ) (Springer T  1994) and its leukocyte surface ligand very  
late antigen-4 (V L A -4 ) o r leukocyte oupi-integrin (A lo n  R  1995).
IC A M -1 , C D 54, a 90kd inducible single chain, surface glycoprotein is a member 
o f the im m unoglobulin (Ig ) super gene fam ily  consisting o f five  extracellular Ig -lik e  
domains, a single transmembrane region and a short (2 9  amino acid) cytosolic ta il. I t  is 
expressed constitutively on resting endothelial cells and expression is upregulated on 
activation by in jury o r infection to  prom ote healing, increasing the attraction and binding  
o f leukocytes (Y ang L  2005 ) v ia  leukocyte p2-integrins lym phocyte function-associated 
antigen-1 (E C A M -l/L F A -1 ) o r macrophage antigen-1 (M a c -1 ) v ia  its firs t or th ird Ig -lik e  
domains respectively. Im proper function o f IC A M -1  results in  an im paired immune 
response in  inflam m ation in  IC A M -1  deficient m ice (Thom pson P  2002). Follow ing  
adhesion, IC A M -1  translocates from  the apical surface to the basal membrane in  areas 
close to the ends o f actin stress fibres (M illa n  J 2006). Norm al circulating levels o f 
s IC A M -1  in healthy adults are 115 to 306ng/m l (GHurich 1 2002). IC A M -1  triggers 
various signalling pathways fo r cell m o tility  and act in  the induction o f  m icro v illi-like  
projections w hich extend out from  the lum inal surface o f the endothelial cell towards the 
leukocyte as a docking structure (Carm an C 2003).
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The sialoglycoprotein V C A M -1 , C D  106, a 110 kD  mem ber o f the 
im m unoglobulin super-gene fam ily , has a short (19 amino acid) cytosolic ta il. This type 1 
membrane protein is not expressed in  resting cells but is expressed in  inflam m ation v ia  
cytokine activation o f the gene o f the same name, increasing both gene transcription (on  
activation by T N F -a  or IL -1 ) and stabilisation o f the m R N A  (on activation by IL -4 ). Its  
extracellular portion binds prim arily  to the leukocyte integrin V L A -4 . V C A M -1 -V L A -4  
ligation results in  leukocyte-endothelial cell adhesion, prom oting the adhesion o f 
lym phocytes, monocytes, eosinophils and basophils to the endothelium . Expression o f  
V C A M -1  has also been observed in  smooth muscle cells. V C A M -1 -lig a n d  binding also 
results in  signalling v ia  the cytosolic ta il, producing reactive oxygen species (R O S ) v ia  
N A D P H  oxidase activation (van Buul J 2004). RO S are highly reactive molecules 
containing oxygen, including oxygen ions and peroxides, produced as a result o f  norm al 
metabolism. L o w  levels o f RO S are thought to be protective by preserving endothelial 
barrier function and preventing m igration and angiogenesis. H igher levels o f RO S can 
activate m atrix m etalloproteinases (M M P s ) w hich degrade surrounding extracellular 
m atrices, resulting in  loss o f  barrier in tegrity and increased leukocyte passage (H o rd ijk  P  
2006). Trans endothelial m igration steps involving V C A M -1  can be enhanced v ia  prior 
expression o f chemokines by the endothelium  (van Buul J 2004) by the activation o f  
R a p l, a signalling protein w hich results in  increased affin ity  o f  the leukocyte integrin  
V L A -4  to endothelial V C A M -1 .
As V C A M -1  and IC A M -1  appear in  close proxim ity on cell surfaces, it has been 
suggested there may be interaction between their functions (H o rd ijk  P  2006). Both  
molecules appear to upregulate certain transcription factors. V C A M -1  upregulates N F -
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k B , one o f the main transcription factors that affects innate im m unity, cell cycle control 
and apoptosis, and c-fos, w hich upregulates M M P s and cell adhesion molecules. IC A M -1  
upregulates p38 M A P  kinase, resulting in  cytoskeletal changes (van B uul J 2004) and is 
also able to  upregulate this pathw ay v ia  the RO S it generates (C o o k-M ills  J 2005). I t  thus 
appeals that, at the transcriptional level, IC A M -1  and V C A M -1  are in  some sort o f co­
operation w ith  one another, how ever, the precise mechanisms rem ain unclear. IC A M -1  
and V C A M -1  are found m ore com m only in  human atherosclerotic lesions than in healthy  
arterial tissue (Poston R  1992; Davies M  1993) and knockout m ice deficient in  E-selectin , 
P-selectin or IC A M -1  develop few er arterial lesions than norm al m ice (Johnson R  1997; 
Nageh M  1997; D ong Z  1998; C ollins R  2 0 00 ) suggesting a possible ro le fo r these 
endothelial ligands in the developm ent and progression o f C V D .
The velocity o f leukocytes ro lling  on the endothelium  is lOO-lOOOx low er than the 
mean blood velocity. The binding o f selectins to leukocytes stimulates ‘outside in ’ 
signals on the leukocytes increasing the a ffin ity  o f  the integrin receptor fam ily , w hich in  
turn bind to adhesion m olecules on the endothelial cells, IC A M -1  and V C A M -1  (A lo n  R  
2002; Sham ri R  2002). Chem okines displayed on the surface o f endothelial cells trigger 
‘ inside out’ signals from  leukocyte chem okine receptors which rapidly increase leukocyte 
integrin a ffin ity  (A lo n  R  2003). This integrin receptor a ffin ity  arrests the ro lling  
leukocytes on the lum inal surface o f the endothelial cells. The chemokine gradient on the 
surface o f the endothelial cell then stim ulates the arrested leukocytes fo r chemotaxis 
(M idd leton  J 2002).
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The projection o f m icro v illi lik e  pseudopodia from  the endothelium , involved in  
leukocyte adhesion (Carm an C  2003 ), involves endothelial surface molecules C D 99, V E - 
cadherin, junctional adhesion molecules and the cellu lar adhesion markers 
platelet/endothelial cell adhesion m olecule-1 (P E C A M -1 ), IC A M -1  and V C A M -1  
(Engelhardt B  2004). P E C A M -1 , C D 31, a  13 OkDa transmembrane glycoprotein found in  
endothelial ce ll-ce ll contacts, is a m ediator o f various m igration steps including trans- 
endothelial m igration and leukocyte m igration through the extracellular m atrix (L iao  F  
1995). Its  role in  m igration has been demonstrated both in vitro and in vivo. B locking  
P E C A M -1 interactions (v ia  antibodies o r com petitive inhib ition) blocks the m ovem ent o f  
m olecules out o f the blood vessels v ia  the endothelium  by approxim ately 90% ; 
leukocytes are tightly adhered but can not extend pseudopodia into the junction (M u lle r J 
2003). P E C A M -1 knockout m ice, however, respond sim ilarly to w ild  type m ice w hich  
can be explained by an expanded function o f other adhesion molecules in  the knockout 
m ice (Duncan G 1999) and indicates the role o f P E C A M -1 as im portant but not essential. 
Knockout m ice exhibit increased cellu lar infiltrations and an exaggerated prolonged 
vascular perm eability compared to the w ild  type m ice due to P E C A M -l’s role in  
restoring junctional in tegrity fo llow ing  inflam m ation (Graesser D  2002).
The fina l step o f trans-endothelial m igration, extravasation, is a  rapid process 
after w hich the endothelial m onolayer remains intact (Engelhardt B  2004). Endothelial 
cells proactively form  m ic ro v illi-lik e  projections extending from  the lum inal cell surface 
towards adhered leukocytes to form  a docking structures rich in IC A M -1 , V C A M -1 , 
adapter molecules and actin (Carm an C  2003). The expression o f P E C A M -1  between 
activated endothelial cells is reduced to increase perm eability o f the endothelium  and
facilitate extravasation (figure 1.3). Proper function o f the endothelium  is evidently 
essential in processes such as imm une surveillance, lym phocyte hom ing and leukocyte 
attraction to inflam m atory sites fo r vascular repair.
As most o f these cell surface adhesion molecules are shed by proteolytic cleavage 
into the circulation upon activation producing ‘soluble’ versions o f each m olecule, 
several studies have measured the soluble form s in serum (G earing A  1993).
Figure 1.3: Leukocyte migration from blood vessels into tissues. Leukocytes m igrate 
from  the lumen o f the blood vessels into tissues through the endothelium  at low  levels 
under norm al im m une function and at increased levels in response to injury or infection. 
Adapted from  (Stanner S 2005). Abbreviations: o xL D L  oxidised L D L , A G E  advanced 
glycosylation end products, L P (a ) lipoprotein a, HSPs heat shock proteins.
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The selectins (C D 6 2) are a cellu lar adhesion m olecule fam ily  o f three lectins 
w hich bind to carbohydrate polymers: E-selectin, P-selectin and L-selectin. Each selectin 
is a single chain transmembrane glycoprotein demonstrating properties sim ilar to C-type  
lectins due to  a related amino term inus and calcium -dependent binding (C otran 1998), 
w ith  an a ffin ity  fo r carbohydrate m oieties (Parham  2005). A ll the selectins appear to bind  
to the P-selectin glycoprotein ligand-1 (P S G L -l), the prim ary ligand fo r P - and L-selectin  
on leukocytes. L-selectin is constitutively expressed on a ll leukocytes and can bind to 
endothelial cellu lar adhesion m olecules (C A M s ) as w ell as glycoproteins. I t ’s activation  
upregulates the chemokine receptor C X C R 4 (also known as fusin) w hich binds to the 
endothelial chemokine strom al cell-derived factor-1 (S D R F-1 (Sm ith C  2008 )). Knockout 
m ice deficient in  E - and P-selectin develop for few er arterial lesions than w ild  type m ice 
(Johnson R 1997; Dong Z  1998; C ollins R  2000 ) reinforcing the role o f E - and P-selectin  
in  arterial lesion developm ent. E-selectin is shed into the circulation as a result o f  
proteolytic cleavage o f the cell-surface expressed molecules as soluble-E-selectin (sE - 
selectin). sE-selectin is proposed to  act as a pro-inflam m atory agent through activation o f  
neutrophils (Ruchaud-Sparagano M  1998) and E-selectin, IC A M -1  and V C A M -1 , are 
generally accepted to be associated w ith  the pathogenesis o f atherosclerosis and are 
predictors o f clin ical events (H ope S 2003).
Chem okines are sm all (8 to l4 k D a ) chem o-attractant proteins that, along w ith  
selectins, participate in  leukocyte ro lling  and influence the action o f endothelial cellu lar 
adhesion molecules. Since chem okine gradients in the blood w ould be washed away by 
blood flow , leukocytes tend to respond to chemokines im m obilised on endothelial cell
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surfaces. Chem okines are known to alter the avid ity o f the cellu lar adhesion molecules, 
the integrins, w ith in  cells (M urdoch C 2000).
In  conclusion, the cellu lar adhesion m olecules play a pivotal role in  the m ovem ent 
o f m olecules from  the vascular lum en through the endothelium , a v ita l process associated 
w ith  inflam m atory events, atherosclerosis and cardiovascular disease.
1.4 Pathogenesis of atherosclerosis
Certain stim uli can cause the endothelium  to  become overly activated and 
overthrow  its homeostatic balance (C ipo llone F  2 0 07 ) w hich m ay result in chronic 
inflam m ation (K um ar V  2003; M a jn o  G  2004). L ittle  is known about the causes of, and 
mechanisms behind, chronic inflam m ation (M edzh itov R  2008 ) w hich occurs in  a range 
o f pathologies including type I I  diabetes and C V D  (Ross R  1999) but are thought to be 
associated w ith  m alfunctions o f  underlying tissue i.e. homeostatic im balance o f  
physiological systems not directly related to host defence o r tissue repair (M edzh itov R  
2008) leading to  and/or characterised by endothelial dysfunction.
Atherosclerosis, responsible fo r the underlying pathogenesis o f most C V D , was 
previously thought o f as solely due to  the accum ulation o f lip id  w ith in  the coronary 
arteries (O sterud B  2003) but is now  understood to be an inflam m atory disease. 
Endothelial dysfunction is one o f the earliest detectable features in  the developm ent o f  
atherosclerosis and C V D  (M o lle r D  2005).
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C H D  is characterized by coronary ostial stenosis, the narrowing o f the mouths o f 
the coronary arteries, causing a short fa ll in the essential nutrients supplied to the heart. 
The narrowing is caused by an accum ulation o f lipids and also leukocytes, mediators and 
structural components w hich eventually form  a plaque w ithin the w all o f  the vessel. I f  the 
plaque becomes unstable, w hich can occur due to the partial degradation o f the fibrous 
cap covering it, the cap can rupture, releasing its contents into the blood stream as a 
bolus, which can partia lly  or to tally  block the vessel, preventing blood flo w  and leading 
to m yocardial ischem ia or stroke depending on the site o f the plaque (figure 1.4 (L ibby P 
2002)).
Reversible fatty Atherosclerotic Partial lumen Plaque rupture
streak plaque occlusion
Figure 1.4: The progression of atherosclerosis. The reversible fatty  streak builds up 
into an atherosclerotic plaque w hich reduces the functional area o f the lum en and can 
rupture at any stage o f the plaque progression leading to occlusion.
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A nim al models o f atherosclerosis, p rim arily  rat and mouse knockouts, have given  
much valuable inform ation on the role o f  many modulators o f atherogenesis. A nim al 
models show that signs o f inflam m ation occur together w ith  lip id  accum ulation (L ib b y P
2002)  and show strong im m unological components in  every stage o f atherogenesis, from  
fa tty  streak form ation to plaque rupture. The predom inant cells involved in  atherogenesis 
appear to be monocytes, platelets and T  lymphocytes from  the circulation and endothelial 
cells and smooth muscle cells in the artery w all, w hich interact in  various ways w ith  L D L  
(O sterud B  2003).
1.4.1 Triggers of atherosclerosis
The precipitating event o r trigger o f atherosclerosis is not yet fu lly  understood 
Shear stress, however, has an im portant effect on the endothelium  and areas o f  the 
endothelium  exposed to disturbed flo w , rather than lam inar flo w , are polygonal in  shape 
w ith  an ill-defined  orientation, as opposed to the ellipsoid shape and defined orientation. 
Areas associated w ith  branches or curvature show increased perm eability to 
macromolecules and are m ore com m only associated w ith cardiovascular plaques than are 
other areas (G im brone M  1999) thus suggesting non-lam inar flo w  as a  trigger o f plaque 
form ation.
Specific processes a llow  the m ovem ent o f L D L  and oxidised L D L  (o x L D L ) into  
the vessel intim a by activation o f the endothelium . These processes include local in jury, 
generation o f  RO S or the presence o f pathogens. Once inside the intim a, non-oxidated  
L D L  undergoes oxidative m odification to  form  o xL D L  w hich causes the form ation o f  
biolog ically active lipids such as lip id  hydroperoxides, lysophospholipids, oxidised
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isoprostanes and carbonyl compounds. These active lipids rem ain localised in the lip id  
fraction o f the atheroma. Sm all dense L D L  (s d L D L ) has been demonstrated as a risk 
m arker fo r the developm ent o f C A D  in  W esternised countries and Japan (Krauss R  1982; 
H irano T  2003). V ery  lo w  density lipoproteins (v L D L ) can also undergo oxidation and, 
lik e  L D L , have atherogenic potential (L ib b y P  2002). There is evidence that (3vLDL may 
its e lf activate inflam m ation in  the endothelium  (D ich tl W  1999).
The actions o f the activated lipids and o x L D L  are diverse and result in  
inflam m ation and activation o f the endothelium . M o d ified  lipids m ediate the expression 
o f adhesion markers, chemokines and inflam m ato iy cytokines (L ib b y P 2002). o xL D L  is 
taken up by macrophages w hich subsequently become foam  cells. Inside the foam  cell, 
proven in  m ice, o xL D L  can upregulate genes fo r monocyte chemotactic protein -1 (M C P - 
1) and macrophage colony stim ulating factor (M -C S F -1 ) (S h i W  2000 ) to activate and 
attract m ore monocytes to the area. In  addition, the apoprotein m oieties o f lipoproteins 
can undergo m odifications inside the arterial w a ll to become antigenic and can e lic it 
responses from  circulating T  lym phocytes (Stem m e S 1995).
The exact causes o f L D L  oxidation are unclear but possibilities include m etal ions 
(C u2+ and Fe3+) superoxide radicals or haem -containing compounds w ith in  the arterial 
w all. I t  has been hypothesised that specific factors influenced by lifesty le, including  
hyperlipidaem ia, hypertension, sm oking and diabetes, share a common pathological 
mechanism in w hich stim uli that m ediate intracellu lar oxidative signals are generated.
The signals affect gene transcription, resulting in an increased production o f reactive 
oxygen species (R O S (Kunsch C  1999)). The R O S, along w ith  their target molecules are
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able to increase the expression o f adhesion m olecules, cytokines and other 
proinflam m atory mediators. Since protective, antioxidant mechanisms such as superoxide 
dismutase, glutathione peroxidise and catalase are throw n out o f balance by the high  
proportion o f oxidative species the result is a state o f oxidative stress and inflam m ation. 
Exposure o f endothelial cells to  superoxide or hydrogen peroxide radicals is also 
associated w ith  their apoptosis (D im m eler S 2000).
1.4.2 Progression of atherosclerosis
Once the endothelium  is activated by infection or in jury the progression o f 
atherosclerosis is mediated by several im portant factors (figure 1.5). The most active 
adhesive markers associated w ith  atherosclerosis in  m ice appear to be P-Selectin, 
V C A M -1  and M C P -1  w hile IC A M -1  appears to have a lesser role as demonstrated in 
ApoE mice knockouts w ith  P-Selectin or IC A M -1  deficiency (M anka D  2001). P-Selectin  
deficiency inhibits neo-intim a form ation by 94%  whereas IC A M -1  deficiency gives no 
protection against plaque form ation. The role o f P-selectin, together w ith  its ligand 
PSG L-1 thus appears to be m ore im portant in atherosclerosis than IC A M -1 . IC A M -1 , 
however, is s till upregulated in lesion-prone areas o f the aorta in early stages o f plaque 
form ation. This is coupled w ith  high recruitm ent o f monocytes and T-lym phocytes and so 
IC A M -1  does appear to have some involvem ent in  leukocyte adhesion in  C V D .
There is evidence fo r the role o f V C A M -1  as w ell as its ligand V L A -4  in  early 
atheromas (A lo n  R  1995). V C A M -1  particularly binds to the leukocytes found in  early 
plaques (including monocytes and T  cells) and its importance in  plaque development has 
been demonstrated in V C A M -1  defective m ice that have interrupted lesion developm ent
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compared to w ild  type mice. The role o f V C A M -1  in human atherosclerotic plaques is, 
however, less certain.
Lymphocyte Monocyte Platelet
Figure 1.5: Mediators in atherosclerosis. The roles o f the key adhesion molecules in 
the attachment and transendothelial m igration o f circulating leukocytes. Abbreviations: 
L F A  leukocyte function associated antigen-1, V L A -4  very late acting antigen-4. Adapted 
from  (Stanner S 2005).
M onocytes differentiate into macrophages in response to local signals such as 
macrophage colony stim ulating factor (M -C S F ). The macrophages are norm ally protected 
from  ingesting cholesterol by various mechanisms but are able to take up o xL D L  via their 
scavenger receptors. Scavenger receptors able to bind to o x L D L  include S R -A , SR -B , 
C D 36, C D 68 and L O X -1 . The cholesterol fille d  macrophages are then known as foam
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cells due to the foam y appearance o f their fa tty  contents. Activated foam  cells secrete the 
cytokines T N F -a , IL -1  (3, IL -8 and M -C S F  w hich alter L D L  m igration patterns by 
enhancing L D L  and become engorged w ith  cholesterol.
IL -8 can induce the firm  attachm ent o f ro lling  monocytes suggesting an im portant 
role in the m onocyte-endothelium  interaction o f extravasation (G erszten R  1999). EL-8 
has been discovered at high levels as both cellu lar and extracellular deposits w ith in  the 
connective tissue m atrix  o f the human arterial atherosclerotic w a ll (Rus H  1996) w ith  
macrophages identified  as the m ain source o f this IL -8 (Apostolopoulos J 1996). H igh  
levels o f IL -8 have also been detected in foam  cells extracted from  human atherosclerotic 
tissues (L iu  Y  1997). IL -8 has been determ ined as an independent predictor o f 
cardiovascular events in  individuals w ith  stable coronary artery disease (Inoue T  2008). 
H ow ever, a large tria l w hich identified high levels o f IL -8 as preceding coronary artery 
disease found it did not qualify as an independent risk m arker after adjustment fo r other 
related risk markers (H erder C  2006). O xidised L D L  has been shown to induce IL -8 and 
M C P -1  secretion in  cultured endothelial cells (D je  N'Guessan P  2009). Further to this, 
levels o f such stim ulated production o f IL -8 and M C P -1  were reduced on subsequent 
treatm ent w ith  statins (G eisel J 2003). M C P -1 , which binds to the chemokine receptor 
C C R 2, seems to be the m ain chem okine responsible fo r monocyte m igration across 
in tim al lesions (B oring L  1998) and is know n to  be highly expressed in  human lesions. 
Furtherm ore, levels o f  EL-8 and M C P -1  were found to be significantly higher in obese 
individuals than in  non-obese controls, and have been shown to be associated w ith  
obesity related parameters including homeostasis model assessment (H O M A  score), body 
mass index (B M I) and w aist circum ference, suggesting IL -8 as a potential m arker linking
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obesity w ith  com plications including atherosclerosis and diabetes (K im  C  2006). This 
cum ulative evidence has led researchers to  pose increased IL -8 levels as a m arker o f 
C V D  risk.
In  addition to monocytes, lym phocytes also m igrate to plaques. Proxim al T  
lym phocytes are activated by antigen presenting cells, e.g. dendritic cells and 
macrophages, w hich present local antigens to them. Local production o f EL-12, IL -1 5  and 
IL -1 8  results in  the differentiation o f T h l cells w hich produce IF N -y , T N F -a  and C D 40L . 
These m ediators propagate further damage by activating macrophages and endothelial 
cells to produce more inflam m atory m ediators (Hansson G 2 0 0 6 ) am plifying the pro- 
inflam m atory m ilieu.
O ther mediators that relate to events in  cardiovascular disease are clotting factors 
such as von W illebrand factor (v W F ), tissue plasm inogen activator-1 (tP A -1 ) and platelet 
activating factor. As discussed in  1.2, the v ita l balance between these factors maintains 
haemostasis. vW F  has an im portant role in  platelet function and its atherogenic role has 
been w idely investigated in L D L R /v W F  mouse knockouts. A fte r being fed a lo w -fa t 
chow diet, the vW F  knockout m ice had a  higher decrease in ro lling  than the non-vW F  
knockouts (Osterud B  2003). This suggests that vW F  m ay contribute to plaque form ation  
by accumulating platelets to the local area. C R P, a com monly used m arker fo r 
inflam m ation and C V D , m ay also have active involvem ent in  atherogenesis as suggested 
by a study on L D L  uptake (Z w aka T  2001 ) in  w hich L D L  uptake was m ediated by CRP  
and so L D L -C R P  complexes could be taken up by the C D 32 Fc receptor w hich binds 
CRP.
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Extravasated plasma proteins are deposited w ithin the subendothelial space and 
form  matrices onto which the leukocyte integrins can bind (Pober J 2007). I f  the 
activation persists, fatty streaks develop into mature plaques w ith the release o f 
cholesterol into the lip id  core on macrophage apoptosis. These plaques consist o f a core 
region o f foam  cells/activated inflam m atory macrophages and extracellular lip id  droplets, 
surrounded by a cap o f smooth muscle cells and collagen rich m atrix (figure 1.6).
Monocyte
Figure 1.6: Atherosclerotic plaque progression. Extravasated macrophages partially  
phagocytose oxidised low  density lipoprotein cholesterol, becoming engorged ‘foam  
cells’ w hich undergo apoptosis, releasing their cholesterol contents into the lipid core o f  
the atherosclerotic plaque, Adapted from  (Stanner S 2005).
Collagen, produced by the smooth muscle cells, gives strength and structure to the 
plaque to prevent rupture. P latelet derived grow th factor (P G F) and transform ing grow th
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factor (TG F|3) increase the rate o f  collagen production. Endothelial M M P s and T  cell 
derived IF N -y  counteract this effect by degrading collagen and extracellular m atrix in the 
fibrous cap or causing the smooth muscle cells to produce less collagen (IF N -y  
(C ipollone F  2 0 07 )). Continued activation causes the plaque to grow , occluding 
progressively more o f the cross sectional area o f  the vessel lumen. As the fibrous cap 
loses structural integrity, particularly at the shoulder regions where the circum ferential 
stress is highest, it becomes w eaker and m ore sensitive to damage and prone to rupture. 
Plaque rupture releases pro-throm botic m aterial into the blood, w hich causes not only a 
block in  the blood flo w  due to the bolus released itself, but can also cause sudden platelet 
aggregation and thrombosis at the site o f damage (figure 1 .7). This is exacerbated by 
elevated fibrinogen concentrations in  the blood and can lead to further, often term inal, 
occlusion due to m yocardial infarction o r stroke, depending on the site o f the damage. 
This atherogenesis is the underlying pathogenesis o f C V D .
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Plaque rupture
Figure 1.7: Atherosclerotic plaque rupture. On rupture o f the fibrous cap the contents 
o f the atherosclerotic plaque are released into the vessel lum en, attracting platelets and 
potentially causing occlusion. Adapted from  (Stanner S 2005).
1.4.3 Co-morbidities
Influences on the endothelium  that lead to atherosclerosis often include 
dyslipidem ia, proinflam m atory cytokines released from  adipocytes, vasoconstrictor 
hormones, hyperglycaem ia and bacterial products. The vasoconstrictor hormone 
angiotensin I I  present in high amounts in hypertension, elicits the production o f 
superoxide from  endothelial and smooth muscle cells. It  can also increase the expression 
o f pro-inflam m atory IL -6 and M C P -1 in smooth muscle cells and V C A M -1  in the 
endothelium  (L ib by P 2002).
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Diabetes, characterized by hyperglycaem ia, results in the glycation o f macro- 
m olecules to  form  advanced glycation end products (A G E ) that bind to their receptors 
(R A G E ) to raise the production o f pro-inflam m atory cytokines and their pathways in the 
endothelium . Obesity contributes in  this w ay also since it is strongly linked w ith  diabetes. 
I t  is also characterized by high levels o f circulating v L D L  and L D L  as w e ll as higher 
activation o f adipocytes that synthesise pro-inflam m atory cytokines such as T N F -a  and 
IL -6 .
1.5 Risk markers
C V D  is a com plex m ultifactorial disease w ith  both m odifiable and non-m odifiable  
risk markers involved separately and in  interaction w ith each other, in  developm ent and 
progression. L ifesty le  factors play a m ajor role in C V D , w ith  high blood pressure and 
smoking being the strongest predictors o f C V D , however, these do not account fo r every 
case o f the disease (figure 1.8).
N on-m odifiab le risk markers include sex, w ith rates o f C V D  in  men significantly  
higher than those in pre-menopausal wom an. Oestrogen is the dom inant protective factor 
w ith  m ore than tw ice the incidence o f C H D  in  men than women below  the age o f 60  
years (N athan L  1997). These rates, how ever, are approxim ately equalised after the 
menopause, possibly due to a  protective effect o f oestrogen or the increase in  central 
obesity (a  significant risk m arker) in wom en post-menopause. E thnicity is also a 
significant risk factor w ith  individuals originating from  the Ind ian  subcontinent at
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Figure 1.8: Risk markers associated with cardiovascular disease. The m odifiable 
(shown w ith  green backgrounds) and non-m odifiable (shown w ith purple backgrounds) 
risk markers for cardiovascular disease. Adapted from (Stanner S 2005).
50%  increased risk o f C H D  (and a 40%  increased risk o f diabetes -  another C V D  risk 
m arker) compared to those o f European origin, and African-Caribeans in the U K  at a 
significantly increased risk o f stroke compared to Caucasians. A  certain proportion o f this 
ethnicity effect may be due to m odifiable risk markers such as diet. Fam ily history 
remains a very significant independent risk m arker fo r arteriosclerosis and C H D  even 
when all other known risk markers are controlled fo r (G oldbourt U  1986).
Age is positively associated w ith risk o f C V D  and stroke (C hristie D  1981; 
Herm an B 1982) and as the population as a whole ages, so the prevalence o f C V D
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increases. E arly lesions o f the aorta are com m only seen w ith in  the first decade o f life  in  
humans, fo llow ed by lesions in  the coronary artery in the second decade and cerebral 
artery in the th ird  or fourth decade.
Type I I  diabetes, otherwise know n as non-insulin dependent diabetes m ellitus, is a 
disorder that is characterized by high blood glucose in the context o f insulin resistance 
and relative insulin deficiency. Individuals w ith  type I I  diabetes have a tw o - to four-fo ld  
greater risk o f death from  C V D  than non-diabetic individuals (H affn er S 1998; Turner R
1998). NO-dependent endothelial dysfunction, im paired vascular responses to exogenous 
N O  donors (W illiam s S 1996) and enhanced responsiveness to vasoconstrictor agents 
(C ard illo  C  2002) are common features o f type I I  diabetes. The availab ility  o f N O  
(G iugliano D  1997) and endothelium  dependent vasodilation (W illiam s  S 1998) are 
im paired by the hyperglycaem ia that can result from  a high refined grain diet. One study 
showed a low er risk o f both C V D  and type I I  diabetes in  individuals who consumed diets 
high in  w hole grains (Jensen M  2004) w hile another showed the substitution o f dietary 
w hole grains w ith  a d ifferent source o f carbohydrates, potatoes, increased the risk o f  both 
C V D  and type I I  diabetes (H alton  T  2006). C V D  and type I I  diabetes are intrinsically  
linked through very sim ilar risk m arkers; approxim ately 50%  o f diabetic patients already 
have established C V D  at the tim e o f diagnosis (Blaschke F  2006 ) and the progression o f  
C V D  precedes the developm ent o f type I I  diabetes, w ith common features including N O - 
dependent endothelial dysfunction and im paired vascular responses to N O  donors 
(W illiam s S 1996). Insulin  is a polypeptide hormone secreted by the beta cells o f the 
healthy pancreas. Its  prim ary function is to  control levels o f  glucose w ith in  the blood.
The level o f insulin in the blood is usually directly affected by the level o f  blood glucose
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but can also be regulated by other factors including intestinal hormones, other beta cell 
secretory hormones and neural influences. Levels o f these blood constituents can be 
altered by changes in  lifestyle factors including diet, exercise and prescription o f statins. 
Insulin  resistance, associated w ith  high fasting circulating concentrations o f insulin  
(Laakso M  1993), is a know n risk factor fo r both type I I  diabetes and C V D  (Reaven G  
1995; Hsueh W  1998; Ruige J 1998).
Individuals o f low er socioeconomic status are at increased risk o f C V D  than those 
o f higher socioeconomic status but this is in trinsically linked to  m odifiable factors such 
as low er education level and poor diet w hich are a ll risk markers in  themselves. One 
study showed that lo w  neighbourhood education and lo w  neighbourhood income were 
independent predictors o f incident coronary heart disease, even after adjustment fo r other 
risk markers (Sundquist K  2004) and another that socioeconomic status is an independent 
risk m arker fo r re-adm ission to hospital fo r heart fa ilure (P hilb in  E  2001).
O verw eight and obesity are risk markers in themselves and also highly correlated  
to other independent risk markers including type I I  diabetes, hypercholesterolem ia and 
hypertension. A  body mass index (B M I) o f  greater than 25kg/m 2 confers a greater risk o f  
C V D  than does a low er B M I. The Fram ingham  H eart Study found the risk o f heart fa ilure  
increased by 5%  in  men and 7%  in  wom en per lk g /m 2 increase in  B M I, w ith  obese 
participants (B M I > 3 Okg/m2)  having double the risk o f heart fa ilure compared to those 
w ith  a B M I o f 20 to 25kg/m 2 (K enchaiah S 2002). Body w eight is a known risk m arker 
fo r C V D  and many other associated diseases (e.g. type I I  diabetes (Bogardus C  1985)). 
The prevalence o f obesity, and that o f  its associated m orbidity, in  both the developed and
3 5
the developing w orld has reached epidem ic levels, increasing by over 75%  w orld w ide  
since 1980 (F legal K  2002). A  2001 audit by the N ational A ud it O ffice , London, found 
that obesity, a known risk m arker fo r C V D , cost the N ational H ealth  Service over £0.5  
b illio n  per anum (Bourne J 2001). One m eta-analysis found the relative risk among 
individuals w ith  the highest B M I compared to those w ith  the low est B M Is  to be 1.57 for 
death due to C H D  and 1.48 fo r death due to C V D  (M cG ee D  2005). The same meta­
analysis found that obesity increases C H D  m ortality by approxim ately 50%  in wom en  
and approxim ately 60%  in  men.
The prevalence o f obesity is usually highest in the low er socio-economic groups 
(Jim enez-C ruz 2005 ) who generally have diets low er in nutrients than those o f higher 
socio-econom ic groups (R icciuto L  2006). This is high ly attributable to W esternised diets 
w hich tend to be high in  fa t and refined carbohydrates (Schulze 2006). Some evidence 
has shown that the type o f carbohydrates in  the diet can directly affect body w eight and 
obesity risk (M a  Y  2004) w ith  lo w  glycaem ic index carbohydrate diets, high in  w hole 
grains, starches, inulin  and oligofructose, having beneficial effects on body w eight 
(Spieth L  E  2000 ), body com position and appetite. O verw eight and obese individuals also 
have higher than norm al levels o f  the cytokines IL -6, IL -8 and T N F -a . (Esposito K
2003). These cytokines are involved in  m any processes associated w ith  C V D  and f
inflam m ation including oxidative stress and the expression o f adhesion molecules. They  
are also know n to reduce N O  production (H a ffiie r S 2003) (please see below ). This 
evidence provides a causal lin k  between obesity and C V D .
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Further to absolute adipose tissue mass, the physiological distribution pattern o f  
the adipose tissue also impacts on risk o f C V D . Large waists (greater than 80cm /32inches 
fo r wom en and 94cm /37inches fo r m en), or high w aist to hip ratios (greater than 0.8 fo r 
wom en or 0.95 fo r m en) showing greater central adiposity o r an ‘apple shape’ are 
associated w ith  greater risk than storing excess w eight on the hips and thighs, o r the ‘pear 
shape’ (Larsson B  1984). This is thought to be due to the greater m etabolic activity o f the 
visceral adipose tissue, stored around the v ita l organs, w ith  facilita ted  delivery o f free  
fatty  acids to the liver. A  10cm increase in w aist circumference was associated w ith  a 
19%  higher rate o f  heart fa ilu re  events in  wom en and a 30%  higher rate in men (Levitan  
E  2009).
Hypertension, a blood pressure o f greater than 140/90m m H g, increases the risk o f  
both haemorrhagic and ischem ic stroke, induces endothelial dysfunction, exacerbates the 
atherosclerotic process and contributes to the instability o f the atherosclerotic plaque. A  
meta-analysis involving 56,000 vascular-associated deaths associated each 20m m Hg  
difference in  usual systolic blood pressure (equivalent to approxim ately a lO m m Hg  
difference in usual diastolic blood pressure) w ith  a tw o -fo ld  difference in  deaths from  
C H D , stroke o r other vascular-related deaths (Prospective Studies Collaboration 2002). 
Random ised trials have also associated modest reductions in  blood pressure w ith  reduced 
risk o f C H D  and stroke m ortality and m orbidity (Bosch J 2002; PRO G RESS  
Collaborative Group 2003).
C irculating lipids are highly correlated w ith  C V D  risk (S tam ler J 1986), for 
exam ple high total cholesterol levels in  serum are associated w ith  an increased risk w ith
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the uptake o f  cholesterol by macrophages at the core o f atherosclerotic plaque 
development. The reference levels recommended by the Joint B ritish Societies (JBS2) 
G uidelines on Prevention o f  Cardiovascular Diseases in C lin ical Practice fo r individuals 
at ‘high risk o f developing C V D ’ are relevant to the ‘at risk’ population groups 
investigated in this research. Recommended ideal to tal cholesterol concentrations for 
adults are < 5 .0m M  fo llow ed by m ild ly  high at 5.0 to 6 .4m M , m oderately high between
6.5 and 7 .8m M  and very high above 7 .8m M . The level recommended fo r to tal cholesterol 
is < 4 .0 m M  (JBS2 2005). The B ritish  H yperlip idaem ia Association give the fo llow ing, 
sim ilar, definitions: < 5 .2 m M  desirable, 5 .2  to  6 .4m M  borderline, 6.5 to  7 .8m M  abnormal 
and >7.8  high (Betteridge D  1993).
L o w  density lipoprotein (L D L ) is the m ajor transporter o f cholesterol in the blood  
and plays a pivotal role in  the early stages o f atherosclerosis. H igher than norm al levels 
o f serum LD L-cholesterol, hypercholesterolaem ia, are associated w ith  an increase in  
C V D  risk (G ordon T  1997) and recommended levels fo r individuals at high risk o f C V D  
are <  2 .0m M  (JBS2 2005). Changes in serum levels, particle size and oxidation status o f 
L D L  cholesterol have a ll been proposed as instrum ental in  the pathogenicity o f  
atherosclerosis and its abnorm alities have even been proposed as the single greatest risk 
m arker fo r atherosclerosis in  W estern societies (N avab M  1996). There is a long 
established lin k , from  prospective observational epidem iological research, between 
circulating L D L  cholesterol and the absolute risk o f prem ature coronary deaths (S tam ler J 
1986). This link is positive and w ithout threshold and was given further w eight when 
L D L  cholesterol was shown to be present in atherosclerotic lesions in  amounts directly  
proportional to  those found in  the blood (Sm ith E  1972). This was the basis o f the
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‘Cholesterol Hypothesis’ fo r the positive relationship between serum L D L  cholesterol 
concentration and risk o f death from  C V D . This was investigated further by A ncel Keys 
who subsequently developed the ‘D ie t-H e art Hypothesis’ as a result o f investigations into  
the relationship between dietary cholesterol, circulating L D L  cholesterol and risk o f heart 
disease (K eys A  1970) although this has not stood up to the rigorous testing applied to the 
Cholesterol Hypothesis. As m entioned previously, oxidised L D L  can be taken up by 
tissue resident marcophages w hich become engorged foam  cells, w hich can degenerate, 
releasing th eir contents into the fatty  core o f the plaque.
Conversely, low  H D L-cholestero l (levels below  l.O m M  (0 .3 8 g /l)) increase C V D  
risk (G ordon T  1997), thought to be due to H D L-cholestero l’s ab ility  to  transport 
cholesterol to the liver fo r excretion. Levels recommended by the N ational Institu te fo r 
H ealth  fo r the general adult population are: < 1 .03m M  low  H D L  and high risk o f C H D ,
1.03 to 1.55m M  m edium  level and > 1 .5 5 m M  high level considered optim al fo r C H D  
protection. Recomm ended levels fo r those at high risk o f developing C V D  are >  l.O m M  
(JBS2 2005). C lin ical trials have shown beneficial effects on risk m arkers fo r C H D  on 
the reduction o f  v L D L  and L D L  (Assm an G 1999). Lipoprotein-a has also been proposed 
as a prom oter early and advanced atherosclerosis (Kronenberg F  1999) although results 
are conflicting.
C irculating T A G  levels w ere found to be an independent risk m arker even when 
H D L  cholesterol levels were corrected fo r (Hokanson J 1996) and TA G s have been 
suggested as being able to m odify the potential atherogenicity o f  lipoproteins. 
Epidem iological data suggest a positive relationship between fasting trig lyceride levels
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and C H D  (G insberg H  1997) at levels greater than 2 .3m M  (2 .0 g /l). This may be due to  
the strong inverse relationship w ith  H D L  cholesterol or perhaps a more subtle alteration  
in  lip id  m etabolism  Levels are defined as follow s: < 1 .69m M  ideal; 1.69 to 2 .25m M  
borderline high; 2 .26  to 5 .63m M  high; > 5 .64  extrem ely high.
The relevant literature cites concentrations o f non-esterified fatty  acids (N E F A ) 
w ith in  the ranges o f 0.44  ± 0 .17m M  (Pedrini M  2006) and 0.5 ±  O.O8111M  in those w ith  
type I I  diabetes (Sm it J 2008). The notion o f a potential role o f N E F A  in  atherosclerosis 
and C V D  is gaining support (Steinberg H  2002; Semenkovic C 2004) and elevated N E F A  
levels have been proposed as influencing insulin secretion, thus contributing to the 
development o f type I I  diabetes (C halkey S 1998). A  possible mechanism o f action is 
activation o f the pro-inflam m atory N F kB  pathway in endothelial cells and associated 
stim ulation o f mononuclear cells to increase production o f inflam m atory cytokines, w ith  
the accompanied generation o f RO S (Shoelson S 2006). Indeed, direct intervention w ith  
five  fo ld increases o f intravenous N E F A  have been shown to induce endothelial 
dysfunction, induce inflam m ation, im pair vascular reactivity and increase circulating  
levels o f soluble cellu lar adhesion molecules (T ripathy D  2003). The direct relevance o f  
this w ork is unclear as levels o f N E F A  investigated were not w ith in  physiologically 
relevant ranges, w ith  research continuing in  this area.
Sm oking is a proven correlator fo r C V D  risk, thought to be due to the resultant 
increases in oxidative stress and the im paired endothelial function. O xidative stress 
increases during inflam m ation, destroys N O  and has been suggested to contribute to 
endothelial dysfunction (Rush J 2005). Cytokines, including IL -8, IF N -y  and T N F -a , are
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involved in oxidative stress, affecting the increased expression o f  adhesion molecules and 
the reduction o f N O  production (H a ffiie r S 2003). Levels o f these cytokines are increased 
in  inflam m ation and obesity (Esposito K  2003).
Physical inactiv ity  is a common factor in  a W esternised lifestyle and is associated 
w ith  increased C V D  risk. Physically active adults experience low er risk o f C V D  and 
C H D  (Lee 1 2001; W annam ethee S 2002 ) w ith  one review  o f 2 7  cohorts showing 
sedentary groups to be tw ice as lik e ly  as more active groups to experience C H D  (B erlin  J 
1990). D ata from  the Nurse’s H ealth  Study showed an association between both w alking  
and vigorous exercise, and a 30 to 40%  reduction in risk o f coronary events (M anson J
1999) and research continues in  this area.
D ie t affects C V D  risk in  both obvious and more subtle ways. For exam ple, a diet 
high in  saturated fats is know n to increase levels o f cholesterol in  the blood. Em erging  
evidence, however, suggests m ore subtle interactions, including the ab ility  o f whole grain  
diets to  reduce risk o f C V D . The inflam m atory process has been shown to be beneficially  
affected by diets high in  w hole grains (Lopez-G arcia E  2004; N ettleton J 2006) and 
suggested mechanisms responsible fo r this beneficial effect include a reduction in  
endothelial activation and im proved endothelium  dependent vasodilation when compared 
w ith  the effects o f a lo w  w hole grain diet.
The m odifiable risk markers fo r C V D  provide a possible route fo r prevention, 
reversal and treatm ent o f the disease. Figure 1.9 displays a  ‘round table’ o f  the factors 
related to diet, obesity, activ ity  and drugs in  their contribution to the prevention and
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treatm ent o f C V D  (A shw ell M  2000). Interventions aimed at reducing risk through 
m anipulation o f the factors illustrated below  provide a combined approach to tackling  
this issue. One o f the most prom ising non-invasive methods o f treating the m odifiable  
risk markers is posed by the diet, w hich has positive effects on a range o f risk markers, 
including total cholesterol, L D L  cholesterol, H L D  cholesterol and TA G s.
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Figure 1.9: A round table of dietary and other factors involved in the prevention of 
coronary heart disease. The contribution o f factors related to diet, obesity, activity and 
drugs to the combined strategy fo r prevention and treatm ent o f cardiovascular disease. 
Taken from  (A shw ell M  2000).
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Epidem iological evidence associates diets high in  w hole grains w ith  a reduction 
in  risk o f  cardiovascular disease (C V D ) although the mechanisms behind, and reasons 
fo r, this association are unknown. W hole cereal kernels, o r grains, consist o f three 
distinct sections: the protective outer o r bran section, the endosperm m aking up the bulk 
o f the grain, and the germ. Nutrients are concentrated w ith in  the bran (w hich contains a 
high proportion o f the fib re ) and the germ  (containing high levels o f vitam ins and 
m inerals) leaving the energy dense endosperm relatively nutrient poor.
The most com m only accepted defin ition o f a w hole grain is that proposed by the 
Am erican Association o f Cereal Chemists (A A C C ) in  2005. This defin ition  states that 
‘w hole grains shall consist o f the intact, ground, cracked or flaked caryopsis, whose 
principal components -  the starchy endosperm, germ  and bran -  are present in  the same 
proportions’ . To  be labelled as ‘w hole grain’ a food must contain at least 51%  w hole 
grains by w eight.
The most com m only consumed grains in  the U K  are wheat, rice, m aize, oats, rye 
and barley. C urrently, grains provide about 30%  o f total energy in  the B ritish  adult diet. 
This value is much greater than that o f any other food group (Trusw ell A  2002). D ietary  
guidelines recom mend increasing the consumption o f w hole grains in  the average U K  
diet to 3 portions per day (Lang R  2003) although the actual intake is substantially less 
than this (Anderson J 2003 ), w ith  certain studies suggesting that w hole grain intake is 
still less than one portion per day (G regory J 1990; Finch S 1998). One portion o f w hole 
grains is defined by the W hole Grains Council (w w w .w holegrainscouncil.org)  as ‘ 16g o f
1.6 Whole grain diets and CVD risk
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w hole grain ingredients’ and is equivalent to approxim ately one slice o f w hole grain  
bread, h a lf a w hole grain p ita  bread or h a lf a cup o f w hole grain rice o r pasta The 
combined advice, therefore, is fo r a  daily intake o f 48g whole grains. This advice is 
grounded in recent epidem iological research link ing  whole grains to beneficial effects on 
cancer (Chatenoud L  1998; Jacobs D  1998; W illiam s M  2005), type I I  diabetes (Jensen 
M  2004; H alton  T  2006), obesity (S lavin  J 2005 ), appetite regulation o r reduction (K oh- 
Banerjee P 2003), body com position (N elson L  1996), m yocardial infarction prevention  
(M artin ez-O rtiz J A  2 006 ), insulin resistance (Esposito K  2004 ) and to tal m ortality from  
all causes (S teffen L  2003). H igh  intakes o f w hole grains have also been shown to low er 
risk o f cardiovascular disease (Jacobs D  1998; L iu  S 1999; L iu  S 2000; L iu  S 2003; 
Steffen L  2003).
Behall et al found that meals high in both oats and barley reduced glycaem ic 
responses compared to a test m eal containing glucose, a factor w hich they related to the 
high soluble fibre content o f these foods (B ehall K M  2005). Glucose responses 
(measured by the area under the curve (A U C )) were reduced after both barley and oats 
when compared to a test m eal containing glucose, w hile insulin A U C s were reduced 
significantly by barley but not by oats. Glucagon and leptin responses to a high oat or 
barley m eal did not d iffer significantly from  those to a test meal containing glucose 
(B ehall K M  2005). Extrem es o f  these physiological responses have been linked w ith  
elevated risk o f C V D .
W hole cereal grains contain im portant amounts o f most nutrients required by the 
‘healthy’ human body (Trusw ell A  2002). The predom inant o il in  cereals is
4 4
polyunsaturated, w ith  50%  being linoleic acid, which may act to low er low -density 
lipoprotein (L D L ) and to tal plasm a cholesterol as seen in the M editerranean diet 
(V incent-B audry S 2005). W hole grains also contain significant levels o f  fo lic  acid w hich  
reduces plasm a hom ocysteine levels (Bem asconi A  2006) and high homocysteine levels 
(hyperhom ocysteinaem ia) are known risk markers fo r C V D . W hole grains are also rich in  
antioxidants including vitam ins, trace m inerals, phenolic acids, lignans, phyto estrogens, 
flavonoids and anti-nutrients such as phytic acid (Thom pson L  1994; S lavin J 2003) and 
are a better source o f selenium  and the intracellu lar antioxidant vitam in E  (especially 
tocotrienols) than are refined grains. Antioxidants delay the onset of, or slow the rate o f  
oxidation of, oxidizable substrates and therefore the form ation o f harm ful free radicals. 
O xidative stress caused by these particles has been im plicated in cancer (K launig  J 1998) 
and C V D  risk (Rush J 2005). The antioxidant phenolic acids (e.g. feru lic, canillic and 
caffeic acid) are found in the outer layers o f w hole grains and have been associated w ith  
potential protection from  C V D  (Thom pson L  1993). W hole grains contain high levels o f 
beneficial phytoestrogens (e.g. isoflavones, lignans and coumestans) and have m ediating 
effects on insulin and glucose responses. Im paired m etabolism  o f  these factors is 
im plicated in C V D  risk (R uige J 1998). W hole grains also contain lignins w hich are 
converted to enterolactone and enterodiol in the body. Lignins are horm onally active 
compounds that m ay protect against horm onally m ediated diseases, cancer and 
atherosclerosis (A dlercreutz H  1990; A d le rc reu tzH  1997).
Research shows that refined grains do not contain the same levels o f bioactive 
nutrients as w hole grains and are not associated w ith  the same health benefits. I t  is 
unknown, however, whether the state o f the w hole grain is a  factor in  its beneficial
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effects. The supposed benefits o f w hole grains to health are w idely accepted w ith  w hole  
grain products, including bread, pasta and cereals being deemed better fo r health than 
their refined grain counterparts. The first evidence fo r this claim  on cardiovascular health 
came in 1977, when a study in  U K  m en showed that those w ith  the highest cereal fibre  
intake had a 80%  low er risk o f heart attacks (M orris  J 1977). Since then, much sim ilar 
w ork has been carried out although most studies are observational to date so no direct 
cause and effect can be determined. Studies show that individuals w ith  a  higher than 
average w hole grain intake o r approxim ately 48g /d  (as defined as the recommended 
intake by the W hole Grains C ouncil) have a significantly reduced risk o f atherosclerotic 
C V D  than those w ith  the lowest intake. This has been associated w ith  w hole grain’s 
ab ility  to  reduce several o f  the m ajor risk markers fo r atherosclerosis: high L D L  
cholesterol, lo w H D L  cholesterol, high serum T A G s, hypertension, type I I  diabetes and 
obesity (Anderson J 2003). The average adult in  the U S A  and W estern Europe has less 
than one serving o f w hole grains per day w hich m ight partly explain w hy C V D  is so 
common in these geographical areas (C leveland L  2000). One study showed a low er risk 
o f both C V D  and type I I  diabetes in  individuals who consumed diets high in  w hole grains 
(Jensen M  2004) w hile another showed the substitution o f dietary w hole grains w ith  a 
different source o f carbohydrates, potatoes, increased the risk o f both C V D  and type I I  
diabetes (H alton  T  2006).
W hole grains consist o f three m ajor components: the husky, protective outer layer 
o f bran w hich is very rich in  dietary fibre and designed to protect the grain; the high 
starch, sim ple carbohydrate rich endosperm designed to feed the grow ing plant; and the 
nutrient rich germ  w hich w ill become the new  plant (figure 1.10). The refin ing process
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removes both the bran and a proportion o f the germ, resulting in an increase in the 
relative starch concentration coupled w ith a loss o f dietary fibre, vitam ins, minerals, 
lignins, phytoestrogens, phenolic compounds and phytic acid. These components, many 
o f which have proven health benefits, appear to w ork synergistically to  produce an effect 
greater than that o f the sum o f their parts.
Pericarp
Figure 1.10: A whole grain kernel showing the major component parts. M ajo r 
components include: the protective bran outer coating, the starchy sim ply carbohydrate 
rich endosperm and the vitam in rich germ  (em bryo) Adapted from  (S lavin J 2004).
A lthough evidence shows a link between increased whole grain intake and 
reduction in risk o f C V D , the parts o f  the whole grain responsible fo r this relationship are 
still unknown. For exam ple, phytochem icals in whole grains have also been suggested as
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being responsible fo r reducing the risk o f C V D  through their horm onal effect on H D L  
levels (Thom pson L  1993). One study reported a  significant rise in to ta l plasma 
cholesterol in subjects, fo llow ing a high wheat fib re  diet (Stasse-W olthuis M  1979). I t  is 
possible in such cases that the H D L  was increased even though to tal cholesterol was not 
reduced (O M o o re  R  1978; Lindegarde F  1984). This w ould still have beneficial effects 
on C V D  risk.
1.6.1 Dietary fibre
W hole grains contain high levels o f both dietary starch and fibre. Starch is a 
polysaccharide com prised p rim arily  o f am ylose and am ylopectin. The relative ratios o f 
these component polysaccharides in  a  food influence the rate o f  starch digestion and 
insulin and glucose responses (B ehall K M  1988) w ith  consequent effects on satiety and 
further intake (Anderson G  2003). The gel-form ing properties o f certain soluble dietary  
fibres (e.g. guar gum , pectin and m ucilages) reduce postprandial glycem ia by delaying  
gastric em ptying (N u tta ll F  1993). Even those w ithout gel-form ing properties appear to 
control food intake to a certain extent thus affecting risk o f overw eight and associated 
m orbidities. A  m eta-analysis investigating evidence fo r a relationship between w hole 
grain intake and C V D  found that cereal fib re  intake was non-significantly (risk  ratio o f 
0 .9 , 95%  C l 0 .8, 1 .01) negatively associated w ith  C H D  but did not account fo r the 
protection from  atherosclerotic C V D  afforded by w hole grain intake (Anderson J 2000).
The term  inulin  describes a heterogenous blend o f fructose polym ers, known as 
the fructans, composed o f  m ainly linear chains o f 6 to > 60  fructose units (G ibson G  
1994) w ith  a term inal sucrose m olecule. In u lin  is w idely distributed in  the storage
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carbohydrates o f approxim ately 36,000 plant species (C arp ita N  1989), which equates to  
approxim ately 15%  o f flow ering plant species (H endry G 1993). As a soluble dietary  
fibre (R oberffo id  M  1993), inu lin  is resistant to digestion in the upper gastrointestinal 
tract (Knudsen K 1995) and thus reaches the large intestine intact (Niness K 1999). This  
stimulates the growth o f intestinal bifidobacteria, resulting in the production o f SCFAs, 
lactic acid and gasses such as H 2, C 0 2 and C H 4 (R oberfroid M  1993). The average 
European diet includes approxim ately 3 to lO g inulin  per day (van Loo J 1995) w ith the 
most significant sources including wheat, onions, bananas, garlic and chicory w ith  most 
com m ercially available inu lin  being synthesised from  sucrose or extracted from  chicory 
(Niness K 1999).
In u lin  is used to fo rtify  foods w ith  fibre. As its caloric content is approxim ately 
lk c a l/g  (R oberfroid M  1993) it is also used to im prove flavour and texture o f lo w  calorie 
foods and low -fa t foods as alternatives to  sugar and fat. Consumption o f soluble fibres, 
including inulin , oligofructose and P-glucose, has been suggested as low ering to tal and 
L D L  cholesterol (Davidson M  1999). In  a review  o f 77 investigations into the effects o f  
soluble fibre, 68 studies showed a reduction in  to tal cholesterol (G lore  S 1994). O f the 49 
studies review ed w hich investigated L D L  cholesterol, 41 showed a reduction due to the 
high soluble fibre diets. D ue to its use as a hypocaloric substitute fo r both sugar and 
sweetener and its reputed lip id  low ering actions, inulin is recommended fo r those at high  
risk o f C V D .
Several factors effect the d igestib ility o f a starch including the cooking and 
cooling processes em ployed, associations between the starch and other components in  the
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food and the type and size o f the starch granules themselves (Stephen A  1994). The 
structure o f foods also affects the blood glucose and insulin responses to that food 
(B jorck 1 1994). As soluble starch binds w ater it has the capacity to  low er the energy 
density o f the diet (Roberts S 2002). The type o f starch used in  the d iet may have 
im portant m etabolic consequences in  norm al and diabetic rats (Lerer-M etzger M  1996). 
Starches can be altered and then added to w hole grain products in addition to those 
already present.
Intervention studies have shown that a high-starch regim en causes a decrease in  
energy intake w ith  no apparent differences in  effects between soluble and insoluble starch 
(H ow arth  N  2001). Bread made w ith  50%  buckwheat groats induce a significantly higher 
satiety score than a reference w hite wheat bread (Skrabanja V  2001), a property attributed  
to its high levels o f insoluble starch. The addition o f starch to  foods is recommended to 
increase their ‘fillin g  powers’ and reduce appetite (H o lt S 2001). N either 75g preloads o f 
high-am ylose cornstarch or 75g o f high-am ylopectin cornstarch, however, in  the form  o f  
sweetened drinks were shown to affect food intake one hour after ingestion (Anderson G  
2002). I t  is possible that this effect is due to the m edium , as liquids tend to be lass 
satiating than solids.
As high starch foods increase distension in  the stomach they m ay increase 
sensations o f follness (Roberts S 2002). In  rats a wheat starch load causes a significant 
reduction in dinner size after the th ird  load (Bensaid A  2002). This study also showed 
that m eal duration was not m odified by a carbohydrate load, but was shortened by a 35%  
protein load. In take o f dietary fibre was found to be inversely related to serum
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concentrations o f C -reactive protein, a know n m arker o f inflam m ation (K in g  D  2003; 
A jan i U  2004) and the N ational H ealth  and N utrition  Exam ination Survey in the US  
determined dietary fibre to be independently and inversely associated w ith  circulating  
C R P, in  a study w ith  approxim ately 4000 participants (A jan i U  2004).
M a  et al (2004) showed that the type o f carbohydrate in  the diet may be related to 
body w eight. A dditional dietary fib re  has been found to reduce body w eight to a greater 
extent than the reduction o f fat, although the effects have been found to be additive 
(Roberts S 2002). W eight loss has been found to  be more than three times as great in  
subjects on a low er-fat, h igher-fibre diet than in subjects on a lo w -fa t diet alone (Y ao  M  
2001). Body w eight reduction rate was significantly increased when feeding a high fibre  
diet compared w ith  a control diet (H ow arth  N  2001) suggesting that the effects o f fibre  
on energy intake do translate to reductions in  body weight.
B ehall et al found that meals high in both oats and barley reduced glycem ic 
responses compared to a test m eal containing glucose, a factor w hich they related to the 
high soluble fibre content o f these foods (B ehall K M  2005). Glucose responses (as shown 
by the ‘area under the curve’)  w ere reduced after both barley and oats when compared to 
a test meal containing glucose and insulin A U C s were reduced significantly by barley but 
not by oats.
In  a study by H o lt et al mean satiety index scores fo r h igh-fibre and protein-and- 
fib re-rich  breads (containing 33.5 and 19.9g o f  fibre respectively) were significantly 
higher than those fo r reference and fru it breads (containing 1.8 and 10.2g o f fibre
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respectively (H o lt S 2001)). These high fib re  breads were also associated w ith  low er 
energy intakes fo r the rest o f the day. The levels o f  fibre used in  this study could 
realistically be added to foods in practice to potentially control satiety and energy intake, 
to m aintain or reduce body w eight (as a m arker o f C V D  risk) as appropriate.
Both oat bran and w heat bran had the same effect on stool w eight, even though 
oat bran contains m ostly soluble fib re  and w heat bran contains m ostly insoluble fibre  
(Chen H  1998), thus suggesting that the laxation properties o f a fibre can not be 
determ ined by its solubility. The source o f the fib re  appears to be im portant in  
determ ining its effects on cholesterol levels. One study reported a reduction in to tal 
plasm a cholesterol after feeding w ith  bran from  hard red spring wheat but not after 
feeding w ith  ordinary soft w hite wheat bran (M unzo J 1979) thus w arranting further 
investigations into d ifferent sources o f fibre.
1.6.2 Refined grain foods
M any o f the nutrients know n to be beneficial or essential fo r health, specifically  
heart health (T rusw ell A  2002 ), including the vitam ins (e.g. riboflavin , niacin and 
th iam ine), m inerals (e.g. iron potassium and copper), fibre, phytonutrients and essential 
fatty  acids, are concentrated w ith in  the germ  and bran layers as previously stated. 
Unfortunately, a ll o f  the nutrients proposed to be protective to heart health are reduced by 
the refin ing process, leaving an energy dense and nutrient poor, smoother w hite flour. 
Therefore, a high proportion o f the vitam ins and m inerals found in w hole grains, and 
credited w ith their beneficial effects, are not found in refined w hite flou r and its products 
(H olland B  1991).
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Some refined flours and cereals are fo rtified  w ith  vitam ins and m inerals, usually 
calcium  or iron and several B  vitam ins (including riboflavin , niacin and fo lic  acid). 
Although these products often display health claim s about their added nutritional 
benefits, only a sm all num ber o f the nutrients removed are replaced (Trusw ell A  2002) 
and fibre is not generally one o f  them. I t  is also not clear whether the addition o f  
components provides a C V D  risk reduction benefit equal to that o f inclusion o f the intact 
whole grain, o f whether the im pact o f the w hole grain is greater than that o f the sum o f its 
parts.
H igh  intakes o f refined carbohydrate foods cause rapid and extrem e swings in  
both blood glucose and insulin levels and may elevate plasma levels o f  free fatty acids 
(Foster-Pow ell K  2002). These effects can cause hunger and over feeding and are 
associated w ith  developm ent o f  C V D  and type I I  diabetes. H yperglycaem ia im pairs 
endothelium  dependent vasodilation (W illiam s  S 1998) and reduces the availab ility  o f  
N O  (G iugliano D  1997). This results in  the unrestrained production o f free radicals w hich  
are also im plicated in the prom otion o f atherogenesis (G iugliano D  1996; Brow nlee M  
2001). Therefore, the habitual consumption o f refined grains can be associated w ith  C V D  
risk. Replacem ent o f total and unsaturated fats w ith  refined carbohydrates is unlikely to 
reduce C V D  risk and may even increase this risk in people who are predisposed to insulin 
resistance (M ozaffarian  D  2005). The same study found that diets rich in  w hole grains 
and low  in refined grains are lik e ly  to  reduce the risk o f C V D .
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1.6.3 Whole grain foods
1.6.3.1 Physical states of whole grains
The nutritional effect o f a w hole grain differs w ith  the sources o f these grains.
The state in  w hich a whole grain is present in  a food has also been shown to determine 
the affect that food has on insulin response (W rick  K  1983) and other markers o f  
physiological response (B ehall K M  2005). W hen fed at the same dosages, course wheat 
bran has a greater faecal bulking effect than fin e ly  ground wheat bran, suggesting that the 
particle size effects physiological response. Course bran also delays gastric em ptying and 
accelerates sm all bow el transit tim e to a greater extent than fin e ly  ground bran (M c In tyre  
A  1997) suggesting the effects are not due to sim ple com position differences between 
whole and refined grains. One study showed that particle size o f both oats and barley had 
no significant effect on the glycem ic response to the food (B ehall K M  2005 ) but did not 
investigate the effects o f wheat bran. Particle size o f wheat bran did not alter the effect on 
stool w eight, but did affect faecal concentrations o f butyrate suggesting increased 
bacterial ferm entation w ith  the sm aller particles (Jenkins D  1999). Hence, it is im portant 
to consider the physical state o f  the w hole grain when conducting research.
1.6.4 Fermentation products of whole grains
Short-chain fatty  acids (S C FA s) are the m ajor anions present, at approxim ately 
100 to 200m M /day (C ook S 1998), in  the large intestinal lum en o f non-rum inant, m ono- 
gastric mammals. They are produced in  the cecum and proxim al colon by the anaerobic, 
bacterial ferm entation of, p rim arily , dietary fibre, w hich is made up o f indigestible 
carbohydrates, those resistant to  breakdown by human salivary and intestinal digestive 
enzymes, but which are broken down by the intestinal m icroflora (Sako T  1999; van
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Laere K  2000). SCFAs are tw o to five-carbon w eak acids, the bulk o f w hich are acetate 
(C 2 ), propionate (C 3 ) and butyrate (C 4). V alerate (C 5) is the next most abundant SCFA  
but is present at significantly low er concentrations in  the low er intestines. The m olar ratio  
o f acetate:propionate:butyrate in  the m am m alian colonic lum en is approxim ately 
60:20:20 respectively (Cum m ings J 1979) although values are conflicting. The m ajority  
(7 0  to 90% ) o f  the butyrate is metabolised as the prim ary fuel o f  the colonocytes but the 
acetate and propionate move into the circulation (Roediger W  1980) w ith  circulating  
levels in  p M  concentrations (Cum m ings J 1979). Interestingly, the production o f SCFAs 
depends on the substrate, fo r exam ple, approxim ately 5 to 20%  insoluble fibre is 
metabolised to SCFAs whereas this value can be 90%  fo r soluble fib re  (C ook S 1998).
The SCFAs are known to have a num ber o f physiological and pathophysiological 
effects on the intestine including a trophic effect on the lin ing o f the intestine itse lf 
(R oyall D  1990). They have demonstrated prebiotic effects and im proved m ineral 
absorption (Teitelbaum  J 2002 ) in  the colon, activation o f endothelial cells and 
involvem ent in the regulation o f lip id  m etabolism  (K aur N  2002). They have 
im m unom odulatory and anti-in flam m atory properties (K elly-Q uag liana K  2003) in  m ice, 
deter the colonisation o f the low er intestine by pathogens (R oyall D  1990) and also aid 
the im m une system as butyrate is one o f its substrates (Jenkins D  1999). They are 
absorbed as nutrients across the intestinal epithelium  and can influence various functions 
o f the gastrointestinal tract (Cum m ings J 1995). The SCFAs are know n to affect colonic 
m o tility  and ion transport (Y a jim a  T  1985; Y a jim a  T  1988; Fukum oto S 2003) and w ater 
thus acting as anti-diarrhoeal agents (Ram akrishna B  1993). They are have also been 
shown to provide 5 to 30%  o f systemic daily energy requirements (Rom beau J 1990),
im prove colonic blood flo w  (M ortensen F  1990) and reduce am m onia uptake from  the 
low er intestine (R oyall D  1990).
The preferred substrate fo r colonocytes is n-butyrate, which has been shown to  
reduce the risk o f colon cancer by stim ulating norm al cellu lar grow th and reducing 
damage to D N A  (Roediger W  1990) and antagonizing the hyperproliferation o f colonic 
cells induced by the secondary b ile  deoxycholate (Scheppach W  1995). The trophic effect 
o f n-butyrate reduces the incidence o f ulcerative colitis (Sm ith J 1998). Propionate causes 
a direct reduction in  hepatic gluconeogenesis and an enhancement in hepatic glycolysis 
(R oberfroid M  1998). I t  also works indirectly on the liver to low er plasm a fatty  acid 
concentrations w hich are closely related to gluconeogenesis (K au r N  2002). They are 
thought to be responsible fo r some o f the health benefits associated w ith w hole grains. 
Raised faecal levels o f  SCFAs can be indicative o f a number o f pathological states, 
including defective metabolism  w ith in  colonocytes (Treem  W  1996), increased blood in  
the colon (H oltug  K  1988), m alabsorption (Scheppach W  1988), rapid gut transit tim es 
(O u fir L  2000) or sm all bow el bacterial overgrowth (Hoverstad T  1985).
Although SCFAs are the most abundant breakdown products o f  a high w hole  
grain diet, im plicated in  the health benefits, they are not the only factors worth 
consideration. Phytoestrogens, w hich are found com m only in  plants and are structurally 
sim ilar to m am m alian oestrogens, have also been suggested to have protective effects 
against diseases including C H D , type I I  diabetes m ellitus and certain hormone related  
cancers (on w hich most o f  the previous w ork has focused).
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The most common class o f phytoestrogens in the W esternised diet are the lignans 
w hich are present in  most plant foods. These lignins are not digested by the human gut 
but are metabolised into the m am m alian lignins by the intestinal bacteria o f non­
rum inant, mono-gastric mammals (Lam pe 2003; Row land 1 2003). The tw o main 
m am m alian lignins produced in the human colon are enterolactone and enterodiol. 
Enterodiol can also be converted into enterolactone on m etabolism  by the same bacteria. 
From  this point onwards enterolignins produced in the human gut from  plant lignans w ill 
be know n sim ply as ‘ lignins’.
L ign in  precursors are found in  a w ide variety o f plant based foods including 
seeds, legumes and w hole grains w ith  flaxseeds being the richest dietary source. They are 
classified as phytoestrogens as they m im ic some o f the effects o f oestrogens. The 
principal source o f dietary lignans in the W esternised diet include pinoresinol, 
lariciresinol, secoisolariciresinol and m atairesinol (K le ijn  M  2002; V a lsta  L  2003).
Both serum and urine levels o f the lignins can be used as markers o f dietary  
intake o f lign in  precursors. In  a population fo llow ing an average W esternised diet, 
plasma concentrations o f enterolactone plus enterodiol have been found to be in the range 
o f 10 to 270n M  but include a very w ide range o f  enterolactone concentrations from  non- 
detectable to greater than 1 pM . The therapeutic use o f antibiotics has been associated 
w ith  low er serum levels o f enterolactone (K ilkk in en  A  2002) suggesting that intestinal, 
and therefore dietary intake, levels are reflected in  the serum. As data on the lignan  
content o f foods is lim ited, serum and urinary levels are used as markers o f intake and 
intestinal levels in studies. One pharm acokinetic study w hich measured plasm a and
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urinary levels o f the m am m alian lignins after a single 0.9m g/kg body w eight dose o f  
secoisolariciresinol (the principal lignan in  flaxseeds) found that at least 40%  was 
available to the body fo r conversion to enterodiol and enterolactone (K uijsten A  2005). 
The concentration o f enterodiol in  plasm a peaked at 73nM  an average o f 15 hours post­
ingestion. The concentration o f enterolactone in plasma peaked at 56n M  after an average 
o f 20 hours post ingestion. Thus, substantial amounts o f ingested plant lignans are 
available to the human gut flo ra  fo r ferm entation into m am m alian lignins. H ig h  lign in - 
precursor feeding studies have shown considerable between and intra-subject variation in 
both the baseline levels o f lignins and the ratios o f enterolactone: enterodiol produced on 
feeding. A  previous in vitro study focusing on the effects o f  enterodiol and enterolactone 
on the breast cancer cell lin e  (M C F -7 ) both lignins were used at concentrations o f lO n M  
to 1 p M  using ethanol as the vehicle (Carreau C 2008). This study showed over-lapping  
yet distinct effects on endogenous gene targets at levels w hich can be achieved in  a high  
lignan diet.
As stated above, diets rich in  plant lignans e.g. fru it, vegetables and w hole grains, 
are consistently associated w ith  a reduction in C V D  risk markers. I t  is s till not clear, 
however, whether lignins themselves confer any cardio-protective effects and no specific 
mechanisms o f action have been proposed.
1.7 Whole grain and CVD interaction
Epidem iological evidence from  observational studies suggests that diets rich in  
w hole grains are associated w ith  a reduced risk o f C V D  (Jacobs D  1998; L iu  S 1999; L iu  
S 2000; M cK eow n N  2001; Anderson J 2003). One prospective cohort study o f healthy
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m ale health professionals found a negative association between habitual w hole grain  
intake and C V D  occurrence (Jensen M  2004). The authors suggested that the bran 
component o f w hole grains could p lay an im portant role in this relationship and thus have 
a clin ical application. A  further recent study showing a low er risk o f C V D  in  persons who 
consume diets high in w hole grains (Jensen M  2004) also showed a low er risk o f type I I  
diabetes. In  addition, a m eta-analysis o f 13 studies compared groups w ith  the highest and 
low est whole grain intake, revealing a risk ratio o f 0.71 (95%  C l 0 .48, 0 .94 ) fo r C H D , 
showing a reduction in  risk o f  C H D  o f  29%  fo r those w ith  the highest intake, above three 
portions per day (Anderson J 2003).
Individuals in the U K  who consume the most w hole grains have a 29%  low er risk 
o f developing C V D  than those who consume the least (Anderson J 2003). Three diets 
have been proposed fo r the prevention o f C V D  (H u  F  2002), one o f w hich expressly 
contained increased w hole grain consumption. In  spite o f a ll o f this research, however, 
only a few  countries have dietary guidelines w hich specify the recommended quantities 
o f whole grains to be included in the daily diet (Lang R  2003). The probable mechanism  
fo r the conferred reduction in  risk o f C V D  associated w ith  w hole grains is due to 
im provem ents in  glycaem ic control, plasma lip id  pro file  and reductions in inflam m atory  
factors, associated w ith  several o f  its constituent parts. Few  nutritional intervention trials  
have investigated the effects o f a high w hole grain diet on risk markers o f C V D  directly.
In  conclusion, mounting evidence associate diets high in  w hole grains w ith  a 
reduced risk o f C V D , C H D  and other co-m orbidities including type I I  diabetes, obesity 
and hypertension. M uch  o f this data, how ever, is observational and controlled dietary
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intervention trials are required to determ ine whether this association w ith  whole grains is 
causal or a symptom o f a w ider range o f lifesty le  factors.
1.8 Hypotheses and objectives
Cardiovascular disease, fo r w hich the inflam m atory disorder, atherosclerosis, is 
an underlying cause, is the leading cause o f m ortality and m orbidity in  the U K . Strong 
evidence exists fo r the relationship between high w hole grain diets and low er risk o f  
C V D . M uch o f the evidence to date, however, is observational suggesting the need fo r 
randomised controlled dietary intervention trials to  establish whether this relationship is 
causal or passive. This research, therefore, aim ed to investigate the relationship between 
high w hole grain diets and m arkers o f risk o f C V D  in healthy individuals displaying risk 
markers fo r C V D  and it was hypothesised that whole grains and their constituents w ould  
have beneficial effects on markers o f C V D  risk both in vivo and in vitro.
The first objective was to  investigate the effects o f w hole intact and w hole m illed  
grains, compared to a reference control grains, on circulating haemostatic, inflam m atory, 
lip id  and insulin sensitivity m arkers as an indication o f C V D  risk in  an at risk population. 
The first objective w ould be achieved through the P ilo t W hole grain Intervention Study 
in  England (P ilo t W IS E ) tria l in  men (aged 30 to  60 year) and post-menopausal wom en 
(both w ith M B I 25 to 35kg/m 2).
The literature poses the effects o f  fibre, found in  high levels in  w hole grain foods 
and proven to have beneficial effects on C V D  related factors including total and L D L  
cholesterol and w eight loss, as a possible mechanism responsible fo r beneficial effects o f
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w hole grains on C V D  risk markers. D iffe ren t types o f fibre, that is, soluble and insoluble 
fib re, are known to have d iffering  levels o f im pact on such markers.
The second objective, therefore, was to investigate the effects o f both insoluble 
and soluble fibre, represented in  this research by wheat fibre and inulin  respectively, on 
circulating haemostatic, inflam m atory, lip id  and insulin sensitivity risk markers o f C V D  
in  at risk men. The markers investigated were as stated in the first objective and 
participants included men aged 30 to 60 years w ith  B M I scores o f 25 to 35kg/m 2 (n =  10). 
This was to be achieved through the Fibre and In u lin  T ria l in  M a le  Adults (F IT M A ).
Nutrients interact w ith  m etabolic pathways at numerous levels w ith  m ultip le  
targets. The range o f  m etabolites present in  the metabolom e at any tim e is a reflection o f  
the m etabolism  at that point in  tim e. Increasing use o f ‘-om ics’ technologies in nutritional 
research now  allows more detailed research o f the influence o f specific dietary changes 
on such physiological processes. M etabolom ics, the most recent o f the ‘-om ics’ 
technologies, is increasingly being applied to dietary intervention studies to determine 
effects o f specific diets, or dietary components, on the m etabolom e (R ezzi S 2007; Lodge 
J 2009). Using metabolom ics allow s fo r research to investigate global changes in  
m etabolite profiles w ith in  biological samples and interest in this area is turning tow ard  
nutritional research (G ibney M  2005; R ezzi S 2007). I t  possible to  investigate the 
interactions o f specific individual nutrients or w hole diet interventions w ith  the m etabolic 
pathways and the m etabolom e, o r to identify  biom arkers fo r dietary exposure. Such 
m etabolom ics’ technology uses an analytical platform , in this case mass spectrom etry, to 
analyse given biological samples w ith  m ultivariate statistical analysis to visualise
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differences between identified  sample groups. To date, m etabolom ics technology has 
been applied to a num ber o f nutritional studies w ith  good effect (R ezzi S 2007).
As such, the third objective was to explore the effects o f diets high in w hole 
intact and m illed  grains, wheat fib re  and inu lin  on circulating m etabolite profiles when 
compared to a reference control refined grain, v ia  an untargeted H P L C /M S  based 
m etabolom ics analysis w ith  the potential fo r investigation o f a biom arker fo r the dietary 
intake o f such products.
A t the m olecular level, fibre is ferm ented anaerobically by the colonic m icroflora  
to short chain fatty acids (S C FA s) and other factors. The SCFAs, the most abundant o f 
w hich are acetate, propionate and butyrate, are known to have anti-in flam m atory effects 
and to  be present in the circulation. These factors are, therefore, posed as m ediating the 
beneficial effects o f w hole grains o f C V D  risk.
The fourth and final objective was to investigate the potential mechanisms o f 
action o f w hole grains and their constituents and ferm entation products at the cellular 
level by exploring the effects o f ferm entation products o f w hole grain constituents 
SCFAs, on markers o f vascular health and dysfunction in vitro. M arkers chosen were the 
secreted inflam m atory m ediators interleukin-8 and n itric  oxide, the haemostatic secreted 
factors tissue plasm inogen activator-1 and von W illebrand factor, and the cell surface 
adhesion markers intercellu lar adhesion m olecule-1, vascular cell adhesion m olecule- 1 
and platelet-endothelial ce ll adhesion m olecule-1.
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Chapter 2
Materials and Methods
2.1 Materials
A ll intervention products used in the P ilo t W IS E  and F IT M A  trials were a g ift 
from  H olgran Ltd.
The Pilot Whole grain Intervention Study in England: the Pilot WISE trial
The three bread ro ll-lik e  intervention products used in the P ilo t W IS E  tria l were:
(i) the control product containing only the refined grain m atrix as a reference; ( ii)  the 
w hole intact grain product containing 48g w hole intact grains w ith in  a refined grain  
m atrix; ( iii)  the whole m illed grain product containing 48g whole but m illed  grains in a 
refined grain m atrix. The approxim ate nutritional com position o f the products per lOOg 
fin a l product, were: control: 258kcal, 5 4 .lg  carbohydrate and 2.7g fibre; w hole intact: 
293kcal, 60 .Og carbohydrate and 5.6g  fibre and w hole m illed: 283kcal, 57.4g  
carbohydrate and 5.4g fibre. Please see appendix 1A  fo r recipes and com plete nutritional 
composition.
The Fibre and Inulin Trial in Male Adults: the FITMA trial
As in  the P ilo t W IS E  tria l, the F IT M A  tria l used three bread ro ll-lik e  intervention  
products. These were: (i) the control product containing the refined grain m atrix  only; ( ii)  
the wheat fibre product containing 4 .6%  by w eight V IT A C E L ®  wheat fibre W F  600 D V , 
a w hite fine-fibrous dietary fibre pow der, (JRS, Netherlands) in  a refined grain m atrix; 
( iii)  the inulin product containing 4 .4%  O ra fti®  H P X  inulin , a fine w hite powder high 
perform ance chicory inu lin  (O ra fti® , B elgium ) in a refined grain bread-roll like  m atrix.
2.1.1 Human intervention products
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Approximate nutritional compositions o f the products per lOOg o f the final product were: 
control: 256kcal, 50.7g carbohydrate and 2.5g fibre; wheat fibre: 220kcal, 43.4g 
carbohydrates and 7.7g fibre; inulin: 239kcal, 47.4g carbohydrate and 7.6g fibre. Please 
see appendix IB for recipes and complete nutritional composition and appendix 2A  and 
B for wheat fibre and inulin data sheets respectively.
2.1.2 Reagents and kits
Reagents and kits used for sample treatment, isolation and analysis during all 
parts o f the investigation are listed below.
Antibodies
For the IL-8 ELISA, mouse anti-human IL-8 antibody and biotinylated mouse 
anti-human IL-8 antibody were purchased from Invitrogen, U K  Mouse mouse anti-tPA-1 
antibody and peroxidase conjugated sheep anti-human anti-tPA-1 antibody were 
purchased from Calbiochem, UK and CEDARLANE, UK respectively. For the vWF 
ELISA, rabbit anti-human vWF and rabbit anti-human vWF-HRP antibody were sourced 
from DAKO Cytomation, U K  Mouse anti-human-TNF-a and biotinylated mouse anti 
human-TNF-a were sourced from BD-Pharminogen, U K  Polyclonal rabbit anti-human 
CRP antibody and polyclonal rabbit anti-human CRP-HRP were sourced from 
Dakocytomation, UK
For the fluorescence activated cell scanning (FACS), referred to in further text as 
flow cytometry, analysis o f activation markers on endothelial cells, antibodies were 
directly conjugated to FITC or phychoerythrin (PE). Anti-PECAM-l-FITC was sourced
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from Sigma-Aldrich, UK. Anti-ICAM-1 -PE, anti VCAM -1-FITC, mouse IgGIK-FITC 
and mouse IgGIK-PE were purchased from BD Biosciences, Belgium.
Chemicals and kits
All chemicals used were o f analytical grade, unless part o f a kit.
Citrate phosphate tablets (Sigma-Aldrich, UK)
Dimethyl sulphoxide (Sigma-Aldrich, UK)
Direct HDL cholesterol kit (Randox, UK)
Griess reagent kit (Invitrogen, UK)
Horseradish peroxidase conjugated-avidin (Dakocytomation, UK)
Human insulin specific radio-immuno assay (Millipore, UK)
Human serum C-reactive protein high control (Dakocytomation, UK)
Human ultrasensitive cytokine 10-plex panel (Invitrogen, UK)
IL Test™ cholesterol kit (Instrumentation Laboratory, Italy)
IL Test™ glucose kit (Instrumentation Laboratory, Italy)
IL Test™ triacylglycerides kit (Instrumentation Laboratory, Italy)
Industrial methylated spirit (Merck, UK)
Interleukin-8 standard (Invitrogen, UK)
MTT based cell growth determination kit (Sigma-Aldrich, UK)
Non-esterified fatty acids kit (Randox, UK)
Novex® HRP chromogenic substrate (TMB, Invitrogen, UK)
Paraformaldehyde (Sigma-Aldrich, UK)
Phosphate-buffered saline (PBS) tablets (Invitrogen, UK)
Polysorbate (Tween®) 20 (Sigma-Aldrich, UK)
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Purified human tissue plasminogen activator-1 standard (Calbiochem, UK)
Purified recombinant human interferon-y standard (National Institute o f Biological 
Standards and Controls, UK)
Purified recombinant human tumour necrosis factor-a standard (National Institute of 
Biological Standards and Controls, UK)
Quintikine® human sIC AM -l/C D 54 kit (R&D, UK)
Saline, sterile Macoflex 0.9%  sodium chloride solution (Macopharma UK Ltd, UK) 
Sodium acetate (Sigma-Aldrich, UK)
Sodium azide (Sigma-Aldrich, UK)
Sodium hypoxanthine, aminopterin and thymidine growth supplement (Invitrogen, UK) 
Sodium propionate (Sigma-Aldrich, UK)
Tetramethylbenzidine dihydrochloride (TMB, Sigma-Aldrich, UK) 
von Willebrand factor standard (National Institute o f Biological Standards and 
Controls, UK)
Buffering solutions
Carbonate/bicarbonate (BIC) buffer, 0.1M , was prepared from 0 .1M anhydrous 
sodium carbonate (Na2C0 3) and sodium bicarbonate (NaHC03), pH adjusted to 9.6 using 
concentrated hydrochloric acid. FACS buffer was prepared from phosphate buffered 
saline (PBS), prepared from tablets as per the manufacturers instructions and 
supplemented with 1% bovine serum albumin (BSA) and 0.05%  sodium azide.
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HPLC grade acetonitrile and methanol, laboratory reagent grade formic acid and 
analytical grade sodium hydroxide were sourced from Fisher Scientific, UK. Water was 
purified using an Elga PureLab Ultra system (Elga, UK) and leucine enkephalin (lock 
mass) was purchased from Sigma-Aldrich, UK.
2.1.3 Cell culture
Cell culture media and chemicals
High glucose Dulbecco’s Modified Eagle Medium (DMEM) with glutamax-1 was 
sourced from Invitrogen, UK and Microvascular Endothelial Growth Medium (EGM -2) 
and Roswell Park Memorial Institute (RPMI) media were purchased from Lonza, U K  F- 
12K medium was sourced from LGC Promochem, UK.
Endothelial Growth Factor (EGF), heparin sodium salt, gelatin and 
hydrocortisone were purchased from Sigma-Aldrich, UK. Hank’s balanced salt solution, 
trypsin-EDTA, foetal bovine serum and penicillin/streptomycin were sourced from 
Invitrogen, UK. The EGM-2 bullet kits containing hydrocortisone, human endothelial 
growth factor, vascular endothelial growth factor, human fibroblastic growth factor-B,
R3-insulin-like growth factor-1, ascorbic acid, gentamicin/amphotericin-b and heparin, 
were supplied by Lonza, U K  Lonza also provided HEPES buffered saline solution, 
tiypsin and trypsin neutralisation buffer as a reagent kit for use with the EGM-2 media; 
Endothelial cell growth supplement was purchased from Millipore, UK.
Metabolomics reagents
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The cell lines HMEC-1 (human microvascular endothelial cell-1) and EA.hy.926 
were gifts from the University o f Reading and Dr. Green at The University o f Surrey 
respectively. The primary human coronary artery endothelial cells (HCAEC) were 
purchased from Lonza, UK.
2.2 Human intervention studies
Human studies were carried out in the Clinical Investigation Unit (CIU) o f the 
University o f Surrey with medical cover available during all participant attendance. 
Favourable ethical opinion from the Advisory Committee on Ethics o f the University o f 
Surrey was gained for both Pilot WISE (reference EC/2006/89/SBM S) and FITMA 
(reference EC/2007/73/FHM S) studies. Laboratory analysis was carried out in the 
Faculty o f Health and Medical Sciences (FHMS) at the University o f Surrey and St 
George’s Hospital.
2.2.1 Participant recruitment
Recruitment material for the Pilot WISE and FITMA trials can be found in 
appendix 3 A  and B respectively. Participants were recruited using poster advertisements 
placed in multiple sites on the campus o f the University o f Surrey and emailed to students 
and staff These adverts were also placed in the local press to attract participants from the 
wider population. Both men and post menopausal women were recruited to the Pilot 
WISE trial (n =  19). Men only were used in FITMA to maintain homogeneity within a 
group o f only n =  10. Inclusion criteria included a post-menopausal state for women, an 
age o f 30 to 60 years for men and a Body Mass Index (BMI) o f 25 to 35 kg/m2 (please
Cells
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see section 2.2.3.1). A  waist circumference greater than 34inches (86cm) for men or 
31.5inches (80cm) for women was included in the posters as an inclusion criteria for the 
Pilot WISE trial. However, this was not found to be useful as participants were not found 
to have accurate knowledge o f their waists and often did not have the equipment to 
accurately measure them. Therefore, this was not used as a recruitment criterion in the 
FITMA trial, although measurements were still taken and recorded. A  BMI o f greater 
than 25kg/m2 confers a greater risk o f CVD than does a lower BMI (Kenchaiah S 2002), 
thus BMI was used as an inclusion criterion.
All potential participants completed a previously validated Health and Lifestyle 
Questionnaire (appendix 4) developed by the researchers for the purpose o f this 
intervention. This was used, with a Food Frequency Questionnaire (FFQ), to screen out 
ineligible participants, such as habitual high consumers o f whole grains. Any reporting a 
history o f type II diabetes, cardiovascular disease or food intolerance were excluded from 
participation. Further exclusion criteria included:
• drinking more than 21 units o f alcohol per week,
• undertaking regular sessions o f vigorous exercise or fitness training (over three 30 
minute aerobic exercise sessions per week),
• previous or current medical conditions such as heart disease, diabetes, 
gastrointestinal disorders, liver disease, depression, psychological disorders, 
eating disorders, drug or alcohol abuse,
• weight-reducing diets or if under dietary restriction,
• regularly including five or more servings o f refined or whole grains per day,
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• taking any prescription medicines or supplements within the past six months.
The previously validated Dutch Eating Behaviour Questionnaire (DEBQ, 
appendix 5) was designed in the light o f increasing appreciation o f the complexity o f 
eating behaviour and the aetiology o f obesity (van Strien T 1986). It was used in this 
research to screen out participants determined to be restrained or disordered eaters, those 
who display strong emotional or external eating cues and tendencies.
A  haemoglobin monitor (201+Hb monitor, HemoCue, Sweden) was used during 
screening to ensure that any participants presenting symptoms o f anaemia (as determined 
by a circulating haemoglobin level o f less than 14g/l) were excluded from the study. 
Fresh blood was immediately placed onto an auto-analyser compatible cuvette which was 
inserted into the auto-analyser to give an instant reading o f haemoglobin concentration as 
per manufacturer’s instructions.
2.2.2 Trial design and protocols
Both the Pilot WISE and the FITMA trials required participants to consume a 
specified amount o f bespoke bread roll-like intervention products per day throughout the 
course o f the trial. This delivery method, providing participants with their complete daily 
requirements in given portions, was aimed to promote compliance and monitoring.
The first intervention o f the FITMA trial was preceded by a 14 day ‘run in’ diet, 
employed to minimise inter-individual variations at baseline. This was not considered 
necessary for the Pilot WISE trial as the number o f participants was much greater, thus
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minimising the effects o f inter-individuai differences without additional requirements for 
the participants.
2.2.2.1 The Pilot WISE trial protocol
The Pilot WISE trial was a randomised controlled parallel dietary intervention to 
investigate the effects o f whole intact and whole milled grain products compared to a 
refined grain control product on risk markers o f cardiovascular disease. Please see 
appendix 1A  for composition and nutrition information o f the intervention products. 
Participants’ levels o f certain CVD risk markers were measured pre- and post-eight week 
interventions with one o f these products. Please see figure 2.1 for a schematic o f the time 
lines involved.
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Figure 2.1: Outline and time course of the 8 week Pilot WISE trial. Men and women 
at risk o f cardiovascular disease (men aged 30 -  65 years and post-menopausal women, 
BMI 25 -  35kg/m2) were screened and completed a 7 day diet diary, followed by the 
initial study day, the 8 week dietary intervention with one o f the three intervention 
products (whole intact grain, whole milled grain or control product), then repeated the 7 
day diet diary and the final study day.
A  power calculation on the estimated fall in post-prandial insulin area under the 
curve o f 20%  between groups (which would be metabolically significant) with a standard 
deviation o f 20%  would give an estimate o f 17 per group. As there is no previous study 
o f this type in this area o f research it was aimed to recruit 20 per group but with an 
interim calculation o f 12 per group for the purposes o f this, the pilot phase o f the trial. 
This calculation was based on work by Frost et al in 1998 also investigating a primary 
end point o f a 20%  reduction in post-prandial insulin area under the curve. If the results 
o f the pilot phase suggest a significant change may be achieved with a fully powered 
study, further participants will be recruited for a Main WISE trial if resources allow. 
Therefore, a further objective o f the Pilot WISE trial was to determine the need for o f a
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Main and fully powered, WISE trial, by assessing the interim data for the possibility o f a 
significant result
Screening required a 12 hour fasted, morning visit to the CIU, University o f 
Surrey, for freely given informed consent (see appendices 6 and 7 respectively for the 
Participant Information Sheet and Consent Form) and a haemoglobin blood test. 
Participants were asked to consent to GP notification o f their participation (see appendix 
8 for the GP letter). This safety measure was designed to enable the GP to contact the 
investigator should they feel participation would not be appropriate. Consented 
participants were randomly assigned via the online tool www.randomisation.com to one 
o f the three study arms: whole intact grain, whole milled grain or control intervention 
products, stratified by sex only.
On the initial day o f the intervention, day one, participants attended the CIU in the 
early morning, having consumed a standardised meal o f their choice on the previous 
evening (to be repeated prior to the subsequent study day) chosen from a list o f pre­
prepared ‘ready meals’ with known macronutrient compositions. Repeating this meal 
before each study morning ensured standardisation between study days to minimize any 
last meal effects. Participants then fasted for 12 hours overnight. Participants refrained 
from strenuous exercise for 24 hours before study initiation. Participants were cannulated 
(Y-Can 21G with syringe valve, Beldico, Belgium) by a suitably trained individual to 
allow blood samples to be taken. Two 30ml fasting blood samples (at minus ten minutes 
and time zero), blood pressure readings and anthropometric measurements were taken. 
Participants then consumed a standard test breakfast o f 250ml o f a hot chocolate-like
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drink (505.8kcal, 18.9g protein, 59.4g carbohydrate and 21.4g fat) containing neither 
whole nor refined grains (please see appendix 9 for further information). Half hourly 
10ml blood samples were then taken for three hours post intake. Participants were offered 
refreshment and a chance to rest and were free to leave with their first allocation o f 
intervention products. Serum and plasma as appropriate were analysed for tissue- 
plasminogen activator-1, von-Willebrand factor, soluble intercellular adhesion molecule- 
1, C-reactive protein, interleukin-8, interleukin-6, full metabolite profiles, total 
cholesterol, HDL-cholesterol, triglycerides, non-esterified fatty acids, insulin and 
glucose.
Following this, participants were required to consume two portions daily o f their 
assigned intervention product for the next eight weeks, with the active products providing 
48g whole grains per day (providing three portions daily o f 16g whole grains) as 
recommended by the Whole Grains Council, (www.wholegrainscouncil.org). The 
products were made available to the participants regularly and were either distributed at 
the CIU or delivered to the participants in a timely fashion to promote compliance. 
Participants were contacted fortnightly during the eight week intervention by a 
Registered Dietitian to answer any questions and to promote compliance. At the 
beginning o f the eighth week (Day 49), participants were posted a food diary for 
recording their habitual intake. On the last day o f the eight week intervention participants 
returned to the CIU for the post-intervention assessment day, a repeat o f day one. 
Participants were remunerated for their time and inconvenience and all reasonable 
expenses incurred as a result o f participation in the study were refunded on provision o f a 
valid till receipt.
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The FITMA trial was a randomised controlled cross-over dietary intervention trial 
of two active dietary reference products, insoluble and soluble fibre, represented for the 
purposes o f this research by wheat fibre and inulin respectively, and a control reference 
product. The lipid lowering effects o f inulin observed in animals followed high doses, the 
equivalents o f which would be unacceptably high in humans, due to the associated 
adverse gastrointestinal (GI) effects. The dose o f 15g/day was chosen following C 
William’s Review on the lipid-lowering effects o f Inulin feeding studies in animals and 
humans (Williams C 1999) as an optimized level to induce lipid lowering effects but 
minimize GI side effects. As such, the dose o f 15g/day was also used for wheat fibre for 
the purposes o f standardisation.
Screening for the FITMA trial required a 12 hour fasted, morning visit to the 
Clinical Investigation Unit o f the University o f Surrey, for an information session, freely 
given informed consent (please see appendices 10 and 11 respectively for the Participant 
Information Sheet and Consent form) and a haemoglobin blood test. I f participants 
consented, a letter was sent to their GP outlining the study and the implications o f 
participation.
The primary end-point o f this study is a statistically significant change in insulin. 
Therefore, sample size calculations based on a change in insulin have been used. A  
sample size o f 12 per group would have at least 80%  power to detect a clinically 
significant drop in insulin o f 20pM (a difference to detect o f 25% ) between the groups, 
assuming that the common standard deviation is 16pM or 20%  and using a two sample t-
2.2.2.2 The FITMA trial protocol
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test with a 0.05 two sided significance level. The sample size allowed for 10% o f the 
subjects to be non-evaluable in each treatment group. The estimate o f the standard 
deviation was based on published data for subjects who took part in a Resistant Starch 
Study o f a similar design conducted by Robertson et al (2005). Ten participants 
successfully completed the trial, thus power was achieved.
Participants were randomly assigned to the wheat fibre, inulin or control group for 
Stage 1 o f the study using the on line randomization tool (www.randomization.com).
Each stage lasted for 28 days. After Stage 1 was complete, the participants were assigned 
to a different intervention group for Stage 2, this process o f rotation continued until all 
participants had completed all three interventions. Between each stage was a ‘wash out’ 
stage o f an equal length o f time, 28 days. Although it was not possible to determine 
whether the wash out period was effective, as baseline measurements were not taken 
prior to each successive intervention diet, it was reasoned that any carry over effects o f 
the diet would be removed by following a washout o f the same duration as the 
intervention. Participants were required to consume three servings per day (5g o f active 
ingredient per serving, providing 15g in total per day) o f the relevant intervention 
product.
Throughout the study, participants were supplied with the appropriate intervention 
products in a timely fashion to promote compliance. Hand over o f the products occurred 
either at the CIU or at a place specified by the participant for delivery o f the product. 
Extra portions were provided to cover any losses reported and participants were asked to 
return any surplus rolls. This encouraged compliance and alerted the investigators to any
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problems with tolerance or missed portions. Products were delivered fresh to the CIU and 
frozen for storage and deliver to participants. Shelf life, once defrosted was 
approximately two days. For an outline o f the protocol and time-line o f events, please see 
figure 2.2.
Figure 2.2: Outline and time course of the FITM A protocol. The 14 day run in diet 
was followed by each o f the three 28 day intervention diets (wheat fibre, inulin and 
control) in turn, in a randomised order, with the 28 day wash out diets between them. 
Post-prandial (PP) study days, taking anthropometric measurements (height, body fat % , 
weight, waist, blood pressure) and blood samples for circulating markers and metabolic 
profiles, occurred at baseline and post-each intervention treatment.
Participants were asked to limit their whole grain consumption to less than three 
portions per day for the two week run-in diet prior to commencing the study, minimising
7 8
whole grain intake and thus individual variation at baseline. Participants refrained from 
strenuous exercise for 24 hours before the initiation o f the study. On the initial study day, 
participants attended the CIU in the morning having consumed a standardised meal o f  
their choice (to be repeated the evening before the remaining study days) the evening 
before and then fasted for 12 hours overnight. Blood pressure and anthropometric 
measurements were taken. Participants were cannulated (Y-Can 21G  with syringe valve, 
Beldico, Belgium) by a suitably trained individual and two fasting 25ml blood samples 
were taken at minus 10 minutes and time zero. An oral glucose tolerance test (OGTT) 
was then carried out over the course o f the following three hours (see section 2.2.3.4) in 
which participants consumed a standard glucose test drink (containing 75g o f glucose in 
water) which did not contain either whole grains or fibre and 5ml blood samples were 
taken every 15 minutes for two hours post intake, then half hourly for the remaining hour. 
After this the cannula was removed and participants were offered refreshments and an 
opportunity to rest Prepared serum and plasma samples (please see section 2.2.3.3) were 
stored and later analysed as appropriate for tissue-plasminogen activator-1, von- 
Willebrand factor, soluble intracellular adhesion molecule-1, C-reactive protein, 
interleukin-8, interleukin-6, full metabolite profiles total cholesterol, HDL-cholesterol, 
triglycerides, non-esterified fatty acids, insulin and glucose.
After the OGTT session, participants were given a 28 day supply o f the relevant 
intervention product to consume over the following four weeks. Participants were free to 
follow their normal lifestyle and diet during this time with the inclusion o f three servings 
o f the intervention products per day in the place o f their habitual grain products, 
including bread, pasta and cereals, so as not to affect the overall energy consumption. It
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was requested that participants return prior to the beginning o f each new intervention diet 
for a repeat o f the baseline study visit but after discussions o f the protocol feasibility with 
potential participants it was felt this would be too much o f a burden on participants and 
would significantly adversely affect recruitment. Therefore, the initial baseline was used 
for comparison across the intervention diet. At the end o f the 28 days, participants 
attended the CIU for a repeat o f the initial study morning followed by an equal length (28 
day) wash-out period aimed to remove any o f the active component or its effects. 
Following the wash-out period, each participant began their 28 day intervention on the 
next product. This was ended with a study day to repeat the measurements taken in the 
previous study day for comparison. The cycle was then repeated with a 28 day wash out 
period and the consumption o f the final investigational product for a further 28 days.
During the wash-out stages, no intervention products were provided to the 
participants and they were required to follow their habitual diets. The final study day 
ended participation. Participants were contacted regularly during the intervention stages 
by a Registered Dietitian (RD) to ensure any questions they had were answered, to 
promote compliance and to take a verbal 24 hour recall o f diet.
All study mornings were identical in methodology and risk markers measured. All 
collected food diaries were reviewed by the RD with the participants. Participants were 
compensated for their time and inconvenience and all reasonable expenses incurred as a 
result o f participation o f the study were refunded on provision o f a valid till receipt.
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2.2.3 Plasma, serum, anthropometric and diet diary collection and storage
2.2.3.1 Anthropometric data collection
Height was measured using a stationary stadiometer. Participants removed their 
shoes and stood erect looking straight ahead in the horizontal plane and with feet together 
and knees to the front. Height was measured to the nearest 0 .1cm. Three readings were 
taken at baseline and averaged and no significant changes in height were assumed to 
occur over the course o f the trial. The participant’s height was entered into the Tanita 
Bio-Impedance Body Composition Analyser TBF-300 (Tanita Europe B V , Netherlands) 
to allow for further anthropometric analysis.
Total body mass (kg) and body fat composition as a percentage o f total body mass 
was measured and calculated using a Tanita analyser (the same instrument was used for 
each measurement on each study day) following the standardised procedures frilly 
described in the literature. Participants were asked to urinate immediately prior to the 
measurement to remove excess body water which can adversely affect measurements. 
Participants wore light clothing, with empty pockets and no shoes or belts, wearing 
similar clothes on each study day to maintain consistency between measurements. An 
allowance was made o f 1.5kg for clothes’ weight. Participants removed their socks and 
shoes and were asked to step onto the foot plates o f the Tanita analyser ensuring equal 
weight distribution between the feet and checking trousers were not beneath the heels 
thus reducing contact area. Measurements were taken to the nearest 0.1kg. The Tanita 
analyser also calculated BM I, via the following equation:
BMI =  weight (kg) 
height (m2)
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A BMI o f 25 to 30kg/m2 (defined as ‘over-weight’) was a pre-requisite for both 
studies. Waist and hip measurements were taken at the navel and widest point around the 
buttocks respectively by an RD to the nearest 0.5cm using a flexible tape measure, with 
participants standing erect as for height measurements, with the arms relaxed at the side 
o f the body and the participant facing straight ahead.
2.2.3.2 Dietary intake
Habitual dietary intakes were recorded using previously validated three or seven 
day diet diaries. The RD explained diary completion to participants and analysed the 
completed diaries using WinDiets (WinDiets Research, 2005, Scotland) to determine the 
effect o f the interventions on the habitual dietary intake o f the participants and monitor 
compliance. Compliance was further monitored by giving each participant an exact 
number o f surplus servings o f each intervention product than required for the study 
period and asking them to return any remaining unused with discrepancies being counted 
and recorded. Participants were also asked on each visit if they had consumed all, or 
missed any, o f the portions.
2.2.3.3 Blood collection
Venous blood was drawn from an intravenous cannula placed in the antecubital 
vein in the forearm o f participants by a suitably trained phlebotomist. Blood was taken 
into the following specific BD vacutainer® tubes: EDTA (dipotassium 
ethylenediaminetetraacetic acid, K2EDTA) tubes for total cholesterol, LDL, TAGs, 
NEFA and insulin determination in plasma; SST™ tubes for determination o f
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inflammatory markers and metabolomic profile in serum; fluoride tubes (containing 
sodium fluoride and potassium oxalate) for determination o f glucose.
SST™ tubes were inverted three times, incubated at room temperature for 30 
minutes and centrifuged at 1750 x g for 10 minutes at 4°C. All other tubes were inverted 
three times and were centrifuged immediately at 1750 x g for 10 minutes at 4°C. 
Supernatants, (serum and plasma) were removed using Pasteur pipettes and aliquoted into 
2ml microtubes for storage (at -20°C for plasma samples and -80°C for serum samples) 
for future analysis as appropriate.
2.2.3.4 Oral glucose tolerance test
The oral glucose tolerance test (OGTT) is a provocation test used by the World 
Health Organisation (W HO) in the primary diagnosis o f diabetes, by examining the 
efficiency o f the body at processing glucose. Participants were prepared for the OGTT as 
stated by W HO guidelines for adults as follows:
• three days unrestricted carbohydrate rich diet and activity,
• no medication on the day o f the test,
• 12 hours fasted,
• no smoking,
• glucose load o f 75g in 300 to 400ml water.
Blood samples (5ml) were taken for baseline at minus 10 minutes and time zero. 
Further 5ml blood samples were taken at 15 minute intervals up to, and including, 120
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minutes, then every 30 minutes for one hour. Glucose concentration in plasma was the 
determined on an iLab 650 and the method outlined in section 2.2.4.2.
2.2.4 Circulating markers of vascular health
Markers chosen for analysis were as follows. The haemostatic factors tissue 
plasminogen activator-1 because o f its critical role in the immune response to injury and 
infection within the vasculature (Kumar V  2003; Majno G 2004) and its relationship with 
increased CHD risk (Gram J 2000), and von Willebrand factor due to its role in blood 
coagulation and its proven status as a risk marker for CHD (Meade T 1994; Thompson S
1995). The inflammatory factor soluble intercellular adhesion molecule-1 was 
investigated because o f its role in leukocyte adhesion to the endothelium (Yang L 2005). 
IL-6 was chosen because o f its involvement o f the proliferation and maturation o f 
granulocytes which is upregulated during the immune response and its regulation o f CRP 
production (Pepys M  2003); IL-8 was investigated as it is responsible for the activation 
and chemoattraction o f neutrophils to the site o f inflammation. CRP was investigated due 
to its role in inflammation via the induction o f ICAM -1 and VCAM -1 (Pasceri V  2000) 
and its suggest role as a risk marker for CVD (Ridker P 2000) and CHD (Koenig W  
1999; Danesh J 1998). The circulating lipid profiles o f total, HDL and LDL cholesterol, 
and TAG were investigated because o f their proven associations with CHD (Gordon T 
1997, Assman G 1999 and Hokanson J 1996 respectively). NEFA levels have also been 
proposed as relating to CVD risk and were investigated as such (Semenkovic C 2004). 
Markers o f insulin sensitivity, fasting and post-prandial insulin and glucose, were 
investigated as insulin resistance is a known risk marker for CVD (Hsueh W  1998; Ruige 
J 1998).
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Tissue plasminogen activator-1
An in-house ELISA was used to measure circulating levels o f tissue plasminogen 
activator-1 (tPA-1) in serum samples. The 96 well, flat bottomed NUNC Immunolon 
ELISA plates were coated with 50pJ/well mouse mouse anti human-tPA-1 at 0.83pg/ml 
in 0 .1M Na2HPC>4 pH 9.0 and incubated overnight at 4°C. Plates were washed four times 
with PBS containing 0.05%  Tween 20 (PBS-T), blocked with 150pl/well PBS containing 
2%  bovine serum albumin (PBS-BSA) and incubated for 60 minutes at room 
temperature. Plates were washed four times with PBS-T containing 0.2%  BSA (PBS-T- 
BSA) then 50pl/well standards (diluted in PBS-T-BSA) over a range o f 30 to O.Olng/ml 
or samples (diluted 1/2 in PBS-T-BSA) were added in triplicate. Plates were incubated 
overnight at 4°C and washed four times with PBS-T-BSA. Fifty pl/well l.Opg/ml 
peroxidase conjugated sheep anti-human tPA-1 antibody (diluted in PBS-T-BSA) was 
added and plates were incubated for 60 minutes at room temperature. Plates were washed 
four times with PBS-T-BSA and 50pl/well 2.0pg/ml horseradish peroxidase conjugated- 
avidin (avidin-HRP) diluted in PBS-T-BSA was added and plates were incubated for 30 
minutes at room temperature and washed three times in PBS-T, twice in PBS and twice in 
citrate phosphate buffer. Tetramethylbenzidine (TMB, 0.1 mg/ml in 0.05M  citrate 
phosphate buffer, pH5.0) at 50pl/well was added to allow colour to develop, followed by 
the addition o f 12.5pl/well 2M  H2SO4 to stop the reaction and the absorbance o f the 
solution was read at 450nm on a BioTek® ELx800 microplate reader (BioTek®, USA). 
The inter-assay coefficient o f variance for this in-house ELISA is routinely 8-10%  
(personal communication, Dr Bodman-Smith).
2.2.4.1 Haemostasis
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An in-house ELISA was used to measure circulating levels o f von Willebrand 
factor (vWF) in serum samples. ELISA plates were coated with 50pi/well 2.0pg/ml rabbit 
anti-human vWF in 0.1M  BIC buffer and incubated overnight at 4°C. Plates were washed 
four times with PBS-T, blocked with 150pl/well PBS-BSA and incubated for 60 minutes 
at room temperature. Plates were washed four times with PBS-T-BSA and 50pl/well 
standards over the range o f 1.0 to O.OOlIU/ml in PBS-T-BSA or samples (diluted 1/2 in
PBS-T-BSA) were added in triplicate. Plates were incubated overnight at 4°C. Plates
*
were washed four times with PBS-T-BSA then 50pl/well 0.125pl/ml rabbit anti-human- 
vWF-HRP (in PBS-T-BSA) was added and plates were incubated for 60 minutes at room 
temperature. Plates were washed three times in PBS-T, twice in PBS and twice in citrate 
phosphate buffer (pH5.0). TMB (50pi/well) was added to each well followed by 
12.5pl/well 2M  H2SO4 and the absorbance o f the wells was read at 450nm. The inter­
assay coefficient o f variance for this in-house ELISA is routinely 6-8%  and quality 
controls o f known concentration were included (personal communication, Dr Bodman- 
Smith).
2.2.4.2 Markers of Inflammation 
Soluble Intracellular adhesion molecule-1
Levels o f circulating soluble intracellular adhesion molecule-1 (sICAM -1) in 
participants’ serum were quantified using a Quintikine® Human sICAM -l/CD 54 
Immunoassay kit according to the manufacturer’s instructions. Briefly, lOOpl sICAM-1 
horseradish peroxidase conjugated anti-sICAM-1 monoclonal antibody was added to 
mouse monoclonal anti-sICAM-1 antibody coated wells. One-hundred pl/well standard,
von Willebrand factor
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control (provided lyophilised recombinant human sICAM-1 in buffer with preservatives) 
or serum sample (diluted 1/20) was added and the plate was incubated at room 
temperature on an orbital shaker (GFL 3005 Orbital Shaker) at 500rpm for 90 minutes. 
Wells were aspirated and washed four times with 400pl wash buffer. Two-hundred 
{il/well o f the reaction substrate, a 1:1 mixture o f stabilized hydrogen peroxide and 
stabilised tetramethylbenzidine (acting as a chromogen) was added. The plate was 
protected from light and incubated at room temperature for 30 minutes. Fifty pl/well o f 
2M  sulphuric acid was added. The intensity o f each well was read at 450nm (reference 
filter 540nm).
Intei leukin-6 and interleukin-8
Serum interleukin-6 (IL-6) and interleukin-8 (IL-8) concentrations were 
determined using the human ultrasensitive cytokine 10-plex panel for GM-CSF, IL -lp , 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-y and TNF-a according to manufacturer’ s 
instructions. Briefly, 200pl/well working wash solution was used to pre-wet plates (30 
seconds at room temperature) and was removed by aspiration. Twenty-five pl/well 
protein-specific capture antibody conjugated bead solution, with beads o f defined spectral 
properties, was added. From this stage, plates were protected from light. Plates were 
washed twice with working wash solution as above. One hundred pl/well o f appropriate 
standards and samples (diluted Vz with assay diluent) was added and incubated for two 
hours at room temperature on an orbital shaker (500 to 600rpm). The liquid was aspirated 
and the plates washed twice. One hundred pl/well biotinylated detector antibody was 
added and incubated for one hour at room temperature on an orbital shaker (500 to 600 
rpm). The liquid was aspirated and the plate was washed twice. One hundred pl/well
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streptavidin-RPE was added and incubated for 30 minutes at room temperature on an 
orbital shaker (500 to 600 rpm). After three further washes, lOOpl/well working wash was 
added and plates were read on a Luminex® 100™  instrument.
C-neactive protein
An in-house high sensitivity ELISA was used to measure circulating levels o f 
CRP in serum samples. ELISA plates were coated with 50pl/well rabbit mouse anti 
human-CRP at 2 jig/ml in 0.1M  BIC buffer and incubated overnight at 4°C. Plates were 
washed four times with PBS-T, blocked with 150pl/well PBS-BSA and incubated for 60 
minutes at room temperature. Plates were washed four times with PBS-T then 50 pl/well 
standards (diluted in PBS-T-BSA) over a range o f 0.3 to O.OOOOlpg/ml or samples 
(diluted 1/100 in PBS-T-BSA) were added in triplicate. Plates were incubated for 60 
minutes at 37°C and washed four times with PBS-T. Fifty pl/well 0.325pg/ml peroxidase 
conjugated rabbit anti-human CRP antibody (diluted in PBS-T-BSA) was added and 
plates were incubated for 60 minutes at 37°C. Plates were washed three times with PBS- 
T, once in PBS and twice in citrate phosphate buffer. TMB (50pl/well) was added, 
followed by 12.5pl/well 2M  H2SO4 and the absorbance was read at 450nm. The inter­
assay coefficient o f variance for this in-house ELISA is routinely 6 to 10% (personal 
communication, Dr Bodman-Smith).
2.2.5 Metabolomics
Fifty pi defrosted serum samples (stored at -80°C) were vortexed for two minutes 
with 200pl chilled (-80°C) methanol and incubated at 4°C for 30 minutes to precipitate
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proteins. Samples were centrifuged at 1800 x g for 10 minutes and supernatants were 
transferred to high pressure liquid chromatography (HPLC) vials for analysis.
Chromatography was performed on a Waters Acquity UPLC™  system (Waters, 
UK) using an Acquity BEH C-18 column (2.1 x 30mm, 1.7pm, Waters, UK). The 
column oven and autosampler temperatures were 40°C and 4°C respectively. The mobile 
phases were: (A) 0.1%  formic acid in water, and (B) acetonitrile with 0.1%  formic acid. 
The linear gradient program was: 100% (A) for 0.5 minutes, a linear increase to 100%
(B) over 8.5 minutes, a switch back to 100% (A) and maintenance for one minute. This 
had a total cycle time o f 10 minutes, a flow rate o f 600pl/min and an injection volume of 
5 pi, using partial loop mode.
Mass spectrometry was carried out on a Waters Mircomass QToF Premier™ 
system (Waters, UK) operating in both positive and negative ion electrospray modes. The 
source and the desolvation temperatures were 120°C and 450°C respectively, with 
nebulisation gas set to 8001/h and collision energy set to 4eV. The capillary and cone 
voltages were: 3.1kV and 30V  respectively in positive ionisation mode, and 3.0kV and 
35V respectively in negative ionisation mode. A  LockSpray™ interface was used to 
ensure mass accuracy. Leucine-enkephalin was infused at 200pg/pl at a flow rate o f 
lOpl/m.
Data was visualized and analysed using Waters MassLynx (V  4.1) and Waters 
MarkerLynx (4.1). Background ions identified in associated blank injections were 
excluded. The mass and retention time windows were set at 0.05 Da and 0. Im
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respectively. Multivariate analysis was performed and visualized using SIMCA-P (V I2, 
Umetrics, Sweden). The dataset was ‘autofit’ and visualized by principal component 
analysis (PCA) to highlight any differences between groups. Further analysis was 
performed to visualise discrimination between the sample groups. Six and four group 
partial least squares discrimination analyses (PLS-DA) were used for the Pilot WISE and 
FITMA trials respectively to further investigate discrimination between groups. Where 
appropriate, a PLS-DA loadings plot and a variable importance on projection (VIP) plot 
o f the first component were used to determine any discriminatory species between 
groups. Any such species were investigated, through their single ion chromatograms 
(SIC) and mass spectra, to remove false positives and identify the parent ions o f any 
adducts. The signal intensities o f those species found to be true ions were analysed 
outside the analysis platform for significant differences and for any species found to be 
significantly different between groups, elemental composition analysis was performed 
using Masslynx. Such ions were then identified putitatively using the metabolite 
databases (Human Metabolite Database, www.hmdb.ca; METLIN, metlin.scripps.edu; 
KEGG, www.kegg.com).
2.2.6 Measurement of circulating markers of CVD risk
As a reflection o f CVD risk, participant’s blood was analysed at baseline and after 
each intervention treatment for a number o f circulating risk markers.
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2.2.6.1 Circulating lipids 
Total cholesterol
Plasma total cholesterol concentrations were measured using an iLab 650 auto­
analyser and an EL Test™ cholesterol kit (Instrumentation Laboratory, Italy) following 
manufacturer’s instructions, via end point trichromatic analysis, with measurements taken 
at primary and blanking wavelengths o f 510 and 700nm respectively.
High density lipoprotein cholesterol
Plasma high density lipoprotein (HDL) cholesterol concentrations were measured 
using an iLab 650 auto-analyser (Instrumentation Laboratory, Italy) using a Randox, UK  
direct HDL cholesterol kit according to manufacturer’s instructions, via a two step 
enzymatic colourimetric method read at 600nm.
T riacylglycerides
Plasma triacylglyceride (TAG) concentrations were measured using an iLab 650 
auto-analyser using an EL Test™ triacylglyceride kit (both from Instrumentation 
Laboratory, Italy) via an enzymatic analysis at 510nm.
Low density lipoprotein
Low density lipoprotein (LDL) concentrations were calculated from the measured 
values o f total cholesterol, HDL cholesterol and TAG via the Friedewald equation 
(Friedewald W  1972):
LDL cholesterol =  total cholesterol -  (HDL cholesterol +  (0.2 x TAG))
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Non-esterified fatty acids
Plasma non-esterified fatty acids (NEFA) concentrations were measured via an 
iLab 650 auto-analyser (Instrumentation Laboratory, Italy) using anRandox, UK, direct 
non esterified fatty acid kit according to manufacturer’s instructions, via a colorimetric 
principal, at 550nm.
2.2.6.2 Markers of insulin sensitivity 
Insulin
Insulin concentrations were determined using a human insulin specific radio- 
immuno assay (RIA) according to the manufacturer's instructions. Assay buffer was 
added to the relevant tubes: 300pl to the non-specific binding (NSB) tubes, 200pi to the 
reference (Bo) tubes and lOOpl to the sample tubes. One hundred pl/tube standards and 
quality controls were aliquoted in duplicate. One hundred pl/tube hydrated 125-insulin was 
added followed by lOOpl/tube human insulin antibody. All tubes were vortexed, covered 
and incubated overnight at room temperature. One ml/tube 4°C precipitating reagent was 
added, tubes were vortexed, incubated for 20 minutes at 4°C and centrifuged at 4°C for 
20 minutes at 2500g. Supernatants were decanted and tubes were drained for 30 seconds. 
Any excess liquid was blotted from the lips o f tubes. Samples were analysed and insulin 
concentrations calculated in a 1470 Wallac Wizzard gamma counter with Multicalc level 
4.M  automated data reduction procedure software (Wallac International, Finland).
Glucose
Plasma glucose concentrations were measured on an iLab 650 auto-analyser 
(Instrumentation Laboratory, Milan, Italy) and an assay kit following the manufacturer’s
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instructions. The glucose contained within the sample oxidised with oxygen and water in 
the presence o f the enzyme glucose oxidase resulting in production o f gluconic oxide and 
hydrogen peroxide. The quinoneimine concentration o f the sample was then determined 
at 510nm.
Area under the curve
The areas under the curve (AUC) o f the post-prandial study interventions were 
calculated using the trapezoid rule: area =  width x (hi +  h2)/2, where hi =  height o f side 
1 and h2 =  height o f side 2.
Insulin and glucose C-max and T-max
The peak concentrations (C-max) o f insulin and glucose reached over each post­
prandial study were calculated as a mean average o f each individual’s peak 
concentration, within each intervention treatment.
The time taken to reach the peak insulin and glucose concentrations (T-max) over 
the course o f each post prandial study were calculated as the mean average o f each 
individual’s time to peak concentration, within each intervention treatment.
2.2.7 Cell culture methods
2.2.7.1 Cell media
EA.hy.926 cells were cultured in Dulbeco’s Modified Eagle Media (DMEM), a 
high glucose media containing glutamax-1, with added 10% heat-inactivated foetal 
bovine serum (FBS), penicillin/streptomycin (pen/strep) at lOOU/ml and 1OOpg/ml 
respectively and HAT supplement (sodium hypoxanthine 0.1 pM, animopterin 0.4pM  and
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thymidine 16.0pM) a post-fusion selective medium. HMEC-1 cells were cultured in 
DM EM  with added 10%  heat-inactivated foetal bovine serum (FBS), 
penicillin/streptomycin (pen/strep) at lOOU/ml and lOOpg/ml respectively, lpg/m l 
hydrocortisone and lOng/ml epidermal growth factor. HCAECs were cultured in EGM ®- 
2M V containing the recommended bullet kit additives of: hydrocortisone, endothelial 
growth factor, vascular endothelial growth factor, fibroblastic growth factor-B, R3- 
insulin-like growth factor-1, ascorbic acid, heparin and gentamicin/amphotericin-B at the 
recommended concentrations.
2.2.7.2 Cell culture maintenance
Methods employed were similar for each cell type, with differences outlined 
below. Cell pellets were frozen down in liquid nitrogen in 90%  FBS and 10% dimethyl 
sulphoxide. Vials were brought up for use by rapid defrosting by immersion in a 37°C  
water-bath. Using aseptic technique, 37°C media was then added drop-wise to the cells. 
Cells were plated at the appropriate seeding density in small cell culture flasks.
Cell detachment
Adherent endothelial cells were detached for sub-culture and seeding as follows. 
Cells were washed with 37°C magnesium and calcium free Hanks' balanced salt solution. 
Two ml/25cm2 0.05%  trypsin-EDTA in Mg2+ and Ca2+ free BBSS was added and 
incubated for the following times by cell type: HMEC-1 2 to 5 minutes, HAAECs 5 to 10 
minutes and HCAECs 2 to 6 minutes. Once cells were fully detached from the flask an 
equal volume o f the relevant media was added to halt tiypsinisation. Cells were 
transferred to 50ml tubes and centrifuged at 240 x g at 4°C for 5 minutes. The supernatant
containing the trypsin and media was discarded and cells were resuspended in medium 
and re-centrifuged as above as a wash step. The supernatant was discarded and cells were 
resuspended in the relevant fresh culture medium, counted using a modified Neubauer 
haemocytometer and plated at the required densities.
Subculture
EA.hy.926 and HMEC-1 cells were seeded at 104/ml weekly for sub-culture and 
at lx l0 5/ml for treatment. HCAECs were seeded at 2.5xl04/ml for subculture and at 
lx l0 5/ml for treatment. Each cell type was confluent for treatment after a 72 hour 
incubation.
2.2.1 YS Cell treatment 
Reagent preparation
Tumour necrosis factor-a and interferon-y were provided as freeze-dried residues 
o f lm l solutions containing either natural BALL-1 cell derived human tumour necrosis 
factor-a or human leukocyte derived interferon-y respectively. The contents o f each 
ampoule, (approximately 46,500IU TNF-a and 3000IU IFN-y), was dissolved in 0.5ml 
sterile, distilled water and transferred separately to sterile tubes. Ampoules were rinsed 
with 0.4ml sterile, distilled water which was also transferred to the relevant tube and the 
volume o f each was made up to lm l, giving concentrations of46,500IU /m l TNF-a and 
3000IU/ml IFN-y. These stock solutions were aliquoted and stored at -80°C. Upon use, 
aliquots were diluted to the required concentrations in the relevant media.
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Fresh 1M stock solutions o f both sodium acetate and sodium propionate were 
filtered through 0.45pm filters and used at final concentrations o f 0.1, 1.0, 10 and lOOpM 
to cells pretreated with TNF-a/EFN-y for 24 hours.
2.2.7.4 Cell culture analysis methods -  cell surface markers
Levels o f expression o f intracellular adhesion molecule-1 (ICAM -1), vascular cell 
adhesion molecule-1 (VCAM -1) and platelet-endothelial cell adhesion molecule-1 
(PECAM-1) were determined by fluorescence activated cell scanning (FACS) referred to 
in future text as flow cytometry. These markers were chosen for analysis because ICAM - 
1 and VCAM -1 are instrumental in the leukocyte-endothelial cell attachment and 
PECAM-1 is involved in the endothelial cell-endothelial cell attachment controlling 
migration out through the endothelium; thus they play important rolls in plaque 
development and altered levels may be associated with risk o f CVD. Fresh cells were 
harvested (as described in section 2,2.7.2) and washed in ice cold FACS buffer. Cells 
were incubated with the relevant fluorochrome-labeled monoclonal antibody stains and 
controls (table 1.1) and made up to a final volume o f 30pl/stain with ice-cold FACS 
buffer, protected from light, at room temperature for 45 minutes at 4°C. Cells were 
washed twice in ice cold FACS buffer and resuspended in 200pl 2%  paraformaldehyde. 
Fixed cells were examined using a Becton Dickinson FACScan flow cytometer and data 
were analysed using WinMDI 2.8 software (Microsoft). Cell populations were gated by 
size and granularity.
Investigational compounds
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Antibody Mg/well
Unstained control -
Iso-PE 0.6
ICAM -1-PE 0.6
Iso-FITC 0.5
VCAM -1-FITC 0.5
PEC A M -1 -FITC 0.5
Table 1: Per well concentration of each antibody stain used for flow cytometry 
analysis. Cells were stained using fluorescently labeled antibodies for determination o f 
surface levels o f the cellular adhesion molecules ICAM -1, VC AM -I and PEC A M -1 via 
FACS; pg/well are indicated and each antibody was made up to 30pl/we 11 with ice cold 
FACS buffer.
2.2.7.5 Cell culture analysis methods -  secreted haemostatic markers
tPA-1 was investigated because o f its role in clot dissolution. It has previously 
been associated with increased CHD risk (Gram J 2000) and acute myocardial infarction 
(Thogerson A  1998). vWF is considered an established risk marker for CHD and was 
investigated as such (Meade T 1994; Thompson S 1995).
Tissue plasminogen activator-1 and von Willebrand factor
Levels o f tPA-1 and vWF in media were determined via in-house ELISA as 
outlined in section 2.2.5.1 above.
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IL-8 was investigated because o f its role in firm attachment o f rolling monocytes 
to the endothelium (Gerszten R 1999) and as it has been suggested as a possible risk 
marker for CVD (Herder C 1006) and cardiovascular events (Inoue T 2008). NO is vital 
in maintaining haemostasis and has a protective effect on the endothelium (Gibbons G
1996); as such it has been suggested that altered levels are associated with CVD risk and 
so this marker was also investigated.
Interleukin-8
An in-house ELISA was used to measure secreted IL-8 in the cell culture 
supernatants. Briefly, ELISA plates were coated with 50pl/well 0.5pg/ml mouse anti­
human IL-8 antibody in BIC buffer and incubated overnight at 4°C. Plates were washed 
four times with PBS-T, blocked with 150pl/well PBS-BSA and incubated for 60 minutes 
at room temperature. Plates were washed four times with PBS-T-BSA. Fifty pi IL-8 
standard (diluted in PBS-T-BSA) over a range o f 100 to 0.03pg/ml, and samples (diluted 
1/2 in PBS-T-BSA) were added in triplicate to the relevant wells. Plates were incubated 
overnight at 4°C. Plates were washed four times with PBS-T-BSA. Fifty pl/well 
0.25pg/ml biotinylated mouse anti-human-IL-8 antibody in PBS-T-BSA was added and 
plates were incubated for 60 minutes at room temperature followed by four washes with 
PBS-T-BSA. Fifty pl/well 2.0pg/ml Avidin-HRP in PBS-T-BSA was added and plates 
were incubated for 30 minutes at room temperature then washed three times in PBS-T, 
twice in PBS and twice in citrate phosphate buffer. Fifty pl/well 0.1M  
tetramethylbenzidine (TMB), in citrate phosphate buffer, was added to each well. To stop 
the reaction 12.5pl/well 2M  H2S 0 4 was added and the absorbance o f the solution was
2.2.7.6 Cell culture analysis methods -  secreted inflammatory markers
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read at 450nm. The inter-assay coefficient o f variance for this in-house ELISA is 
routinely 5 to 8% (personal communication, Dr Bodman-Smith).
Nitric oxide
The Griess reagent kit employs the diazotization reaction to 
spectrophotometrically detect nitrite as a marker o f nitric oxide. Samples or standards 
(150pl), 130pl de-ionised RO water and 20pl Griess reagent (equal volumes o f JV-(1- 
naphthyl) ethylenediamine and sulfanilic acid) were incubated in duplicate for 30 minutes 
in 96 well plates. Spectrophotometric absorbance was measured at 550nm.
2.2.7.7 Cell culture analysis methods — cell viability
Mitochondrial dehydrogenase activity, which reduces 3-(4,5-dimethyl-thiazol-2- 
yl)-2 ,5-diphenyl tetrazolium bromide to a purple formazan in active mitochondria, was 
used to determine cell survival in a colorimetric assay as per manufacturer’s instructions 
(MTT assay, ViaLight®, Lonza). Cell viability was calculated using the following 
equation:
Cell viability =  Absorbance (treated sample) x 100 
Absorbance (medium treated sample)
2.3 Statistical analysis
The statistical analysis package, GraphPad Prism® version 5.01 (GraphPad, 
USA), was used for all data and statistical analysis. Due to their biological nature and the 
small values ofn , data were considered to follow a Gaussian distribution for the purposes 
o f analysis. In the Pilot WISE trial, paired Student’s t-tests were used were to determine
9 9
the significance o f any differences within groups, pre- to post-intervention for all 
correlations. In the FITMA trial, a repeated measures analysis o f variance (ANOVA) 
with a Bonferroni’s multiple comparison post-hoc test was used to determine any 
significant differences between treatment interventions.
In the in vitro work, the nitrite time course was analysed using a Student’s t-test to 
determine any significant differences between the nitrite levels at each time point and 
treatment. Two way AN OVA was used to look for any effect o f the treatments on the 
expression and/or secretion o f endothelial markers. Statistical significance was assumed 
if p<0.05.
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Chapter 3
T h e  Pilot W I S E  trial
A  pilot r a n d o m i s e d  c o n t r o l l e d  parallel d i e t a r y  in t e r v e n t i o n  
trial investigating t h e  effects o f  h i g h  w h o l e  intact g r a i n  a n d  
w h o l e  milled g r a i n s  o n  risk m a r k e r s  o f  c a r d i o v a s c u l a r  
d isease in a t  risk individuals
3.1 Study rationale and alms
The pathology o f CVD involves the inflammatory condition atherosclerosis, the 
build up o f fatty plaques within the artery wall and the dysfunction o f the vascular 
endothelial functions: vasodilation, thrombosis, haemostasis and tissue perfusion (Rush J 
2005). Known risk markers include a chronic inflammatory state, insulin resistance and 
dyslipidaemia. Many CVD risk markers are non-modifiable (e.g. age, sex and ethnicity) 
but certain factors are modifiable, with dietary interventions posed as a non-invasive 
method o f reducing risk. High whole grain diets have a history o f association with 
reduced CVD risk. Most evidence, however, is observational. The aim, therefore, o f the 
Pilot Whole grain Intervention Study in England (Pilot WISE) trial was to investigate the 
impact o f whole grains by providing a high whole grain diet via a randomised controlled 
parallel dietary intervention trial and monitoring CVD risk markers for changes. This was 
assessed in at risk men and post-menopausal women (aged 48.4 ±  11.7 years, BMI 28.8 ±
3.1 kg/m2) as their baseline levels o f CVD risk markers would be more responsive to an 
intervention than those o f low risk individuals (figure 3.1). The delivery method was 
unusual as interventions were provided in bespoke bread-like products to be substituted 
into the diet in the place o f the habitually consumed grain products such as bread, cereals 
and pasta. Eligible, consented participants were randomised in a ratio o f 1:1:1, stratified 
by sex only, to receive an eight week dietary intervention o f whole intact or whole milled 
grain or the refined control grain products. Participants consumed two portions daily 
(providing 48g whole grain as recommended by the Whole Grains Council) o f their 
intervention product. End points covered a range o f markers associated with endothelial 
function, dysfunction and whole body risk and were measured (fasting and post- 
prandially) pre- and post-each intervention treatment.
This chapter contains the products of joint research between myself, Laura Tripkovic
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Figure 3.1; Pilot WISE trial protocol. The Pilot WISE trial was a randomised 
controlled parallel dietary intervention trial involving participants at risk o f CVD (aged 
30 -  65 years, BMI 25 -  35kg/m2). Screening including food frequency questionnaires 
(FFQ to exclude those with a high intake o f whole grains) and Dutch eating behaviour 
questionnaires (DEBQ) were followed by randomisation to one o f three, eight-week 
intervention treatments o f whole intact grain, whole milled grain or control products. 
Study days involving anthropometric and fasting and post prandial blood measurements 
were carried out before and after the intervention.
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The author worked in equal collaboration with Drs L. Tripkovic and C. Bodinham 
on the Pilot WISE trial. The author was responsible for one third o f all activities 
including, but not limited to: trial design, authorship o f trial paperwork (including 
protocol, participant information sheets, recruitment paperwork and Trial Master File), 
informed consent sessions, management o f participants’ completion o f paperwork 
including FFQ and Health and Lifestyle Questionnaire, phlebotomy, participant 
management and care, sample preparation, storage and analysis. The author was not 
responsible for the collection or analysis o f the diet diary data; this was carried out by Dr 
L. Tripkovic. The author was entirely responsible for all other data analysis presented; 
data analysis was not carried out in collaboration.
Markers o f vascular haemostasis and inflammation such as tissue plasminogen 
activator-1 (tPA-1) and von Willebrand factor (vWF), soluble intra-cellular adhesion 
molecule-1 (sICAM -1), interleukin-6 (IL-6), interleukin-8 (EL-8) and C-reactive protein 
(CRP), have been demonstrated to vary with inflammatory status and CVD pathology 
and were, therefore, chosen as useful indicators o f endothelial health.
Metabolite profiles, as determined via liquid chromatography/mass spectrometry 
(LC/M S), reflect the current status o f the metabolome as a snap-shot in time and, as such, 
provided a novel approach to determine the effects o f whole grain on metabolic pathways 
and metabolite profiles possibly identifying diet-specific biomarkers.
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Levels o f the circulating lipids have a well established link with CVD, as do 
insulin and glucose with respect to type II diabetes, which itself is a strong risk marker 
for CVD. Thus, these factors provided important surrogate markers for the risk o f CVD.
It was hypothesised that levels o f risk markers would vary to reflect a lower CVD  
risk state post-intervention with the active high whole intact and milled grain diets, when 
compared to the baseline and the control refined grain diet.
3.2 Pilot WISE trial anthropometric and dietary data 
Anthropometric data
Anthropometric measurements were taken at the beginning o f each study day. No 
significant differences were seen in any measurements when comparing pre- to post­
intervention with any o f the three dietary interventions.
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Control Pre-intervention Post-intervention
Age/years 45.9 + 12 .2
Weight/kg 86.5 ±  13.7 86.8 + 1 3 .4
BMI/kg/m2 28.3 3.1 28.5 +  3.1
Waist circumference/cm 101.7 ± 8 .4 101.4 ± 7 .7
Body fat/% of total body weight 29.6 ±  8.2 29.5 ± 8 .1
Systolic BP/mmHg 120.9 ± 1 0 .5 123.6 +  13.2
Diastolic BP/mmHg 71.9 5.6 79.6 ± 6 .5
Whole Intact Grain Pre-intervention Post-intervention
Age/years 51 .4+4.8
Weight/kg 90.9 +  22.2 90.8 ± 2 2 .1
BMI/kg/m2 28.9 ± 3 .9 28 .9+3.8
Waist circumference/cm 103.6 +  13.1 101.8 ± 1 2 .6
Body fat/% of total body weight 32.4 ± 5 .6 32.7 ± 6 .1
Systolic BP/mmHg 132.1 ± 7 .9 125.4 ± 1 0 .3
Diastolic BP/mmHg 82.4 ± 9 .5 78.4 ±  6.4
Whole Milled Grain Pre-intervention Post-intervention
Age/years 45.4 + 1 6 .7
Weight/kg 92.1 ±17 .1 93.7 ±16 .1
BMI/kg/m2 29.5 ± 2 .8 30.0 +  2.7
Waist circumference/cm 102.11 ± 1 2 .0 102.8 +  8.9
Body fat/% of total body weight 31.6 +  6.4 31.0 ± 7 .1
Systolic BP/mmHg 128.7 ± 1 0 .3 129.1 ± 1 2 .3
Diastolic BP/mmHg 77.0 ± 3 .7 72.0 ± 6 .2
Table 2: Pilot WISE trial anthropometries. Age, weight, body mass index (BMI), 
waist circumference, body fat percentage and systolic and diastolic blood pressure (BP) 
data are separated to pre- and post- each dietary intervention o f control (n =  6), whole 
intact grain (n =  6) and whole milled grain (n =  5). Data displayed as mean ±  standard 
deviation.
Diet diary data
Seven day diet diary data (post-intervention data including the intervention 
products) were collected during each intervention. Data was collected and analysed by 
Dr. L. Tripkovic, University o f Surrey. No significant differences were observed either at 
baseline between the intervention groups or following any o f the interventions.
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Control Pre-intervention Post-Intervention
Calories/kcal 2094.7 +  378.9 2348.7 +  450.6
Fat/g 66.1 +  15.3 79.7 +  26.3
Saturated fatty acids/g 2 2 .3 + 4 .6 28.3 +  11.7
Non-starch polysaccharides/g 15 .1+5.1 14.6 +  4.6
Protein/g 81.2 +  31.5 84 .5+ 2 4 .6
Polyunsaturated fatty acids/g 11.4 +  4.9 12 .5+ 6 .2
Cholestcrol/mg 260.3+208.1 237.7 +  37.6
Starch/g 102.3 +  48.1 159.7 +  45.9
Carbohydrates/g 274.8 +  80.1 286 .2+ 49 .6
Sugar s/g 118.7 +  72.0 106.7 +  35.3
Whole intact grain Pre-intervention Post-intervention
Calories/kcal 1970.5 +  354.5 2510.0 +  526.7
Fat/g 74.7 +  22.9 74 .3+ 2 0 .5  '
Saturated fatty acids/g 26.7 +  8.2 25.9 +  7.8
Non-starch polysaccharides/g 14.1+5.1 2 3 .5 + 6 .5
Protein/g 7 3 .1 + 9 .4 90.4 +  12.5
Polyunsaturated fatty acids/g 10.9 +  6.9 11.8 +  7.4
Cholesterol/mg 214 .8+118 .0 234.2 ±1 1 7 .4
Starch/g 98.3 +  21.9 197.5 +  83.6
Carbohydrates/g 246.0 +  46.5 355,1 +87 .4  i
Sugars/g 117.4 +  40.8 112.5 +  58
Whole milled grain Pre-intervention Post-intervention
Calories/kcal 2674.6 +  448.2 2393.2 +  293.9
Fat/g 108.6 +  12.3 85.6 +  22.1
Saturated fatty acids/g 3 6 .2 + 4 .5 27.4 +  9.5
Non-starch polysaccharides/g 18.6 +  3.5 15.82 ± 7 .5
Protein/g 92.9 +  26.6 87.6 +  18
Polyunsaturated fatty acids/g 17.0 +  3.1 15 .3+ 5 .8
Cholesterol/mg 226.2 +  82.3 189.0 +  66.3
Starch/g 144.8 +  98.5 163.8 +  22.2
Carbohydrates/g 340.6 ±77 .1 309.8 +  41.6
Sugars/g 153.2 +  38.6 115.0 ± 2 9 .7
Table 3: Pilot WISE trial diet diary data. Seven day diet diary data are separated to 
pre- and post- each dietary intervention o f control (n =  6), whole intact grain (n = 6) and 
whole milled grain (n =  5). Data displayed as daily mean +  standard deviation. Data were 
compiled and analysed by Dr L. Tripkovic.
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3.3 The effect of whole intact and whole milled grains on serum markers of vascular
health
3.3.1 Haemostatic factors
Due to their roles in maintaining haemostasis and their contribution to vascular 
health, the haemostatic factors selected for analysis were tissue-plasminogen activator-1 
(tPA-1) and von-Willebrand factor (vWF).
Tissue plasminogen activator-1
Fasting concentrations o f the fibrinolytic factor tPA-1 were measured at baseline 
and after each eight week intervention o f control, whole intact grain or whole milled 
grain products as described in 2.2.4.1. Figure 3.2 shows no significant differences at 
baseline. The mean tPA-1 concentration after the control diet was 6.31ng/ml compared to 
5.04ng/ml before it. The test diets gave slightly lower tPA-1 levels when compared to 
pre-intervention, with pre-to post-ratios o f7.50:7.03ng/ml for the whole intake grain and 
8.25:6.19ng/ml for the whole milled grain. There were, however, no significant 
differences in fasting total tPA-1 concentration due to any o f the interventions when 
comparing pre- to post-intervention with all mean concentrations in the range o f 5.04 to 
8.25ng/ml.
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Figure 3.2: Fasting tPA-1 concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Fasting 
tPA-1 concentrations were measured in each participant (n = 18) pre- and post-each 8 
week intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain 
(W M G A ) products using an in-house ELISA. Individual values displayed with mean +  
standard error. No significant differences were found using a paired Student’s t-test.
von Willebrand factor
As illustrated in Figure 3.3, no significant differences in concentrations between 
groups were found at baseline. A trend is displayed in the data, with each intervention 
reducing the level o f vWF. The control diet concentrations average to 11.4IU/ml pre- and 
7.8IU/ml post-intervention. The whole intact grain intervention concentrations were 
12.7IU/ml pre- and 9. llU /m l post-intervention and the whole milled grain concentrations 
were 18.6IU/ML and 10.13IU/ml. There were, however, no significant differences in 
fasting total vWF concentration due to any o f the interventions, when comparing pre- to 
post-intervention, per treatment intervention.
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Figure 3.3: Fasting vWF concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Fasting 
vWF concentrations were measured per participant (n = 18) pre- and post-each 8 week 
intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain (W M G  
A ) products via in-house ELISA. Individual values displayed with mean + standard 
error. No significant differences were found using a paired Student’s t-test.
3.3.2 Inflammatory markers
Due to their role in vascular inflammation and potential contribution to CVD risk, 
the markers soluble-ICAM-1, IL-8, IL-6 and CRP were selected for measurement.
Soluble intracellular adhesion molecule-1
As alterations in the levels o f shedding of, and therefore circulating levels of, 
adhesion molecules can be indicative o f vascular activity, fasting soluble-ICAM-1 
concentrations were measured at baseline and after each eight week intervention o f 
control, whole intact grain or whole milled grain products as described in 2.2.4 2. Figure
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3.4 shows that mean concentrations o f sICAM-1 did not vary significantly at baseline and 
were not altered significantly due to the intervention.
Figure 3.4: Fasting sICAM-1 concentrations pre- and post-each 8 week dietary 
intervention of control* whole intact grain or whole milled grain product. Fasting 
sIC A M -1 concentrations were measured in each participant (n = 19) pre- and post-each 8 
week intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain 
(W M G A ) products using a Quantikine® human sICAM-1 immunoassay kit. Individual 
values displayed with mean +  standard error. No significant differences were found using 
a paired Student’s t-test.
Interleukin-8
Figure 3 .5 illustrates an increase in IL-8 concentrations for both the control and 
whole intact grain diets, at 5.21pg/ml pre- and 7.01pg/ml post-intervention and 
7.189pg/ml pre- and 8.2pg/mlpost-intervention respectively. The whole milled grain diet 
shows a very little difference pre- to post-intervention at 7.88 and 7.30pg/m, with no 
significant differences.
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Figure 3.5: Fasting IL-8 concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Fasting IL- 
8 concentrations were measured in each participant (n = 17) pre- and post-each 8 week 
intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain (W M G  
A ) products using a human ultrasensitive cytokine 10-plex panel kit on a Luminex® 100. 
Individual values displayed with mean ±  standard error. No significant differences were 
found using a paired Student’s t-test.
Interleukin-6
The pro-inflammatory cytokine interleukin-6 was measured at baseline and after 
each treatment intervention o f control, wheat fibre and inulin. Circulating levels were 
below the level o f detection o f the high sensitivity Luminex kit used (data not shown).
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As a stable, yet sensitive marker o f inflammation and a putative risk marker for 
CVD (Ridker P 1998), fasting levels o f CRP were measured. Figure 3.6 shows that all 
mean values were in the range o f 0.465 and 0.915mg/l and there were no significant 
differences in fasting total CRP concentration due to any o f the interventions.
C-reactive protein
Figure 3.6: Fasting CRP concentrations pre- and post-each 8 week intervention of 
control, whole intact grain or whole milled grain product. CRP concentrations were 
measured in each participant (n = 18) pre- and post-each 8 week intervention of control 
(C •), whole intact (W IG ■) or whole milled grain (W M G A ) products via high 
sensitivity in-house ELISA. Individual values displayed with mean +  standard error. No 
significant differences were found using a paired Student’s t-test.
3.4 The effect of whole intact and whole milled grains on metabolite profiles
An untargeted liquid chromatography linked mass spectrometry (LCZMS)-based 
metabolomics analysis was carried out in order to assess whether the applied dietary 
intervention rich in whole intact or whole milled grains has an affect on plasma 
metabolite profiles o f high risk men and post-menopausal women.
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Figure 3.7: The principal component analysis and partial least squares discriminate 
analysis score plots illustrating the metabolite profiling data No significant 
differences were found for any ions o f pre-control , post-control ■ , pre-whole intact
grain ■, post-whole intact grain •, pre-whole milled grain ♦ and post-whole milled grain 
♦. A) shows the PC A plot with variation o f 4.6%  and model parameters R20 .102 and Q2 
0.0498. B) shows the PLS-DA score plot with 3.6%  variation and model parameters R2 
0.193 and Q2 0.675.
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Figure 3.7 A  above shows a principal component analysis (PC A) score plot o f the 
data with no grouping. Variation was observed to be 4.6%  and 3.2%  respectively, due to 
the first 2 principal components. Figure 3.7B illustrates a score plot from a six-group 
partial least squares discriminate analysis (PLS-DA) model o f the data. No clear 
discrimination was observed between groups. Furthermore, the model parameters R2 
(goodness o f fit o f the model) o f 0.193 and Q2 (predictive ability o f the model) o f 0.675 
were poor, demonstrating low discriminatory power and predictive ability. This 
information suggests that a more extensive analysis o f the data was unnecessary and, 
therefore, no further investigations were carried out.
3.5 The effects of whole intact and whole milled grains on circulating markers of 
CVD risk
3.5.1 Circulating lipids
Traditional risk markers for CVD include high blood levels o f total cholesterol, 
low density lipoprotein (LDL) cholesterol, triacylglycerides (TAG), non-esterified fatty 
acids (NEFA) and low levels o f high density lipoprotein (HDL) cholesterol. It was, 
therefore, important to measure levels o f these risk markers to investigate the impacts o f 
the intervention products in this study.
Total cholesterol
Fasting total cholesterol concentrations were measured at baseline and after each 
eight week intervention o f control, whole intact grain or whole milled grain products as 
described in 2.2.6.L  Figure 3.8 illustrates slight differences at baseline between the three 
groups, none o f which were found to be statistically significant. No significant
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differences in fasting total cholesterol concentration due to any o f the interventions, when 
comparing pre- to post-intervention was observed and all mean levels were in the range 
o f 3.9 to 5.05mM.
Figure 3.8: Fasting total cholesterol concentrations pre- and post-each 8 week 
dietary intervention of control, whole intact grain or whole milled grain product.
Fasting total cholesterol was measured in each participant (n = 19) pre- and post-each 8 
week intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain 
(W M G ▲) products using an IL Test™ cholesterol kit on an iLab autoanalyser. 
Individual values displayed with mean ±  standard error. No significant differences were 
found using a paired Student’s t-test.
High density lipoprotein cholesterol
Figure 3.9 shows that the mean HDL cholesterol concentrations varied over a 
range o f 1.03 to 1.23mM with no significant differences in fasting HDL cholesterol 
concentration, when comparing pre- to post-intervention.
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Figure 3.9: Fasting HDL cholesterol concentrations pre- and post-each 8 week 
dietary intervention of control* whole intact grain or whole milled grain product.
Fasting HDL cholesterol was measured in each participant (n = 19) pre- and post-each 8 
week intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain 
(W M G ▲) products using a direct HDL cholesterol kit on an iLab autoanalyser. 
Individual values displayed with mean +  standard error. No significant differences were 
found using a paired Student’s t-test.
T riacylgly cerides
Baseline levels were not significantly different between groups. Treatments with 
the control and whole milled grain interventions giving the mean TAG as 1.70 and 
1.99mM and 1.235 1.45mM respectively. Figure 3.10 illustrates that there were no 
significant differences in lasting TAG concentration due to any o f the interventions, 
when comparing pre- to post-intervention.
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Figure 3.10: Fasting TAG cholesterol concentrations pre- and post-each 8 week 
dietary intervention of control, whole intact grain or whole milled grain product.
Fasting TAG was measured in each participant (n = 15) pre- and post-each 8 week 
intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain (W M G  
A ) products using an IL Test™ triacylglycerides kit on an iLab autoanalyser. Individual 
values displayed with mean ±  standard error. No significant differences were found using 
a paired Student’s t-test.
The post prandial TAG  response can be altered by dietary changes. To investigate 
if any such long term effect occurred as a result o f the Pilot WISE trial, participant’s 
TAG concentrations were further investigated by measurement before, and for 180 
minutes at 30 minute intervals after, ingestion o f a standard breakfast containing neither 
whole nor refined grains to reflect post-prandial responses as described in 2.2.4.1. This 
occurred pre- and post-each intervention treatment o f control, whole intact grain or whole 
milled grain products. Areas under the curve (AUC) were calculated for each treatment 
intervention to determine the overall effect and no significant differences were shown 
between interventions, or between any intervention and baseline (data not shown).
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Low density lipoprotein cholesterol
LDL cholesterol was calculated from the measurements o f total cholesterol, HDL 
cholesterol and triacylglycerides, using the Friedewald equation and no significant 
differences were determined due to any treatment interventions (data not shown).
Non-esterified fatty acids
Each diet reduced the mean NEFA concentrations but all changes were non­
significant. There were no significant differences, however, in fasting NEFA 
concentration due to any o f the interventions, when comparing pre- to post-intervention 
and no significant differences were observed between the groups at baseline (figure 3.11).
Figure 3.11: Fasting NEFA concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact or whole milled grain product. Fasting NEFA as 
measured (n = 15) pre- and post-intervention o f control (C •), whole intact (W IG ■) or 
whole milled grain (W M G  ▲) products using an IL Test™ non-esterified fatty acids kit 
on an iLab autoanalyser. Individual values displayed with mean ±  standard error. No 
significant differences were found using a paired Student’s t-test.
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To investigate the impact o f the interventions on participants’ post-prandial 
NEFA responses, concentrations were measurement before, and for 180 minutes at 30 
minute intervals after, ingestion o f a standard breakfast to reflect post-prandial responses 
(figure 3 .12). This occurred at baseline and after the eight week interventions o f control, 
whole intact grain or whole milled grain products. Areas under the curve (AUC) were 
calculated for each treatment intervention. The control intervention product AUC was 
showed very little difference at 55.8 pre- and 50.9 post-intervention. The whole intact 
grain intervention AUC showed a similar small difference at 48.1 and 45.0 pre- to post­
intervention and the whole milled grain intervention AUC also showed little difference at
60.1 and 51.0. None o f the differences observed were significantly.
lime (irimrtes)
Figure 3.12: Postprandial NEFA concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Post­
prandial NEFA concentrations were measured before a standardised test breakfast and at 
30 minute intervals for 180 minutes afterwards, to represent post-prandial responses 
Fasting was measured in each participant (n = 15) pre- and post-each 8 week intervention 
of control (Pre-C dashed •, Post-C full •), whole intact grain (Pre-WIG dashed ■ , Post- 
W IG block ■) or whole milled grain (Pre-WMG dashed A , Post-WMG foil A ) products 
using an iLab autoanalyser. Mean displayed +  or - standard error.
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Raised fasting and post-prandial insulin and glucose levels are associated with 
insulin resistance and type II diabetes. These factors have long established links to CVD  
and as such were important to measure in the current study.
3.5.2 Insulin sensitivity
Fasting insulin concentrations were measured at baseline and after each eight 
week intervention o f control, whole intact grain or whole milled grain products as 
described in 2.2.6.2. Figure 3.13 illustrates that no significant differences were seen at 
baseline or following treatment.
Figure 3.13: Fasting insulin concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Fasting 
HDL cholesterol was measured in each participant (n = 15) pre- and post-each 8 week 
intervention o f control (C •), whole intact grain (W IG ■) or whole milled grain (W M G  
A ) products using a human insulin specific radio-immuno assay. Individual values 
displayed with mean ±  standard error. No significant differences were found using a 
paired Student’s t-test.
Insulin
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To investigate the effects o f the intervention treatments on participant’s post­
prandial insulin responses, as indicators o f insulin resistance and type II diabetes risk, 
insulin concentrations were measured over the course o f 180 minutes after ingestion o f a 
standard breakfast containing neither whole nor refined grains to reflect post-prandial 
responses (figure 3.14) via a human insulin specific radio-immuno assay. This occurred 
at baseline and after the eight week treatment interventions. AUC were calculated for 
each treatment intervention and no significant differences were observed between 
interventions, or between any intervention and baseline. The control, whole intact and 
whole milled grain intervention AUC altered from 58,170 to 59,680, from 85,700 to 
63,978 and from 114,513 to 111,672 respectively.
Time (minutes)
Figure 3.14: Postprandial insulin concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Post­
prandial insulin concentrations were measured before a standardised breakfast and at 30 
minute intervals for 180 minutes afterwards. Fasting insulin was measured (n = 16) pre- 
and post-each 8 week intervention o f control (Pre-C dashed •, Post-C full •), whole 
intact grain (Pre-WIG dashed ■, Post-WIG block ■) or whole milled grain (Pre-WMG 
dashed A , Post-WMGfiill A ) products using a human insulin specific radio-immuno 
assay. Mean displayed ±  standard error.
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As there were observed differences in both the maximum insulin concentrations 
reached (C-max), and the times taken to reach maximum concentration (T-max) during 
the post-prandial response, these data were further investigated. The mean C-max o f the 
control intervention treatment group showed little difference at 659pM pre- and 691pM  
post-intervention. This was reversed in the whole intact grain group with the mean peak 
concentration o f the group changing from 935 to 544pM altered from 1371 to 1271pM at 
the mean maximum concentration. None o f these differences, however, were found to be 
statistically significant.
The mean T-max pre- and post- intervention values for the groups were as 
follows: control varied from 48 to 54 minutes; whole intact grain remaining unchanged at 
54 minutes; whole milled grain also unchanged from 50 to 51 minutes. No significant 
differences were found in insulin T-max when comparing pre- to post-any treatment 
intervention (data not shown).
Glucose
Fasting glucose concentrations were measured as a marker o f insulin sensitivity 
and, therefore, type II diabetes risk. Figure 3.15 shows that although baseline levels o f 
fasting insulin were not significantly different between intervention groups and there 
were no significant differences in fasting glucose concentration due to any o f the 
interventions, when comparing pre- to post-intervention. The mean glucose 
concentrations varied from 4.9 to 5.2mM.
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Figure 3.15: Fasting glucose concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Fasting 
glucose was measured in each participant (n = 15) pre- and post-each 8 week intervention 
of control (C •), whole intact grain (W IG ■) or whole milled grain (W M G  A ) produces 
using an IL Test™ glucose kit on an iLab autoanalyser. Individual values displayed with 
mean ±  standard error. No significant differences were found using a paired Student’s t- 
test.
Measurements o f glucose concentration were taken at baseline and after the 8 
week treatment interventions o f control, whole intact grain or whole milled grain 
products.
The control intervention reaches a similar concentration peak pre- and post­
intervention at 7.15 and 7.20mM respectively, with an apparent difference in the times 
taken to reach the peak concentration. The whole intact grains peaked in concentration at 
6.79mM pre-intervention and 6.96mM  post-intervention showing very little variation 
over the intervention and the time taken to reach the peak concentration appears to differ 
pre- to post-intervention. The whole milled grain group’s mean glucose concentration 
was reduced slightly from 8.33mM at baseline to 7.49mM after the intervention although
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this change was not significant, and again the times taken to reach the peak concentration 
appear different when comparing pre- to post-intervention. These data suggest potential 
changes in C- and T-max. AUC were calculated for each treatment intervention. The 
control intervention AUC decreased from 1029 to 1015, the whole intact grain AUC from 
1085 to 1060 and the whole milled from 1033 to 1005. No statistically significant 
differences were observed for any intervention when comparing pre- to post-intervention 
treatment.
Time (minutes)
Figure 3.16: Postprandial glucose concentrations pre- and post-each 8 week dietary 
intervention of control, whole intact grain or whole milled grain product. Post­
prandial glucose concentrations were measured before a standardised breakfast and at 30 
minute intervals for 180 minutes afterwards. Fasting glucose was measured (n = 15) pre- 
and post-each 8 week intervention o f control (Pre-C dashed •, Post-C full •), whole 
intact grain (Pre-WIG dashed ■ , Post-WIG block ■) or whole milled grain (Pre-WMG  
dashed A , Post-WMG full A ) products using an iLab autoanalyser. Mean displayed +  
standard error.
As small differences were seen in both the peak glucose concentration reached 
over the course o f the post-prandial study, and the time taken to reach this peak, these
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factors were further investigated. The post-prandial glucose maximum concentration (C- 
max) reached in the 180 minutes after ingestion o f a standardised test breakfast was 
compared between treatment interventions. C-max was decreased non-significantly in the 
control and whole milled intervention groups and no significant differences were found 
when comparing pre- to post-intervention for any treatment group (data not shown).
The time taken to reach the maximum glucose concentration (T-max) reached in 
the 180 minutes after ingestion o f a standardised test breakfast was compared between 
treatment interventions. The mean glucose T-max for the control intervention group was 
reduced from 45 to 40 minutes. The whole intact grain group showed a reduction from 54 
to 42 minutes and the whole milled grain group showed a reduction from 54 to 48 when 
comparing pre- to post-intervention mean glucose T-max values. No statistically 
significant differences, however, were observed for any intervention treatment Overall, 
mean values for T-max ranged from 42 to 54 minutes (data not shown).
3.6 Discussion
The primary aim o f this research was to investigate the effects o f diets high in 
whole intact grains and whole milled grains on risk markers o f CVD in high risk 
individuals. W e hypothesised that markers o f CVD risk would be altered to reflect a 
reduction in risk following dietary interventions with whole intact and whole milled grain 
intervention products, when compared to the control refined intervention products.
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CVD and the underlying pathology, atherosclerosis, are inflammatory disorders 
reflecting endothelial dysfunction (Rush J 2005). It was key, therefore, to investigate the 
circulating levels of both haemostatic and inflammatory markers, as a reflection of any 
such dysfunction. A protective effect of the diets was hypothesised to have been reflected 
in a reduction in circulating levels o f tPA-1 (a pivotal component of the fibrinolytic 
cascade), in response to reduced levels o f coagulation/fibrinolysis. This was observed in 
49 overweight or obese men and women (BMI 33.7 ±  0.6kg/m2) aged 50.0 +1.1 years, 
showing a significant reduction (p<0.001) in tPA-1 after 52 week interventions of both 
very low carbohydrate, high fat diets and isocaloric high carbohydrate, low fat diets, 
when accompanied by weight loss of 14.9 and 11.5kg respectively (Wycherley T 2010). 
Levels of circulating tPA-1 in the current research, however, showed no significant 
differences at baseline or due to the intervention treatments.
With the exception o f the control intervention baseline each mean, both pre- and 
post-intervention, was found to be within the normal range o f tPA-1 for healthy adults of 
7.77 ±  1.63ng/ml (Gram J 2000). Several groups have shown levels o f 9.3 to 10.9ng/ml 
in individuals with established CVD (Jansson J 1993; Gram J 2000), which are above the 
mean values o f each group in this research, suggesting that baseline levels o f tPA-1 may 
not have been raised enough to reflect a protective response. In support of the current 
study, a similar high whole grain dietary intervention study using the inflammatory 
marker plasminogen activator inhibitor-1 (PAI-1), an inhibitor of tPA-1, showed no 
significant changes after eight weeks of 60g o f whole grains per day, or on a further eight 
week treatment with either 60 or 120g per day (Brownlee 1 2010). Work by Andersson et 
al further supports these results, showing no effect on PAI-1 o f a six week high whole
Haemostatic factors
111
grain intervention (Andersson A 2007). The reduction in tPA-1 observed by Wycherley 
et al was accompanied by significant reductions in PAI-1 (p<0.01) suggesting that levels 
of both markers are responsive to such interventions and may be associated to the weight 
loss. Weight loss also accompanied significant reductions in tPA-1 concentrations in a 
trial investigating meal replacements (Clifton P 2003). As such, this reduction in tPA-1 
could be associated with weight loss rather than the intervention diet, which may explain 
why no reduction was observed in the current study, as weight loss did not occur.
In this study, the participants’ vWF concentrations showed no significant 
differences at baseline, suggesting a physiological homogeneity between the groups in 
terms of coagulation status with respect to vWF. Circulating vWF concentrations were 
reduced after each of the dietary interventions, suggesting a possible alteration in the 
regulation of pro-coagulants, but differences were not statistically significant. Several 
reports have shown that levels of circulating vWF in healthy controls vary between 1.2 
and 1.3IU/ml (Rumley A  1998; Wiman B 2000; Bongers T 2006). The current values are 
similar or higher than these values, perhaps suggesting some of the participants, those 
with the raised levels, may have been at higher risk of CVD, although this is not seen 
across the entire population.
It was hypothesised that the protective effects of the intervention diets would 
reduce circulating levels of the pro-coagulant vWF as was observed in 25 healthy males 
after a 28 day high mono-unsaturated fat diet when compared to a standardised National 
Cholesterol Education Diet (p<0.001 (Perez-Jimenez F 1999)). Such a response could 
potentially reflect reduced risk of coagulation associated with CVD, and, as this was not
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observed in the current research, there may be a role for an intervention investigating the 
fat composition of the diets as a method o f reducing risk markers.
The current results support those of a similar study by Brownlee et al, in which 
the effects o f high whole grain diets on CVD risk markers showed no significant impacts 
on another pro-coagulant fibrinogen, in a trial o f over 300 participants (Brownlee I 2010). 
Brownlee’s participants were overweight so would be expected to be likely to reflect a 
reduction in risk due to the intervention diets, had one occurred. It is possible, therefore, 
that the interventions do not affect vWF as expected. Interestingly, one study observed 
significantly lower levels of vWF and fibrinogen after a 12 week diet including 37 ±  
4g/day of the novel whole grain Salba (Salvia hispanica L) when compared to a control 
high wheat fibre diet and a non-significant trend towards a reduction in the alternative 
coagulation marker factor VUI (Vuksan V  2007) showing that vWF has the potential to 
be altered by dietary interventions. The portion size was similar between the two studies 
but the increased intervention length of the Vuksan et al work may account for the 
differing results. Alternatively, Salba may be more effective than wheat at reducing these 
markers.
If the dietary interventions were protective as hypothesised, the levels of both 
tPA-1 and vWF would have been expected be increased at baseline and to decrease in 
response the active interventions if the participants were at high risk of CVD. This was 
not reflected, though, in the results with baseline levels being in the healthy or slightly 
raised brackets and not changing significantly with the interventions.
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As stated previously, CVD and atherosclerosis are inflammatory disorders, thus it 
was important to investigate cir culating inflammatory factors as markers of risk. Similar 
fasting circulating sICAM-1 levels between intervention groups at baseline suggest 
physiological homogeneity and thus comparable groups. No significant changes occurred 
as a result of the interventions. These data are within the normal circulating range found 
in healthy adults o f 115 to 306ng/ml (Glurich 1 2002) and suggest that none of the diets 
had a significant impact on circulating sICAM-1 levels. As ICAM-1 levels are associated 
with pathogenesis o f atherosclerosis (Hope S 2003), a beneficial effect on the 
endothelium was expected to manifest as a reduction in sICAM-1 levels as observed after 
a three week high fibre, low fat intervention including physical activity in diabetic men 
also showing weight loss (Roberts C 2006). Interestingly, the research by Wycherley et al 
showed a significant reduction (p<0.01) in circulating ICAM-1 following a low 
carbohydrate diet and weight loss but not following a low fat diet and weight loss. 
Additionally, although no significant differences were seen in circulating VCAM-1 
levels, a significant reduction (p<0.001) was observed in circulating E-selectin levels 
(Wycherley T 2010) suggesting, again, that weight loss may play a major role in 
reduction of such circulating factors.
The current results, however, do not reflect such a change and agree with data 
from another high whole grain dietary intervention trial which showed no changes in 
circulating levels of ICAM-1 after eight and 16 week diets of 60g whole grain per day 
(Brownlee 1 2010). Further to this, Brownlee et al also observed no significant changes in 
VCAM-1 and E-selectin, perhaps further suggesting a role for weight loss in alteration of 
circulating markers.
Inflammatory factors
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Other studies have found higher levels o f both IL- 8  (7.8 ±  3.6 pg/ml) and IL- 6  
levels in obese subjects (BMI 47.5 ±  9.4kg/m2  (Jarrar M  2008)) suggesting that IL- 8  and 
IL- 6  levels increase with BMI and, as such, with CVD risk. Levels of circulating IL- 8  in 
patients with CAD were found to be significantly higher than those of controls 
(3.27pg/ml compared to 2.36pg/ml (JhaH 2009)). As such, levels of IL- 8  were 
hypothesised to fall in response to a cardio-protective intervention such as whole grains. 
This was observed in ten participants in response to a high conjugated linoleic acid 
cheese intervention (Sofi F 2009) and twenty healthy participants due to a ten week 
intervention of bespoke ‘Old Italian Grain’ bread (Sofi F 2010), although this was not 
observed in the current research.
No significant differences in EL- 8  were found. Values were higher than those in 
the literature, quoted as 5.6 ±  0.6pg/ml in obese subjects (Bruun J 2005) although other 
research also provides differing values.
Unfortunately, levels of IL- 6  were below the limit of detection in this study 
although as levels of EL- 8  and IL- 6  have been found to correlate with one another (Jarrar 
M 2008) it may be assumed that no significant change in IL- 8  may be indicative of no 
significant change in IL- 6  although this is speculative. Indeed, IL- 6  showed no changes 
in response to a six week high whole grain dietary intervention (Andersson A 2007). As 
an inflammatory cytokine, any protective effect of a dietary intervention on CVD risk 
would be expected to manifest itself as a reduction in circulating IL- 6  levels as was 
shown by the previously mentioned high conjugated-linoleic acid cheese intervention 
(Sofi F 2009) and a three week very low calorie diet in overweight women, when 
accompanied by weight loss (Bastard J 2000). These differences in results may, in part,
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be due to Bastard et aVs participants’ circulating levels already being elevated at baseline 
and, therefore, potentially more responsive to an intervention. The additional intervention 
of the weight loss may also account for the disagreement between studies as previously 
suggested.
As a sensitive marker for inflammatory status, and a putative marker for CVD risk 
(Ridker P 1998), circulating concentrations of CRP were hypothesised to reduce in 
response to the test diet, as was observed in response to high fatty or lean fish 
(300g/week) diets over six months in 52 participants (Pot G2009). Levels o f circulating 
C-reactive protein showed very little variation, with all treatments when compared pre- to 
post-intervention, covering a range of 0.465 to 0.915mg/l, These data are within the 
ranges o f circulating concentrations of CRP for healthy subjects (1.68 + 1.42mg/l) and do 
not reach levels associated with CVD (3.35 +  1.56mg/l, (Glurich I 2002). These data 
support work by Brownlee et al who showed, with a far longer intervention period, that 
no significant differences in circulating CRP levels after eight and 16 week interventions 
of 60g whole grains per day occurred (Brownlee 1 2010) with levels of circulating CRP 
similar to this study.
These data are further supported by a 12 week high fibre whole grain intervention 
in type II diabetic patients also showed no significant reduction in circulating CRP, even 
considering that levels were higher at baseline than in the current research, at 2 . 6  to
3.1 {Jig/ml (Vuksan V  2007). Andersson et al further support these findings, showing no 
significant effect on circulating CRP levels after a six week high whole grain intervention 
(Andersson A 2007) in participants of similar age and BMI values to the current research. 
As CRP is predominantly produced in the liver under the control o f EL-6 , longer
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interventions may be required to alter its circulating levels than those of products 
produced mainly by the endothelium.
As such, the data illustrates that the inflammatory markers sICAM-1, IL- 8  and 
CRP were not significantly altered by any o f the intervention products suggesting that 
either changes in levels o f the markers investigated were not great enough to be detected 
or that the intervention products do not have a significant impact on the endothelium.
Metabolomics
Non-targeted liquid chromatography linked mass spectrometry (LC-MS) 
metabolomic analysis aimed to identify any significant differences in metabolite profiles 
between intervention treatment groups. On analysis o f the data, the relatively weak model 
parameters (R2  0.193 and Q2  0.675) and poor discrimination between sample groups 
meant that no further investigation into the data was conducted. These data suggest that 
the control, whole intact and milled grain intervention products themselves and the wider 
ranging dietary effects of incorporating them into the diet, did not have a significant 
overall impact on metabolite profiles (positive ionisation mode).
As this is an emerging research area and few intervention studies have been 
completed to date it is difficult to compare the results with those expected, although 
limited research has been carried out into the comparison of dietary patterns on the 
circulating metabolic profiles (Stella C 2006) and monitoring the metabolism of specific 
nutrients and identifying novel metabolic pathways (Zhao X  2009). Indeed, in a very 
recent metabolite profiling study, Lankinen et al found a significant increase in multiple 
proinflammatory lysophosphatidylcholines following a wheat bread diet, suggesting that
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dietary carbohydrate modification has the capacity to alter metabolite profiles, 
particularly with respect to the lysophosphatidylcholines (Lankinen M  2010). These 
results may differ from the current research as participants in Lankinen et a /’s study were 
previously diagnosed with metabolic syndrome and were more numerous (n = 1 0  per 
leg). The intervention itself was also longer, at 12 weeks.
Circulating lipids
With known roles in the pathogenesis of atherosclerosis and as established 
markers for CVD risk, measurement o f the circulating lipid profiles was central to this 
research. Differences were observed between the groups at baseline but these were not 
statistically significant. No statistically significant changes were observed in any markers 
measured or calculated i.e. total cholesterol, HDL cholesterol, TAGs, LDL cholesterol or 
NEFAs, due to the intervention diets.
Changes in lipid profiles were expected to mimic those of other similar 
investigations such as those which were observed on an intervention o f 123g/day oat bran 
in 23 mildly hypercholesterolaemic men (Whyte J 1992) and on a four week calorie 
restricted legume-based diet in 30 obese participants (as accompanied by weight loss 
(Hermsdorff H 2010)) which both showed significant reductions in total and LDL 
cholesterol. Similar research showed a significant reduction in total and LDL cholesterol 
and TAG in response to a four week addition of a wheat whole-grain based dietary 
product (200g/day) in 31 obese participants with elevated fasting blood glucose (Rave K  
2007). Differences between such results and those of the current research may be due to 
their higher numbers o f participants, increased amounts of intervention products, a higher 
risk profile population group at baseline, including obesity and elevated blood glucose
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and cholesterol levels which would be expected to be more responsive to dietary 
influence than levels associated with healthy individuals, or the accompanying weight 
loss observed in their studies.
Apart from the baseline mean level for the whole intact grain group at 3.9mM, all 
mean total cholesterol concentrations were found to be above the recommended 4.0mM 
(JBS2 2005), with levels spanning the ‘ideal’ and ‘mildly high risk’ concentrations for 
the general population suggesting that the study population was at mildly raised risk of 
CVD both pre- and post-interventions and, therefore, potentially likely to respond to an 
intervention such as whole grains. These levels, however, were lower than those observed 
at baseline in the trials which did show significant reductions (Whyte J 1992; Rave K  
2007; Hermsdorff H 2010). Both at baseline and post-intervention, levels of HDL 
cholesterol were slightly raised above the recommended values for individuals at high 
risk of CVD (JBS2 2005) showing protective and positive effects. These were reflected, 
however, in the slightly higher total cholesterol levels. Levels o f fasting NEFA 
concentrations fell within the range cited in the literature, of 0.44 to 0.5mM for healthy 
and type II diabetic participants respectively (Pedrini M 2006; Smit J 2008) and showed 
no significant changes, thus suggesting no significant alterations in CVD risk, with 
respect to NEFA, due to the intervention diets.
Once again, these findings are in support of those of the similar dietary 
intervention study by Brownlee et al including 316 participants aged 18-65 years with 
BMI values >25kg/m2 who also showed no significant changes in total cholesterol, HDL 
cholesterol, LDL cholesterol, TAGs or NEFAs in response to eight or 16 week 
interventions of 60g whole grain per day (Brownlee 1 2010). The higher numbers of 
participants included in Brownlee et aV s study reflect higher power of the data and a
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broader representation of the population as a whole. Although the age range was greater 
than in this research it is likely that the group were also at increased CVD risk due to 
their high BMIs and, therefore, likely higher risk of atherosclerosis progression and 
insulin resistance. These results also concur with those of Andersson et al who observed 
no significant differences in total cholesterol, HDL or LDL cholesterol, free fatty acids or 
TAGs in a randomised controlled cross-over trial investigating the effects of a six week 
high whole grain intervention (Andersson A 2007). Participants included 30 men and 
women of similar ages to the current research (35 to 70 years) with similar high BMI 
values o f 28 +  2kg/m2  but with previously diagnosed type II diabetes which might 
suggest an increased CVD risk as hyperglycemia and insulin resistance play pivotal roles 
in the pathogenesis of atherosclerosis (Neri S 2005) and, therefore, more potential for 
alterations in the risk markers. Furthermore, Vuksan et al observed no significant changes 
in total cholesterol, HDL cholesterol, LDL cholesterol or TAGs in response to a 12 week 
intervention of 37 ±  4g/day of the novel whole grain Salba (Salvia hispanica L), rich in 
fibre and minerals (Vuksan V  2007). Participants were both men and women, with a 
higher average age than those of the current research (64 ±  8  years), with similar BMI 
values (28 ±  4kg/m2) and previously diagnosed type II diabetes. Similar concentrations to 
those of the current research were found Vuksan et aVs research.
Overall, investigation o f the established risk markers, the circulating lipid profiles 
suggested that the treatment interventions conferred no reduction in risk of CVD. These 
data suggest that the control, whole intact and whole milled grain interventions had no 
statistically significant impacts on the circulating lipid profiles o f the high risk group 
investigated in this research.
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Fasting and post-prandial serum insulin and glucose concentrations were 
measured as hyperglyacemia and insulin resistance are known to be pivotal in the 
pathogenesis o f atherosclerosis (Neri S 2005) and previous studies have indicated that 
whole grain dietary interventions may beneficially affect factors reflective of insulin 
sensitivity, type II diabetes and CVD risk.
These studies include work by Rave et al, who showed a significant reduction in 
fasting blood glucose and insulin and in the homeostasis model assessment of insulin 
resistance (HOMA IR) in response to high whole grain-based dietary intervention, 
accompanied by significant weight loss (Rave K  2007). Participants in Rave et aVs 
research, however, were obese with elevated fasting glucose levels which are expected to 
be more responsive to protective interventions such as whole grains than healthy levels 
and may explain the differences seen between those results and current research, which 
showed no significant changes in levels o f fasting insulin or glucose in response to any o f 
the treatment interventions. Post-prandial effects, as investigated using the area under the 
curve and although there is a right shift in the curve indicating a beneficial delaying of 
response, no significant effects o f the interventions. This work supports that by 
Andersson et al who showed no significant differences in insulin sensitivity following a 
high whole grain diet as determined by a euglycemic hyperinsulinaemic clamp 
(Andersson A 2007). Brownlee et a /’s results also concurred with this study, showing no 
significant differences in fasting insulin or glucose due to high whole grain interventions, 
in a randomised controlled dietary intervention trial o f the significantly higher number of 
316 participants (Brownlee I 2010). Their group used a modified quantitative insulin 
sensitivity check index as a marker of insulin resistance finding no changes in insulin
Insulin Sensitivity
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sensitivity or resistance. Further support was given by a 12 week study providing 37 ±  
4g/day whole grain intervention in type II diabetics showing no significant reduction in 
fasting insulin or glucose levels of 7.1 to 7.4mM, higher than those observed here 
(Vuksan V  2007).
A high whole grain, controlled cross-over trial in overweight hyperinsulinaemic 
adults lasting six weeks, however, did show a significantly lower fasting insulin 
concentration following a high whole grain diet compared to a control refined grain diet 
(Pereira M  2002). This may be due to the higher baseline levels of insulin than those of 
this study, at 169 ±  16.9pM, which may have been more responsive to positive treatment 
than the levels of this study. In agreement with the current study, Pereira et al showed no 
significant change in fasting glucose levels after a whole grain intervention when 
compared to the refined control diet and no significant difference in post prandial insulin 
AUC.
Overall, this research provides no evidence of whole intact or milled grains 
having an impact on insulin sensitivity as reflected by fasting and post-prandial 
concentrations of insulin or glucose.
Trial limitations
Certain issues are common to all human intervention trials such as those related to 
the population groups investigated, compliance and power. The population group 
investigated in the Pilot WISE trial benefited from including both men and post­
menopausal women although, unfortunately, they were not equally represented with 13 
men and only six women taking part. Participants were also, through no methodological 
design, homogenously Caucasian, thus reducing the potential application of the data
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across the general population. Due to the unavoidable restrictions placed upon 
recruitment, participants were recruited from the University o f Surrey and its associates 
which passively homogenised the group as well educated. Surrey is known to be an 
affluent area, so inhabitants are likely to be at lower risk for incident CHD than those of 
average income (Sundquist K 2004). The general population to whom we hope to apply 
the research would have been better represented had a wider range of socio-economic and 
educational backgrounds been sampled. Although the number of participants involved 
was sufficient for the current pilot research, this value limited the power of the data. 
Involving a higher number of participants in future work would increase the power of the 
data and also allow for stratification o f the data by sex for analysis where relevant.
Pre-menopausal women did not participate as CVD risk is far greater in men and 
post-menopausal woman than in pre-menopausal women due to the protective effects 
conferred by their higher oestrogen levels (Nathan L 1997). Participants were chosen as 
those at increased risk of CVD, as reflected by their age and sex (men and post 
menopausal women aged 30 to 60 years) and high BMI values (25 to 35 kg/m2) as these 
factors are indicative o f high risk (Christie D 1981, Herman B 1982, Nathan L 1997, 
Kenachaiah S 2002). Participants were, therefore, expected to present with altered levels 
of other risk markers (including the inflammatoiy, haemostatic, lipid and carbohydrate 
metabolism markers measured) at baseline and thus a greater potential for change due to 
the interventions.
Unfortunately, this increased risk profile was not observed at baseline, which 
could account for the lack of change in these markers due to the intervention i.e. if they 
did not reflect high risk they were unlikely to be possible to reduce. Levels of markers 
may have been more responsive to interventions in a higher risk population group, for
139
example, participants who smoked, were older with higher BMls or who had clinically 
high blood pressures. Alternatively, clinical screening of participants could have ensured 
a higher risk population of participants were recruited with, for example, high total 
cholesterol, TAG or LDL cholesterol or low HDL cholesterol levels. However, this was 
not viable within the constraints of the trial.
A power calculation for the Pilot WISE trial was based on an estimated fall in 
post-prandial insulin area under the curve of 2 0 %  between groups (which would be 
metabolically significant) with a standard deviation of 20%. This gave an estimate of 17 
per group. Unfortunately, it was not possible to recruit such a high number of participants 
within the restraints o f the Pilot WISE trial. Therefore, the trial is underpowered but, as 
there were no similar such studies published at the time of the inception of the trial, it was 
considered that the research question justified the completion of a pilot trial to explore the 
area. The recent similar trial by Brownlee et al in 2010, the WHOLEheart trial, 
conducted 316 participants, also failed to show significant changes in the markers 
measured, including post-prandial area under the curve. This suggests the Pilot WISE 
trial may not have shown significant differences even if it was fully powered.
Participants reported that trial participation, including the completion of diet 
diaries, encourage them to more actively contemplate their diets and lifestyles and small 
numbers o f participants reported altering their eating habits as a result of their 
participation. A  control intervention leg was employed to normalise for the direct effect 
of participation itself but this behaviour change also extended to exercise, which has been 
shown to cause significant reductions in total and LDL cholesterol, TAG, fasting glucose
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and markers of insulin resistance in overweight and obese individuals (Saremi A  2010) 
suggesting the potential future measurement o f physical activity as a marker or for 
control puiposes. Compliance issues are always of note in dietary intervention trials. We 
aimed to ensure compliance by encouraging our participants and developing a rapport 
and good working relationships with them. Compliance was also monitored by providing 
a known number of intervention product portions to the participants and asking them to 
return any which remained unused. Diet diaries were further used to monitor compliance 
and phone contact made by a Registered Dietitian reminded the participants to consume 
their intervention products. Compliance could have been reinforced further by more 
frequent contact by the research team but such contact was balanced with the negative 
effects of excess intrusion and demand in the participant’s lives. Participants did 
comment that they would not have maintained the diets for any longer, suggesting, with 
other anecdotal information, that the intervention products were not well accepted, which 
could have negatively affected compliance. Intervention products were included into the 
participants’ normal diets in the place of regular bread type products thus preventing a 
significant overall increase in intake and it is possible that the palatability of intervention 
products was enhanced with fatty additions, thus increasing dietary fat intake. This could, 
potentially, have had negative impacts on weight and circulating fats, with a resultant 
increase in atherosclerosis development. Overall, however, compliance was found to be 
generally good as determined by diet diaries and no significant changes were observed in 
nutritional intakes (data not shown).
Alternative methods o f presenting the intervention products were investigated 
before trial initiation. Although fibre is now more widely available in the form of drinks, 
this was not a viable option for the whole intact grains. The unusual delivery method, of
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providing the intervention in bespoke, bread roll-like portions, proved minimally invasive 
to implement. It also enabled thorough monitoring of compliance. Information was 
collected and reported to the manufacturer on the participants’ preferred methods of 
preparing the products, the most ingenious o f which was incorporating them into a bread 
and butter pudding, to enable product development for future studies.
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Chapter 4
T h e  F I T M A  trial
A  r a n d o m i s e d  controlled dietary intervention trial 
investigating the effects o f  w h e a t  fibre a n d  inulin o n  risk 
m a r k e r s  of cardiovascular disease in at risk m e n
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The pathology of CVD involves the inflammatory condition atherosclerosis and 
the dysfunction of the vascular endothelial functions: thrombosis, haemostasis and tissue 
perfusion (Rush J 2005). Known risk markers and co-morbidities for CVD provide 
possible methods for prevention and treatment and can also act as risk markers for the 
disease with dietary interventions, including high fibre diets, promoted as non-invasive 
methods for preventing and treating CVD. Whole grains contain a variety of components 
which may be responsible for their protective effects and, as such, it is interesting to 
investigate these components individually. The aim of the FITMA trial, therefore, was to 
investigate the effects o f specific components o f whole grains, insoluble and soluble 
fibre, on various factors reflecting changes in CVD risk status. A cross-over methodology 
was used to remove inter-individual variations at baseline.
The Fibre and Inulin Trial in Male Adults (FITMA trial, summarised in figure 
4.1) was a randomised controlled cross-over dietary intervention trial investigating the 
effects o f insoluble and soluble fibre, represented for the purposes of this research by 
wheat fibre and inulin respectively, as compared to a control reference broduct, on risk 
markers of cardiovascular disease in at risk men, aged 30 to 60 years with body mass 
index scores of 25 to 35kg/m2. Several studies have shown the positive effects of high 
fibre diets on CVD risk markers, hence their investigation here. The cross-over study 
design lends high significance to the results and at risk participants were chosen as their 
levels of risk markers are likely to be more responsive to manipulation than those at 
lower risk. As participant numbers were limited in this trial, only men were chosen to 
homogenise the population group. Eligible, consented participants were randomised to an
This chapter contains the products of joint research between myself and Laura * ^ 4
Tripkovic.
4.1 Study rationale and aims
order of the three intervention products in stratified blocks. Participants attended a post 
prandial intervention day before their first four week dietary intervention and 
immediately after each intervention. Four weeks was considered the optimum length of 
time required to encourage compliance and allow for changes in the markers and 
metabolites investigated. Interventions were separated by four week washout periods 
when participants consumed their habitual diets.
Markers of vascular haemostasis (vWF and tPA-1) and vascular inflammation 
(sICAM-1, IL- 8  and CRP) were measured as indicators of vascular health and function 
which are associated with the underlying pathogenesis of CVD. Metabolomic profiling of 
participant’s serum was carried out to assess any changes in metabolite profiles with high 
fibre intake and to investigate a possible marker for whole grain intake and, as all 
metabolomic research is challenged by inter-individual variations, the present study used 
a relatively homogenous population group to minimise these variations. Established risk 
markers for CVD were measured, including the levels o f the circulating markers of lipid 
metabolism and insulin resistance as these are associated with CVD risk and type II 
diabetes risk respectively.
One set of baseline measurements was taken at the beginning o f the trial, after the 
14 day ‘run in’ diet and before the first intervention. The data from this baseline were 
used as the baseline data for comparison to the intervention diets. Order effects were 
minimised by randomising each participant to a random order of intervention diets, thus 
preventing any one diet from repeatedly preceding or following another. Carry over
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effects were minimised by the wash out period between, and equal to in length, each 
intervention diet.
The author worked on the FITMA trial in equal collaboration with Dr L, 
Tripkovic. The author was responsible for one half of all activities including, but not 
limited to: trial design, authorship of trial paperwork (including protocol, participant 
information sheets, recruitment paperwork and Trial Master File), informed consent 
sessions, management of participants’ completion of paperwork including FFQ, Health 
and Lifestyle Questionnaire and diet diaries, phlebotomy, participant management and 
care, sample preparation, storage and analysis. The author was not responsible for the 
collection or analysis o f the diet diary data; this was carried out by Dr L Tripkovic. The 
author was entirely responsible for all data analysis presented -  data analysis was not 
carried out in collaboration.
It was hypothesised that levels of risk markers would vary to reflect a lower CVD 
risk state post-intervention with the active high fibre diets, when compared to baseline 
and to the control diets of wheat fibre and inulin.
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Figure 4.1; FITMA trial protocol. The FITMA trial: a randomised controlled cross­
over dietary intervention trial. Male participants aged 30 -  60 years, BMI 25-35kg/m2, 
following screening and consent, were randomised to the three 28 day interventions of 
control, wheat fibre and inulin with a 28 day wash out diet between interventions and 
post prandial study days (PP study days, measuring anthropometries and circulating 
markers) at baseline and after each intervention.
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4.2 Anthropometric and dietary data 
Anthropometric data
Anthropometric measurements were taken from each participant at the beginning
of each study day.
Measurement Baseline Control | Wheat fibre Inulin
Age/years 39.8+9.6
Height/cm 183.1 ±5.4
Weight/kg 101.6 ±13.4 101.7 ±12.9 103.1 ±12.2 1 0 2 . 0  ±  1 2 . 2
BMI/kg/m2 30.2 + 3.0 30.2±2.9 30.7 ±2.6 30.4 ±2.7
Body fat/% of total 
body weight 28.5+4.1 28.5 ±4.3 28.6 ±4.2 29.4 ±4.5
Waist circumference 106.4 ±7.6 105.9 ±7.4 107.0 ±7.9 105.1 ±6.3
Hip circumference 110.9 + 6 . 8 111.5 ±5.8 111.3±5.8 110.4 ±5.3
Waist to hip ratio 1 .0 + 0 . 0 1 .0 + 0 . 0 1 . 0  ± 0 . 0 1 . 0  ± 0 . 0
Systolic blood 
pressure/mmHg 124.8 + 9.5 121.5 ±11.2 126.8 ± 8 . 0 125.2 ±11.6
Diastolic blood 
pressure/mmHg 71.9 ±9.9 70.9 ±  10.8 76.5 ±8.7 73.3 + 12.2
Table 4: FITMA trial anthropometric data. Age, height, weight, body mass index 
(BMI) body fat percentage, waist and hip circumferences and systolic and diastolic blood 
pressure were recorded at each study day and waist to hip ratio was calculated. No 
significant differences were shown in any measurements over the course of the 
intervention. Data are displayed as mean ±  standard deviation, n = 10.
Diet diary data
Three day diet diaries were collected for each participant during each intervention 
trial. This work, and the analysis o f the data, was carried out by Dr. L. Tripkovic.
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Baseline Control Wheat Fibre Inulin
Energy/kj
8563.2 ±  
3006.1
12425.6 ±  
5198.7
12705.0 ±  
4684.2
12534.0 ±  
4946.4
Fat/g 86.7 + 39.5 84.1 ±24.7 90.5 ±34.9 ! 76.0 ±  20.4
Saturated fat/g 32.4 ±14.9 32.0 ±11.3 33.6 ±16.0 29.5 ±  12.0
Protein/g 81.7 + 28.8 118.7 ±53.9 119.7 + 63.5 120.6 ±47.6
Sodium/g 2449.4 + 1131.4 2155.0 ±697.9 2276.4 ±686.9 2046.1 ±777.1
Polyunsaturated
fat/g 12.6 ±7.6 12.0 ±3.1 15.9 + 5.1 13.4 ±3.3
Water/g 1412.3 ±203.1 1666.0 ±614.2 2105.8 ±1168.4 1495.9 ±892.4
Energy/kcal 2041.0 + 719.7 2945.6 +1225.1 3018.6 + 1112.1 2969.0 + 1169.6
Monounsaturated
fat/g 28.9 ±11.5 26.7 ±8.0 31.3 ±12.1 23.6 ±8.4
Sugars/g 86.4 + 57.9 95.7 + 64.9 115.1 + 118.3 66.3+33.9
Starch/g 119.4 ±37.7 320.3+237.8 281.6+200.5 370.2 +189.6
Carbohydrate/g 217.7 + 85.8 426.5+241.7 407.2 +189.2 440.2 + 211.7
Table 5: FITMA diet diary data. Macro- and micro-nutrient compositions o f the 
participants’ diets were recorded and analysed at base line and within each of the three 
trial intervention diets. Data are displayed as daily mean ±  standard deviation. No 
significant differences were seen in any nutrients investigated between intervention diets. 
This work was carried out by Dr. L. Tripkovic.
4.3 The effect of wheat fibre and inulin on serum markers of vascular health
4.3.1 Haemostatic factors 
Tissue plasminogen activator-1
In order to investigate whether the wheat fibre, inulin or, indeed, control 
intervention products could affect endothelial expression of the fibrinolytic factor tPA-1, 
the soluble levels of this haemostatic marker were assessed in the serum of participants 
undertaking the FITMA trial as described in 2.2.4.1 (figure 4.2). Each of the diets slightly 
increased circulating tPA-1 concentrations above the baseline o f2.385 ±  0.65ng/ml but 
none of the intervention diets significantly altered circulating levels o f tPA-1 when 
compared to baseline or control.
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Figure 4.2: Fasting tPA-1 concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting tPA-1 was 
measured in each participant (n = 1 0 ) at baseline (A ) and after each 28 day dietary 
intervention treatment of control (•), wheat fibre (♦) and inulin (T )  using an in-house 
ELISA. Individual values are displayed with mean ±  standard error. No significant 
differences were found using a repeated measures ANOVA.
von Willebrand factor
Fasting concentrations o f the pro-coagulant vWF were measured to investigate 
whether the intervention products could affect vascular endothelial expression of such 
factors. Figure 4.3 illustrates a slight reduction in mean fasting vWF concentrations after 
the wheat fibre and inulin interventions when compared to the control. No differences 
between any groups, however, were significant and all group mean values fell within the 
range of 2.49 (wheat fibre) and 3.52 (control).
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Figure 4.3: Fasting vWF concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting vWF was measured 
in each participant (n = 9-10) at baseline (A ) and after each 28 day dietaiy intervention 
treatment of control (•), wheat fibre (♦) and inulin (T ) using an in-house 
ELISA. Individual values are displayed with mean ±  standard error. No significant 
differences were found using a repeated measures ANOVA.
4.3.2 Inflammatory markers
Soluble intra-cellular adhesion molecule-1
In order to investigate whether soluble or insoluble fibre, represented by inulin 
and wheat fibre respectively, could affect endothelial cell shedding of sICAM-1, a marker 
of vascular inflammation, the soluble levels of this adhesion molecule were assessed in 
the fasting serum of participants as described in 2.2.4.2. Figure 4.4 illustrates that mean 
levels o f sICAM-1 remained similar throughout the intervention, at 188.5,180.0, 190.8 
and 193.3ng/ml at baseline and after the wheat fibre, inulin and control interventions 
respectively. None of the intervention diets significantly altered circulating levels of 
sIC AM -1 when compared to baseline or control.
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Figure 4.4: Fasting sICAM -I concentrations at baseline and after each 28 day 
dietary intervention treatment of control, wheat fibre and inulin. Fasting sICAM-1 
was measured in each participant (n = 1 0 ) at baseline (A ) and after each 28 day dietary 
intervention treatment of control (•), wheat fibre (♦) and inulin (▼ ) using a Quintikine® 
human sICAM-1 immunoassay kit. Individual values are displayed with mean ±  standard 
error. No significant differences were found using a repeated measures ANOVA.
Interleukin-8
Circulating levels o f the inflammatoiy cytokine IL- 8  were assessed in the fasted 
plasma of participants undertaking the FITMA trial. The mean fasting serum 
concentrations of IL- 8  altered from 5.538pg/ml at baseline to 6.01 lpg/ml following the 
wheat fibre intervention and 6.288pg/ml following the inulin intervention. The 
concentration changed to 4.363pg/ml after the control diet (figure 4.5), however, none of 
the changes were statistically significant.
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Figure 4.5: Fasting IL-8 concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting IL- 8  was measured 
in each participant (n = 7-9) at baseline (A ) and after each 28 day dietary intervention 
treatment of control (•), wheat fibre (♦) and inulin (▼) using a human ultrasensitive 
cytokine 10-p lex kit on a Luminex® 100. Individual values are displayed with mean +  
standard error. No significant differences were found using a repeated measures 
ANOVA.
Interleukin-6
Interleukin-6 , another potent mediator o f inflammation, was also measured as 
described in 2.2.4.2, at baseline and after each treatment intervention of wheat fibre, 
inulin and control. Unfortunately, circulating levels were below the limit of detection of 
the high sensitivity Luminex kit thus all results read as zero.
C-reactive protein
To investigate whether soluble or insoluble fibre, as represented by the inulin and 
wheat fibre products respectively, could affect circulating levels of CRP, levels of this
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marker of inflammation were assessed in the serum of participants undertaking the 
FITMA trial as described in 2.2.4.2. The mean levels of CRP remained low at 
2.001pg/ml at baseline and 1.663, 2.451 and 1.129pg/ml after the control, wheat fibre and 
inulin interventions respectively, although certain individual values did reach 9.0pg/ml 
(figure 4.6). No significant differences were seen between any of the treatment 
interventions or when compared to baseline.
Figure 4.6: Fasting CRP concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting CRP was measured 
in each participant (n = 1 0 ) at baseline (A ) and after each 28 day dietaiy intervention 
treatment of control (•), wheat fibre (♦) and inulin (T ) and using an in-house high 
sensitivity ELISA. Individual values are displayed with mean ±  standard error. No 
significant differences were found using a repeated measures ANOVA.
4.4 The effect of wheat fibre and Innlin on metabolomic profiles
Untargeted LC/MS based metabolomics analysis was used in this research to 
investigate the effects of the interventions on participants’ metabolite profiles to reflect 
changes to metabolic pathways and potential biomarkers in dietary intake. In total, 2334
154
ions were detected in positive ionization mode. Principal component analysis (PC A) was 
unable to discriminate between the four sample groups; baseline, control, wheat fibre and 
inulin (figure 4.7A). Further investigation of the data using a four-group partial least 
squares discrimination analysis (PLS-DA) model is shown in figure 4.7B. This PLS-DA 
model accounted for 5% of the variation between the four different intervention groups
*y
and discrimination was observed between the groups. The PLS-DA model parameters R 
(goodness of fit) and Q2  (predictive ability) were 0.363 and 0.715 respectively.
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Figure 4.7: PCA and PLS-DA score plots of metabolite profiles in the FITMA trial.
Metabolite profiles of sera at baseline ■ and after each dietary intervention of control ♦, 
wheat fibre and inulin ♦ of the FITMA trial, illustrated from A) PCA and B) a four 
component PLS-DA model (R2 0.363 and Q2 0.715).
To determine the discriminatory species, the data was further explored through a 
PLS-DA loadings plot and by a variable importance on projection (VIP) plot of the first
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component. The loadings plot showed limited spread of ions, mainly along the principal 
component 1 axis (figure 4.8).
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Figure 4.8: PLS-DA loadings plot of ions detected by LC/MS in the sera of 
participants in the FITMA trial. Discriminating ions are those separated away from the 
origin. Each individual ion is represented by A , with mass and retention time.
The VIP plot of the first component (figure 4.9) highlights the most important 
discriminatory species in descending order.
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Figure 4.9: VIP plot illustrating of the major discriminatory species determined 
participants9 sera in the FITMA trial in descending order. The mass and retention 
time are given for each of the major discriminatory ion species between the groups of 
baseline, control, wheat fibre and inulin in the FITMA trial.
Ions highlighted by the VIP and loadings plots are potentially discriminatory 
between sample groups. These ions were further investigated, by examination of their 
single ion chromatograms (SIC) and mass spectra, to remove any false positives and 
determine any adduct formation. Figure 4 .10A shows a region of the total ion 
chromatogram (TIC) of a representative FITMA plasma sample with the major ions and 
their adducts labeled by retention time and mass to charge ratio. Figure 4 .10B, C and D 
show the extracted SIC of several discriminatory ions (determined from the VIP plot, 
figure 4.9) with the mass to charge ratio 568.341m/z, 520.34m/z and 524.371m/z 
respectively, and several related adducts (with lower intensities). Figure 4.11 shows mass 
spectra of specific ions recognized in the single ion chromatograms in figure 4 .10B, C
and D. Figure 4.1 IB indicates that the signal identified with a mass to charge ratio of 
544.3423m/z (figure 4.1 IB) is, in fact, an adduct of a parent ion with the mass to charge 
ratio of 520.3439m/z. The signals o f those found not to be true ions on examination of 
their SIC and mass spectra were disregarded, while signals o f true ions were statistically 
analysed for differences between groups.
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Figure 4.10: Total ion chromatogram and representative positive ion mode single 
ion chromatograms from the FITMA trial. A  shows the total ion chromatogram as 
determined by LC/MS. B, C and D show single ion chromatograms of ions of mass to 
charge ratio 568.341m/z, 544.341m/z and 524.371m/z respectively, with apeak 
representing each retention time for that specific ion signal.
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Figure 4.11: Mass spectra of peaks of discriminatory signals determined in the 
FITMA trial showing molecular ions and adducts. Mass spectra of ions of mass to 
charge ratios A 568.34m/z, B 520.3439m/z and C 524.37m/z, as analysed by LC/MS. 
Peaks shown with mass to charge ratio.
These signals identified as significantly different between groups underwent 
putative identification. Potential elemental composition analysis was performed using 
Masslynx. Exact masses were then entered into metabolite databases (Human Metabolite 
Database, www.hmdb.ca; METLIN, metlin.scripps.edu; KEGG, www.kegg.com) and 
compared with the possible elemental composition, taking into account adducts from 
molecular ion analysis, and potential metabolites were assigned. Further confirmatory 
analysis of the ions was beyond the scope of this research, due to time limitations, and as 
such, assignments are putative.
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A major discriminatory signal was determined at 6.61 minutes, 568.3408m/z. The 
intensity of this species was significantly reduced by the control diet than at baseline 
(p<0.05) with the inulin measurement also being higher than the wheat fibre control 
measurements (pO.OOl and p<0.05 respectively). The best match for this signal from 
metabolite databases was found to be lysophosphatidylcholine (LysoPC, C22:6), based 
on the m/z ratio of 567.694 and the formula C3 0H50NO7P compared to the elemental 
composition analysis.
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Figure 4.12: Signal intensities of the discriminatory signal at 6.61 minutes, 
568.3408m/z determined in the FITMA trial. Measurements were taken at baseline and 
post-each intervention treatment of control, wheat fibre and inulin. Non-targeted LC-MS 
based metabolomic analysis revealed a discriminatory signal at 6.61 minutes, 
568.3408m/z, putatively identified as LysoPC (Cl 8:2) from a comparison of mass. 
Individual values displayed with mean + SE where * and ** denote p<0.05 and 0.01 
respectively, using a repeated measures ANOVA.
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The discriminatory signal at 6.64 minutes, 544.3408m/z was putatively identified 
by it’s m/z ratio and chemical formula (C2 6H50NO7PNa), as a [M + Na+] adduct of 
520.340m/z (Cl 8:2). The intensity o f this ion was found to be significantly lower after 
the control than when compared to the baseline and inulin interventions (p<0.05 and 
p<0.005 respectively, figure 4.13).
Figure 4.13: Signal intensities of the discriminatory signal at 6.64 minutes, 
544.3408m/z determined in the FITMA trial. Measurements were taken at baseline and 
post-each intervention treatment of control, wheat fibre and inulin. Non-targeted LC-MS 
based metabolomic analysis revealed a discriminatory signal at 6.64 minutes, 
544.3408m/z, putatively identified as a [M + Na+] adduct of lysophosphatidylcholine 
(C l8:2). Individual values displayed with mean + SE where * and *** denote p<0.05 and 
p<0.005 respectively, using a repeated measures ANOVA.
The third discriminatory signal at 7.61 minutes, 524.3715m/z was putatively 
identified from the metabolite databases as LysoPC (18:0) C26H54NO7P, with a recorded 
m/z ratio of 523.3637. The intensity of this signal was significantly higher following all 
interventions than at baseline (p<0.005, p<0.005 and p<0.01 for control, wheat fibre and
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inulin diets respectively) and significantly higher in the control intervention compared to 
inulin diet (p<0.05, figure 4.14).
Figure 4.14: Signal intensities of the discriminatory signal at 7.61 minutes,
524.3715m/z determined in the FITMA trial. Measurements were taken at baseline and 
post-each intervention treatment of control, wheat fibre and inulin. Non-targeted LC-MS 
based metabolomic analysis revealed a discriminatory signal at 6.61 minutes, 
568.3408m/z, putatively identified as an adduct of lysophosphatidylcholine (C l8:0). 
Individual values displayed with mean + SE, where *, ** and *** represent p<0.05, 
p<0.01 and p<0.005 respectively, using a repeated measures ANOVA.
4.5 The effect of wheat fibre and inulin on serum markers of CVD risk
4.5.1 Circulating lipids
It was important to determine any changes in lipid profiles occurring as a result of 
the dietary interventions.
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Fasting total cholesterol concentrations were measured as described in 2.2.6.1. 
Figure 4.15 illustrates that the mean of total cholesterol concentration varied between 
5.17mM at baseline and 4.97,4.88 and 5.15mM following the control, wheat fibre and 
inulin interventions respectively and there were no significant differences between 
treatment interventions, or between the baseline and any intervention.
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Figure 4.15: Fasting total cholesterol concentrations at baseline and after each 28 
day dietary intervention treatment of control, wheat fibre and inulin. Fasting total 
cholesterol was measured in each participant (n = 1 0 ) at baseline (A ) and after each 28 
day dietary intervention treatment of control (•), wheat fibre (♦) and inulin (▼ ) using an 
IL Test™ cholesterol kit on an iLab autoanalyser. Individual values are displayed with 
mean ±  standard error. No significant differences were found using a repeated measures 
ANOVA.
High density lipoprotein cholesterol
Fasting HDL cholesterol concentrations were measured as described in 2.2.6.1. 
No significant differences in fasting HDL concentration were found with baseline levels
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at 1.22mM and levels post each intervention at 1.17, 1.14 and 1.24mM for the control, 
wheat fibre and inulin interventions respectively (figure 4.16).
Figure 4.16: Fasting HDL cholesterol concentrations at baseline and after each 28 
day dietaiy intervention treatment of control, wheat fibre and inulin. Fasting HDL 
cholesterol was measured in each participant (n = 9-10) at baseline (A ) and after each 28 
day dietaiy intervention treatment of control (•), wheat fibre (♦) and inulin (T ) using a 
direct HDL cholesterol kit on an iLab autoanalyser. Individual values are displayed with 
mean ±  standard error. No significant differences were found using a repeated measures 
ANOVA.
Triacylglycerides
Fasting TAG concentrations were measured at baseline and after each 28 day 
intervention as described in 2.2.6.1. Figure 4.17 shows that, although the wheat fibre 
increased TAG concentrations, there were no significant differences in fasting TAG  
concentration between treatment interventions, or between the baseline and any 
intervention.
165
Figure 4.17: Fasting TAG concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting TAG was measured 
in each participant (n = 7-8) at baseline (A ) and after each 28 day dietaiy intervention 
treatment of control (•), wheat fibre (♦) and inulin (▼ ) using an IL Test™ 
triacylglycerides kit on an iLab autoanalyser. Individual values are displayed with mean 
±  standard error. No significant differences were found using a repeated measures 
ANOVA.
Low density lipoprotein
LDL cholesterol was calculated, as described in 2.2.6.1, from the measurements 
of total cholesterol, HDL cholesterol and triacylglycerides, using the Friedewald equation 
(Friedewald W  1972). No significant differences were determined due to any treatment 
interventions, data not shown.
Non-esterified fatty acids
Fasting NEFA concentrations were measured at baseline and after each 28 day 
intervention of wheat fibre, inulin and control products, as part o f the lipid profile. No
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significant differences were observed with mean values at baseline, control, wheat fibre 
and inulin at 0.4247, 0.5244, 0.4706 and 0.4783mM respectively (figure 4.18).
Figure 4.18: Fasting NEFA concentrations at baseline and after each 28 day dietaiy 
intervention treatment of control, wheat fibre and inulin. Fasting NEFA 
concentrations were measured in each participant (n = 8 ) at baseline (A ) and after each 
28 day dietaiy intervention treatment of control (•), wheat fibre (♦) and inulin (▼ ) using 
an iLab autoanalyser. Individual values are displayed with mean +  standard error. No 
significant differences were found using repeated measures ANOVA.
As post-prandial NEFA responses can change over time in response to changes in 
diet, participant’s NEFA concentrations were measured before, and for 120 minutes at 15 
minute intervals after, ingestion of a standard glucose test drink (containing 75g of 
glucose in water) to reflect post-prandial responses (see figure 4.19). This occurred at 
baseline and after each of the 28 day treatment interventions of wheat fibre, inulin and 
control products. The control diet has the highest concentrations of NEFA at every time 
point so areas under the curve (AUC) were calculated for each treatment intervention to 
investigate the physiological NEFA response. The AUC at baseline was 31.19, with
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values of 31.59, 26.33 and 24.29 for the control, wheat fibre and inulin treatment 
interventions respectively. No significant differences were shown between baseline and 
interventions, or between any interventions.
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Figure 4.19: Post-prandial NEFA responses, measured at baseline and after each 28 
day dietary intervention treatment of control, wheat fibre and inulin. Post-prandial 
(75g glucose in water) NEFA concentrations were measured before a standard 75 g 
glucose drink and at 15 minute intervals for 120 minutes afterwards, to represent post­
prandial responses. These post-prandial measurements were taken in each participant (n = 
8 ) at baseline (■) and after each 28 day dietary intervention treatment of control (■), 
wheat fibre (■) and inulin (■) using an iLab autoanalyser. Means displayed ±  standard 
error.
4.5.2 Insulin sensitivity
Insulin insensitivity or resistance, as suggested by circulating levels of insulin and 
glucose, are important to measure as surrogate markers for CVD risk as the two 
conditions are strongly related.
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Fasting insulin concentrations were measured at baseline and after each 28 day 
intervention of wheat fibre, inulin and control products as described in 2.2.6 .2. Figure 
4.20 demonstrates that the wheat fibre and inulin interventions raised the concentration of 
insulin to 93.25 and 83.47pM respectively compared to the baseline at 79.64pM and the 
control at 77.07pM, although there were no statistically significant differences.
Insulin
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Figure 4.20: Fasting insulin concentrations at baseline and after each 28 day dietary 
intervention treatment of control, wheat fibre and inulin. Fasting insulin 
concentrations were measured in each participant (n = 8 ) at baseline (A ) and after each 
28 day dietaiy intervention treatment of control (•), wheat fibre (♦) and inulin ( V ) using 
a human insulin specific radio-immuno assay. Individual values are displayed with mean 
±  standard error. No significant differences were found using a repeated measures 
ANOVA.
Post-prandial insulin responses can alter in response to diet and signify alterations 
in insulin sensitivity and the ability to process glucose. Insulin concentrations, therefore, 
were measured before, and at 15 minute intervals for 120 minutes after, ingestion of a 
standard glucose test drink (containing 75g of glucose in water) to reflect post-prandial
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responses (figure 4.21). This occurred at baseline and after each of the 28 day treatment 
interventions of wheat fibre, inulin and control products. Peak concentrations reached 
varied between interventions, as did the time taken to reach them AUC were calculated 
at baseline and the control, wheat fibre and inulin interventions and found to be 69341, 
69577.8, 62807 and 65885.6 respectively. No significant differences were shown 
between interventions, or between any intervention and baseline.
lime (minutes)
Figure 4.21: Post-prandial insulin responses, measured at baseline and after each 28 
day dietary intervention treatment of wheat fibre, inulin and control. Post-prandial 
(75g glucose in water) insulin concentrations were measured before a standard 75g 
glucose drink and at 15 minute intervals for 1 2 0  minutes afterwards, to represent post­
prandial responses. These post-prandial measurements were taken in each participant (n = 
8 ) at baseline (■) and after each 28 day dietary intervention treatment of control (■), 
wheat fibre (■) and inulin (■) using a human insulin specific radio-immuno assay. Means 
displayed ±  standard error.
As differences in insulin responses were suggested from the post-prandial curves, 
the peak insulin concentration and the time take to reach this peak post-prandial ly were 
further investigated. The mean maximum postprandial insulin concentration (C-max) 
reached in the 120 minutes after ingestion o f 75g glucose in water per treatment 
intervention group was compared between groups. Although each intervention treatment
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reduced the insulin C-max when compared to baseline, no significant differences were 
found (data not shown). The mode times to maximum insulin concentration (T-max) per 
group are as follows: baseline 45, wheat fibre 60, inulin 30 and control 60. The mean T- 
max values for each treatment intervention were compared and although this was 
increased post-wheat fibre and decreased post-inulin, no significant differences were 
found (data not shown).
Glucose
As an indication of insulin sensitivity, fasting glucose concentrations were 
measured described in 2.2.6 .2. Although levels increased from 5.325mM at baseline to 
5.588, 5.528 and 5.491pM by the control, wheat fibre and inulin interventions 
respectively, no significant differences were observed between groups (figure 4 .2 2 ).
Figure 4.22: Fasting glucose concentrations at baseline and after each 28 day dietary 
intervention treatment of wheat fibre, inulin and control. Fasting glucose 
concentrations were measured per participant (n = 8 ) at baseline (A ) and after each 28 
day dietary intervention treatment of control (•), wheat fibre (♦) and inulin (▼ ) using
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iLab auto-analyser. Individual values are displayed with mean ±  standard error. No 
significant differences were found using a repeated measures ANOVA.
The physiological ability to remove glucose from the circulation post-prandially 
is, in part, an indication of responsiveness to insulin. Therefore, participants’ glucose 
concentrations were measured before, and for 1 2 0  minutes at 15 minute intervals after, 
ingestion of a standard glucose test drink (containing 75g of glucose in water) to reflect 
post-prandial responses (figure 4.23). Measurements occurred at baseline and after each 
of the interventions of wheat fibre, inulin and control products. The control intervention 
shows the highest concentrations o f glucose beyond 30 minutes and the wheat fibre 
appears to be very low throughout. AUC were calculated for each treatment intervention 
to further investigate these differences and were found to be 890, 865.5, 927.3 and 987.9 
for the baseline, control, wheat fibre and inulin groups respectively, with significant 
differences shown between interventions, or between any intervention and baseline.
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Figure 4.23: Post-prandial glucose responses, measured at baseline and after each 
28 day dietary intervention treatment of wheat fibre, inulin and control. Post­
prandial (75g glucose in water) glucose concentrations were measured before a standard 
75g glucose drink and at 15 minute intervals for 120 minutes afterwards, to represent
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post-prandial responses. These post-prandial measurements were taken in each 
participant (n =  8 ) at baseline (■) and after each 28 day dietaiy intervention treatment of 
control (a), wheat fibre (□) and inulin (□) using an iLab autoanalyser. Means displayed ±  
standard error.
As the maximum glucose concentrations reached and the time taken to reach these 
peaks varied between intervention groups, these data were fijrther investigated. The mean 
maximum postprandial glucose concentration (C-max) reached in the 120 minutes after 
ingestion of 75g glucose in water per treatment intervention group was compared 
between groups. No significant differences were found between the C-max values 
between the intervention groups (data not shown). The mode glucose T-max values in 
minutes reached in the 120 minutes after ingestion of 75g glucose in water per treatment 
intervention were as follows: baseline 45, wheat fibre 30, inulin 60 and control 60. The 
mean T-max was compared between groups showing higher values post-control and 
inulin treatment compared to baseline and post-wheat fibre, but these differences were 
not significant (data not shown).
4.6 Discussion
The aim of this study was to investigate the effects of wheat fibre and inulin on 
CVD risk markers in a population group at risk o f CVD but without clinical symptoms. 
Wheat fibre and inulin were representative of insoluble and soluble fibre respectively. 
Approximately 9 to 17% ingested soluble fibre and 5 to 2 0 %  of insoluble fibre is 
anaerobically fermented to SCFAs in the colon (Cook S 1998). SCFAs have been posed 
as anti-inflammatory agents and investigations of these products, therefore, may reflect 
the activity of SCFAs (Tedelind S 2007). It was hypothesised that these high fibre diets 
would reduce CVD risk as reflected by altered levels of the markers investigated. Since
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this study used a cross-over design, it was assumed that any differences seen between 
each intervention treatment and the baseline occurred as a result of the intervention 
product. In addition, a metabolomic approach was used to investigate the effects of such 
diets on the circulating metabolic profiles.
Haemostatic markers
As CVD and atherosclerosis are inflammatoiy disorders reflecting endothelial 
dysfunction, it was imperative to investigate the circulating levels o f both haemostatic 
and inflammatory markers. Levels o f tPA-1 were expected to decrease in response to a 
protective intervention, as was shown with 52 week interventions of both low 
carbohydrate and low fat diets when accompanied by significant weight loss, in 49 
overweight or obese participants (aged 50.0 ±1 .1  years, BMI 33.7 ±  0.6kg/m2, 
(Wycherley T 2010)) although this was not seen to be the case here. As outlined in 
chapter 3, this could be because there was no significant impact of the intervention 
products or because the interventions themselves were not extensive enough. 
Alternatively, tPA-1 may not a suitable marker although this is unlikely given its high 
sensitivity and it’s putative role as a CVD risk marker (Ridker P 2000). Weight loss may 
be the key factor in reduction of circulating tPA-1 levels. Concentrations of tPA-1 were 
slightly, but not significantly altered by each intervention treatment, when compared to 
baseline. All mean values varied between 2.39 and 2.69ng/ml which was considerably 
lower than the range for healthy adults of 7.77 + 1.63ng/ml, and for adults with proven 
CVD of 9.3 to 9.67+ 1.55ng/ml (Jansson J 1993; Gram J 2000) potentially suggesting 
that fibrinolysis and clot dissolution were at healthy levels. These data were also below 
those concentrations of tPA-1 determined in the Pilot WISE study, potentially reflecting a
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low level of coagulation and thus protective effects on CVD risk. The participants of the 
FITMA trial were homogenously male, whereas post-menopausal women were involved 
in the Pilot WISE trial, which may have altered the levels. Alternatively, the lower tPA-1 
levels of the FITMA trial could be due to the participants’ lower average age of 39.8 +
3.0 years compared to that of the Pilot WISE trial o f 48.4 ±  11.7 years. These data were 
in agreement with similar randomised controlled dietary intervention studies 
investigating the effects of high whole grain and therefore high fibre diets on markers of 
cardiovascular risk which found no impact on circulating levels o f the tPA-1 inhibitor, 
PAI-1 (Andersson A 2007; Brownlee I 2010).
tPA-1 and vWT have opposing functions associated with fibrinolysis and 
coagulation respectively within the coagulation cascade. The literature cites vWF levels 
of 1.23 ±  0.50IU/ml in healthy controls, rising significantly to 1.47 ±  0.66 U/ml in 
participants having suffered ischaemic stroke (Bongers T 2006), whereas, other studies 
have determined healthy levels o f vWF as 1.2 to 1.3IU/ml (Rumley A 1998; Wiman B 
2000). The circulating levels found in the current research were consistently above both 
the Tow’ and ‘high risk’ levels found in the literature, potentially reflecting a high level 
of coagulation. Levels, therefore, were hypothesised to reduce in response to a protective 
dietary intervention. This has been reported in the literature where reductions in 
circulating vWT levels were observed after a 28 day high mono-unsaturated fat diet 
(p<0.001 (Perez-Jimenez F 1999)) suggesting that modification of the fat content of the 
diets would have improved responses.
Although concentrations of the pro-coagulant vWF were increased slightly by the 
control treatment and reduced slightly by the whole intact and whole milled grain
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treatments, none of these changes were statistically significant. Concentrations of vWF 
were hypothesised to reduce after the active diets. Such a response was observed in a 
study of men with angiographically proven coronary atherosclerosis who consumed a 
lipid-lowering diet for three years and showed significant reductions in circulating vWF 
when compared to controls on a control habitual diet (Blann A 1995). These participants 
also showed reductions in serum total and LDL cholesterol and TAGs, and interestingly 
their diets were significantly higher in fibre than those of the control group. Another high 
fibre whole grain dietary intervention study did show significantly lower levels of both 
vWF and fibrinogen after the intervention diet when compared to a control diet and a 
non-significant trend towards a reduction in the alternative coagulation marker factor 
VIII (Vuksan V 2007). These discrepancies may be due to the longer intervention period 
of 12 weeks in that research, or the increased average age of participants (64 ±  8  years) as 
age is a further risk marker for CVD.
Inflammatory factors
CVD and the underlying pathology, atherosclerosis, are inflammatory disorders, 
marked by increased circulating concentrations of soluble inflammatory factors such as 
sICAM-1, IL-8 , IL- 6  and CRP, thus highlighting these markers for investigation in the 
current research. Levels o f endothelial adhesion molecules were hypothesised to 
decrease in response to the protective effects of the intervention diets as was observed in 
response to a very low carbohydrate diet, with concurrent significant reductions in E- 
selectin and body mass but not VCAM-1 (Wycherley T 2010) and to high fat diets and 
high exercise interventions with concurrent changes in PAI-1 (Eriksson M  2008).
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The concentration of sICAM-1, however, did not alter significantly in response to any of 
the dietaiy interventions of the FITMA trial, with levels falling within the normal 
circulating range found in healthy adults o f 115 to 306ng/ml (Glurich 1 2002). The results 
suggest that the intervention diets did not have a significant impact on sICAM-1 levels as 
a marker of CVD risk, perhaps because they were not significantly raised at baseline and 
that the addition of weight loss or exercise into the study design may promote reductions 
in this marker.
Although the control intervention appears to have reduced the concentration of 
the inflammatory mediator IL-8 , the whole intact and whole milled grain products 
reversed this effect and increased levels slightly beyond those found at baseline. No 
significant differences, however, were seen between any treatment interventions, or when 
compared to baseline. Levels o f IL- 8  in the literature are quoted as 5.6 ±  0.6pg/ml in 
obese subjects (Bruun J 2005) which correlates with the results o f this study. As higher 
levels o f IL- 8  have been identified in patients with coronary artery disease (CAD) (Jha H
2009), protective effects o f an intervention would be expected to reduce circulating levels 
of the inflammatory marker IL-8 , although this was not seen to be the case. This may be 
because levels were not significantly raised above those expected when measured at 
baseline. As outlined in chapter 3, significant reductions in IL- 8  concentration were 
observed due to a ten week intervention of bespoke ‘Old Italian Grain’ bread (Sofi F
2 0 1 0 ), perhaps suggesting that the length of the intervention may need to be increased.
Circulating levels of the alternative inflammatory marker IL- 6  were undetectable
but would have been expected to fall in response to a protective intervention as was 
observed in response to a very low calorie diet in overweight women, when accompanied
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by weight loss (Bastard J 2000). The additional intervention of weight loss could, 
therefore, aid reduction of this circulating marker. The results of a high fibre whole grain 
intervention study similar to the current research investigating circulating levels o f IL- 6  
support these results, reporting no significant changes post-intervention (Andersson A
2007).
The current research, although showing inter- and intra-individual differences, as 
expected with such a highly sensitive and extremely variable marker o f inflammation, 
showed no significant differences in mean concentrations due to the interventions, 
possibly suggesting a longer intervention period was required. Data were within the 
ranges o f circulating concentrations of CRP for healthy subjects (1.68 ±  1.42mg/l) 
(Glurich I 2002) which was unexpected. As the population group investigated displayed 
other risk markers for high CVD risk, it was thought that levels of CRP would also reflect 
a high risk state. Levels o f this sensitive inflammatory marker would be expected to fall 
in response to cardio-protective interventions such as high fibre diets but this was not 
seen in the current research, however, perhaps because the levels were not raised at 
baseline so could not be reduced by a protective intervention. These results are supported 
by those o f Andersson et al who showed no changes in concentrations of circulating CRP 
in response to high whole grain diets (Andersson A 2007). In further agreement, fasting 
CRP levels also showed no significant change in response to an eight or 12 week high 
whole grain diet o f 60g/day whole grain (Brownlee 1 2010). Dietary supplementation 
with high fibre whole grains also showed no significant change on circulating CRP levels 
in type II diabetic patients, even considering that their baseline levels were higher than 
those of the current study (Vuksan V  2007). Interestingly, data from Ajani et al found a
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correlation between fibre in-take and circulating CRP concentrations (Ajani; Ajani U  
2004) in disagreement with the current research. That data was from a prospective 
National Health and Nutrition Survey, though and not from a randomised controlled 
dietary intervention trial so no cause and effect can be proven.
Metabolomics
The aim of this non-targeted LC/MS based metabolomic investigation was to 
demonstrate the impact o f diets high in wheat fibre or inulin on metabolite profiles and to 
investigate potential biomarkers for such dietary regimens. PCA could not discriminate 
between samples when comparing each of the four groups of baseline, control, wheat 
fibre and inulin intervention products. This is not uncommon in nutritional studies, as 
PCA may not be sensitive enough to discriminate between groups in which ions display a 
high degree o f variation with only minimal differences between those groups, or between 
groups where only a small percentage of the total number of ions display differences 
(Kemsley E 2007). The data was analysed further by establishing a four component PLS- 
DA model, (R2 and Q2 model parameters of 0.363 and 0.715 respectively), which 
partially discriminated between sample groups indicating modest dietary-induced 
changes to the metabolome.
Following confirmatory analysis the intensities o f three discriminatory species 
were found to be statistically significantly different between intervention groups, 
confirming that the effects on individual species following the dietary interventions were 
genuine. Assignments were based on the closest matches to parent ions on metabolite 
databases. This could be further confirmed by comparison of the ion’s mass spectroscopy
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behaviour with that of pure standards. Unfortunately, this was not possible within the 
scope of the current research due to time and financial constraints.
In the current study, significant differences were seen between groups in three 
lysophospatidylcholine (lysoPC) species (18:0, 22:6 and 18:2). This may simply reflect 
an effect o f participation in a trial, rather than the intervention products themselves 
although this is unlikely as changes have been observed between active intervention arms 
of the trial. The data suggest that dietary supplementation with the control, wheat fibre 
and inulin products influences phospholipid metabolism, altering circulating 
concentrations of LysoPCs.
These data agree with the principal metabolomic profiling results of Lankinen et 
al, who also showed a significant effect on circulating levels of multiple LysoPC species, 
including (18:0) and (18:2), after a dietaiy carbohydrate modification including wheat 
bread. Lankinen et al investigated the metabolic profiles of 20 overweight or obese 
participants aged 55 +  6  years with BMI values of 32 ±  3.8kg/m2, that is, a similar but 
higher risk participant population than the FITMA trial investigated. In contrast to the 
current study, the investigational diet using wheat bread also included oats and potatoes, 
which could have accounted for the slight differences seen between the LysoPC profiles 
of the two trials.
LysoPCs are products of phospholipid metabolism and are formed predominantly 
through the action of either phospholipase A2  (PLA2) on biological membranes (Aiyar N  
2007), or lecithin cholesterol acyl transferase (LCAT) on lipoproteins, or during
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oxidative modification of LDL (Kougias P 2006). LysoPCs have specific actions 
including a pro-inflammatory activity and the capacity to activate a variety of cell lines 
(Ojala P 2007). LysoPCs are also known mediators of endothelial function (Kougias P 
2006), capable of inducing endothelial dysfunction. They have been evidenced as the 
major bioactive lipid component o f oxLDL, potentially being responsible for certain of 
oxLDL’s inflammatory effects (Aiyar N 2007). They have also been shown to induce 
platelet activation (Murohara T 2002) and migration of smooth muscle cells (Kohno M  
1998) and are, thus, linked to the underlying pathogenesis of CVD, with an increase in 
circulating levels indicating a pro-inflammatory state. The non-consistent results show 
inulin significantly increased the concentrations o f two of the LysoPC species and 
reduced the concentrations o f one other, with no effect shown to be due to wheat fibre, 
which is not suggestive o f a protective effect.
In conclusion, the intervention diets significantly altered circulating levels of 
three ion species, putatively defined as the LysoPCs (2 2 :6 , 18:0) and (18:2), suggesting, 
in agreement with previous research, that diets high in wheat fibre or inulin can influence 
metabolite profiles (Lankinen M  2010). Metabolomics is an emerging technique in 
nutritional research, showing increasing use (Lodge J 2009) and the current study is one 
of only a limited number of reports using metabolomics to investigate the impact of 
dietary modifications in human intervention studies. The current research highlights the 
potential o f metabolomic technology in nutritional research, for example, in defining 
alternative functions for nutrients and in elucidating how diet influences metabolic 
pathways, and offers potential for use in determining personalised dietary interventions 
for the prevention or management o f obesity or disease.
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To confirm identities of discriminatory ions, pure compounds could be purchased 
when possible and analysed under identical conditions to that of the plasma samples, 
including spiking of original samples. Comparison of molecular ion and fragmentation 
patterns of the standards and the associated peak in original samples, retention time and 
sample spiking could then confirm the assignments. Further confirmatory analysis o f the 
ions was beyond the scope of this research, due to time limitations, and as such, 
assignments were putative.
Circulating lipids
Circulating total cholesterol levels have long been associated with atherosclerosis 
and CVD risk (Stamler J 1986), as posed in the Cholesterol Hypothesis, and thus are 
central to such research. Fasting circulating total cholesterol levels showed no significant 
differences either when compared to baseline or between the intervention products. Each 
group’s mean total cholesterol concentration was above the 4.0mM recommendation for 
those with heightened risk o f CVD, falling within the ‘ideal’ and ‘mildly high 
ranges’(JBS2 2005). As total cholesterol is reflective of CVD risk, this reflects an 
increased risk in the population group investigated. A  protective effect of the diets would 
be expected to manifest as a reduction in total cholesterol. As no significant changes in 
total cholesterol were found it was assumed that this did not reflect a significant change 
in CVD risk due to the intervention diets.
Investigation of the fasting circulating levels o f the individual components of total 
cholesterol gives a more detailed reflection of risk. Means of HDL at baseline and after 
each intervention were above the recommended level o f l.OmM (JBS2 2005), suggesting 
a protective effect afforded by HDL on CVD risk, however, this could have been a
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reflection of the increased total cholesterol levels in this group. The mean levels of 
fasting TAG at baseline, of 1.68mM, was on the cusp of the ‘ideal’ range of <1.69mM 
(JBS2 2005) suggesting a slightly increased risk. The mean NEFA concentrations fell 
within the ranges cited in the literature for healthy adults, of 0.44 ±  0 .17mM (Pedrini M  
2006), suggesting that the population group under investigation was not at increased risk 
of CVD according to this marker at baseline or post-interventions. Fasting concentrations 
of HDL cholesterol and TAG showed no significant changes due to the interventions and 
as concentrations of LDL cholesterol were calculated from measured concentrations of 
total and HDL cholesterol and TAG, it was expected, and observed, that no significant 
differences were determined in LDL concentrations. Concentrations of total and LDL 
cholesterol, TAG and NEFA were hypothesised to fall in response to protective 
interventions such as whole grain and circulating HDL levels were hypothesised to rise. 
Such protective effects in certain lipid markers were shown in previous research in 
response to a high performance inulin intervention, oat bran, calorie restricted legume- 
based diet and a wheat whole-grain based dietary product (Whyte J 1992; Letexier D 
2003; Rave K 2007; Hermsdorff H 2010). Participants in those interventions, however, 
displayed a higher risk profile at baseline than those of the current research, including 
obesity and elevated blood glucose and cholesterol levels which would be expected to be 
more responsive to dietary influence than levels associated with healthy individuals. 
Weight loss was also observed and levels o f certain intervention products were higher 
than of the current research, suggesting possible methodological changes for future work 
(i.e. higher baseline risk profiles, the addition of weight loss to the intervention and the 
possible need to increase the amount o f intervention products used).
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Despite finding a significant reduction in plasma TAG levels, Letexier et al found 
no significant differences in fasting total, HDL or LDL cholesterol levels due to a three 
week lOg/day high-performance inulin dietary cross-over study in eight healthy 
participants (Letexier D 2003), thus supporting the current research. Jackson et al 
investigated the effects o f lOg inulin per day for eight weeks on healthy participants with 
moderately raised total cholesterol and TAG levels (Jackson K 1999). No significant 
changes were observed in total, HDL or LDL cholesterol despite the moderately raised 
total cholesterol at baseline. Results did show a significant reduction in circulating free 
fatty acids after an eight week inulin intervention, but this result was also shown in the 
control group, suggesting it may have been a result of participation rather than the inulin 
itself. Concentrations of TAG, however, did show a significant reduction, suggesting that 
moderately raised levels are potentially more responsive to beneficial interventions such 
as inulin and that higher risk individuals might be more responsive to such interventions 
in future research.
A six week high inulin dietary intervention in 25 participants with mild/moderate 
hypercholesterolaemia aged 30 to 75 years also showed no significant changes in total, 
HDL or LDL cholesterol or TAGs, despite the baseline hypercholesterolaemia (Davidson 
M  1999). The inulin, however, was provided naturally contained within commonly 
available foods, rather than in the controlled delivery system used in the current research.
These results are further supported by other previous dietary interventions which 
found no change in LDL, HDL or TAG levels in response to high fibre whole grain diets 
(Andersson A 2007; Vuksan V  2007) or high inulin diets (Davidson M  1999). Brownlee 
et al also observed no significant changes in total, HDL or LDL cholesterol, TAG or
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NEFA in response to a high fibre high whole grain diet in further agreement with this 
study (Brownlee 1 2010).
These data also agree with those of Andersson et al and Brownlee et al who 
showed no significant changes in levels of circulating NEFA concentrations due to high 
fibre high whole grain diets, with similar circulating concentrations to the current 
research (Andersson A  2007; Brownlee 1 2010). Further supportive evidence is provided 
by Letexier et al who showed no significant change in NEFA in response to a six week 
high inulin diet (Letexier D 2003). (Jackson K 1999).
Insulin sensitivity
Fasting and post-prandial insulin and glucose levels were determined as markers 
of insulin resistance and, therefore, the risk of type n  diabetes, a major co-morbidity of 
CVD. Levels of insulin and glucose were hypothesised to fall in response to the 
protective diets of wheat fibre and inulin as was shown in overweight hyperinsulinaemic 
adults after a six week whole grain intervention (Pereira M  2002) and a high fibre diet 
(Chandalia M 2000) respectively. This was not observed, however, in the current 
research which showed no significant differences in fasting or post-prandial insulin.
These differences between results may have been due to their higher baseline levels of 
insulin in Pereira’ s participants, and the higher mean age and BMI of Chandalia’s 
participants, which could be more responsive to change than the lower levels seen in the 
current research. The same study also showed no significant reduction in fasting glucose, 
in agreement with the current study.
In agreement with these results, circulating insulin and glucose concentrations 
were found not to change in response to a six week high fibre high whole grain
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intervention (Andersson A 2007) or a six week high inulin diet (Letexier D 2003). A  
further randomised controlled intervention trial, showing lower fasting concentrations of 
insulin compar ed to the data shown here, also showed no significant change in response 
to high whole grain diets (Brownlee 1 2010). Brownlee et al also used a qualitative 
insulin sensitivity check index to further investigate insulin resistance and no significant 
changes were shown. A  high fibre 12 week whole grain intervention in type II diabetics 
showed no significant reduction in fasting insulin levels (Vuksan V  2007) with baseline 
levels higher of those found in the current research.
Although Pereira et al observed a significant reduction in fasting insulin after a 
six week whole grain intervention, no significant changes were observed in insulin AUC 
(Pereira M  2002). Andersson et al analysed insulin sensitivity using a euglycemic 
hyperinsulinaemic clamp and showed now change in response to a six week high whole 
grain intervention (Andersson A 2007).
In conclusion, wheat fibre and inulin have been shown to alter the levels o f three 
LysoPC species but have no further significant impacts on the blood markers investigated 
in a population group at risk of CVD.
Trial limitations
As outlined in chapter 3, certain limitations are common to all human 
interventions, such as population sampling, population size and compliance. Men only 
were chosen to participate in the FITMA trial to homogenise the small group involved (n 
= 10). Participants were also all Caucasian, well educated, university associated Surrey 
residents. Unfortunately, this limits the relevance of the results to women and the wider
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population, with implications for future research. Due to the increased requirements 
placed on participants in the FITMA trial, it was necessary to limit the number of 
participants included to 12, with ten participants successfully completing the trial. This 
was sufficient for the pilot research but would ideally be increased in future work.
Although participants were at risk of CVD, as defined by their sex and age (men 
aged 30 to 60 years) and high BMI values ( 2 5 - 3 5  kg/m2, Christie D 1981, Herman B 
1982, Nathan L 1997, Kenachaiah S 2002) they were not at high risk and, as such, a high 
risk profile was not reflected in their baseline makers measured for change within the 
study. Had higher levels been present it is likely these would be more responsive to the 
beneficial interventions, thus suggesting that any similar future work might benefit from 
involving higher risk participants.
The cross-over design of the study controlled for inter-individual differences and 
increased the power of the data but required a reduction in intervention length to 28 days 
compared to the Pilot WISE trial Increasing the length of the trial may have enhanced 
changes in risk markers. For example, other studies have shown significant differences in 
certain circulating risk markers after longer interventions (Jackson K 1999; Letexier D 
2003), however, no significant differences were observed in the longer eight week 
interventions of the Pilot WISE trial.
The FITMA trial required data from ten participants to be fully powered as the 
original sample size of n= 1 2  allowed for 1 0 %  of the subjects to be non-evaluable in each 
treatment group. This was based on a detecting a clinically significant drop in insulin of 
20pM (a difference to detect of 25%) between the groups with at least 80% power,
187
assuming that the common standard deviation is 16pM or 20% and using a two sample t- 
test with a 0.05 two sided significance level. The estimate of the standard deviation was 
based on published data for subjects who took part in a Resistant Starch Study of a 
similar design conducted by Robertson et al (2005). Ten participants successfully 
completed the trial as so power was achieved.’
Compliance was reported as slightly better in the FITMA than the Pilot WISE 
trial. This may be due to the shorter intervention periods which, although totalled 84 (3 x 
28) days, were only 28 days long individually. Also, the intervention products used in the 
FITMA trial were reportedly more palatable than those of the Pilot WISE trial as they 
were developed with feedback from participants in that study. The delivery system, of 
providing the bespoke bread roll-like intervention products to be included in the diet, was 
widely very well accepted and proved very easy to monitor for compliance.
Interestingly, unlike in the Pilot WISE trial, participants did not report altering 
their habitual dietaiy intake or exercise as a result o f participation. This is potentially due 
to better general acceptance of the FITMA intervention products which were very similar 
in appearance and organoleptic qualities to commercially available bread and, therefore, 
didn’t highlight participation in a dietary intervention trial. Monitoring exercise, or 
adding a structured exercise protocol for participants, may still be valuable for future 
work.
It is not possible to conclude, therefore, that either soluble or insoluble fibre, 
represented in this research by wheat fibre and inulin respectively, actively reduce CVD 
risk markers in an at risk population.
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Chapter 5
T h e  e ffe c t o f  w h o le  g r a in  f e r m e n ta t io n  p r o d u c ts  o n  th e  
v a s c u la r  e n d o th e liu m  a t  th e  c e l lu la r  lev e l
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Endothelial dysfunction is a major player in atherosclerosis, the underlying 
pathogenesis of CVD, and whole grain diets are associated with decreased risk of this 
disease. The components of a whole grain diet would never interact with the endothelium 
under normal physiological circumstances but the breakdown products of such diets 
could.
Pathology of the vascular endothelium is associated with haemostasis and is 
reflected by altered levels of the haemostatic molecules, von Willebrand factor and tissue 
plasminogen activator-1 which play major roles in regulating the clotting and fibrinolytic 
pathways, respectively. Alterations in the levels of these factors secreted by endothelial 
cells may, therefore, be indicative of endothelial dysfunction. The cellular adhesion 
molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion-1 
(VCAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) are known to 
vary with inflammation with endothelial cell surface expression of ICAM-1 and VCAM- 
1 increasing during inflammation and surface levels of PECAM-1 decreasing. In 
addition, endothelial derived levels of interleukin-8 (IL-8) and nitric oxide (NO) alter 
during inflammation and have been proposed as markers of the inflammation associated 
with CVD.
The short chain fatty acids acetate, propionate and butyrate are the products of 
fermentation of fibres by the colonic micro-flora and have been shown to have anti­
inflammatory effects in vitro (Tedelind S 2007). Butyrate is predominantly metabolised 
by the colonocytes, for which it provides the major source of fuel, but acetate and
5.1 Study rationale and aims
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propionate pass into the circulation and thus come into direct contact with the cells of the 
vascular endothelium.
The SCFAs were made up in RO water to the appropriate concentrations and 
added to the cell medium. To detect and control for any possible changes caused by the 
water, both a medium alone and a medium and water control were used. The true control, 
treated with medium alone, is referred to as ‘Control’ or ‘C’; this is unactivated. All other 
samples are activated. Of these, the ‘Medium’ or ‘M’ control is treated with medium 
alone and the ‘Water’ or ‘W’ control is treated with medium and water.
SCFAs occur in the colon at mM concentrations (Tedelind S 2007) but are 
absorbed to a great extent by the colonocytes associated with enhanced sodium 
absorption and bicarbonate secretion. Therefore, concentrations ultimately found 
circulating in the blood and interacting with the endothelial cells are significantly lower 
than this. Concentrations of propionate were found to range from 5+ 4  pM in the 
peripheral blood to 21 ± 21 pM in the hepatic blood. Acetate ranged from 70 ± 41 pM in 
the peripheral blood to 115 ± 63pM in the hepatic blood (Cummings J 1987). Ranges of 
test SCFAs chosen to represent these levels in the blood were 0.1, 1.0 10.0 and lOO.OpM.
It is thought that the association between high whole grain diets and low levels of 
CVD may be due to the protective effects of the SCFAs produced as a result of the 
breakdown of whole grains. The SCFAs acetate, propionate and butyrate have been 
shown to have anti-inflammatory properties when investigated in vitro (Tedelind S 2007). 
Therefore, the aim of this research was to investigate the potential anti-inflammatory 
effect of whole grain fermentation products, the short chain fatty acids sodium acetate 
and propionate, on endothelial cell function. It was hypothesised that treatment of
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endothelial cells with sodium acetate and propionate would act in opposition to activation 
by TNF-a/IFN-y, thus reducing markers of dysfunction.
In this chapter, we have investigated the effects of the SCFAs on both a cell line, 
human microvascular endothelial cells (HMEC-1), and in the more physiologically 
relevant model, primary human coronary artery endothelial cells (HCAEC).
,5.2 The effect of SCFAs on endothelial cell secreted inflammatory mediators
5.2.1 Interleukin-8
The concentration of IL-8 secreted by HMEC-1 cells and HCAECs treated with 
medium alone, TNF-a/IFN-y and by cells treated with TNF-a/IFN-y and further treated 
with sodium acetate or sodium propionate (0.1, 1.0, 10 or lOOpM) or with a water control 
was determined as described in 2.2.1.6.
HMEC-1
In HMEC-1 cells, treatment with TNF-a/IFN-y caused a higher secretion of IL-8 
from 5.0 to 11.8pM/ml, however, this difference was not statistically significant. 
Similarly, the levels of IL-8 secreted by cells treated with the water control were not 
significantly different from cells treated with medium alone. Treatment of TNF-a/IFN-y 
activated cells with acetate at 0.1 and l.OpM had no impact on the secretion of IL-8 
whereas treatment with 10 and lOOjxM acetate, and all concentrations of propionate 
investigated, resulted in lower secretion of EL-8 compared to the water control (figure 
5.1), however, these differences were not significant.
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Figure 5.1: IL-8 secreted by HMEC-1 cells. Cells were grown to confluency then 
treated with either medium (control, C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 
hours. TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or 
sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of 
IL-8 secreted into the supernatant was determined by an in-house ELISA. Data are 
displayed as mean + standard deviation of 3 experiments. No significant differences were 
found using a two way ANOVA test.
HCAEC
Treatment of HCAECs with TNF-a/EFN-y significantly increased the secretion of 
IL-8 from 1.2 to 5.0pM/ml (p<0.05). Similarly, the levels of IL-8 secreted by cells treated 
with the water control were significantly greater compared to cells treated with medium 
alone to 4.9pM/ml (p<0.05). Treatment of TNF-a/IFN-y activated cells with acetate gave 
lower secreted levels of IL-8, but this difference was not significant. Treatment with 
propionate showed a lower IL-8 secretion at 0. ImM, but no differences at the higher 
concentrations. No differences were statistically significant when compared to the water 
control (figure 5.2).
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Figure 5.2: IL-8 secreted by HCAECs. Cells were grown to confluency then treated 
with either medium (control, C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 hours. 
TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or sodium 
acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of EL-8 
secreted was determined by an in-house ELISA. Data are displayed as mean + standard 
deviation of 5-6 experiments where * denotes p<0.05 using a two way ANOVA test.
5.2.2 Nitric oxide
Preliminary work was carried out in the form of a pilot study in EA.hy926 an 
‘endothelial like’ cell line derived from the fusion of human umbilical cord endothelial 
cells and the rat carcinoma cells A549. A time course was run to determine the optimum 
time to measure nitrite concentration, as a marker of nitric oxide secretion following 
stimulation with TNF-a /IFN-y and nitrite was assayed in the supernatants by Griess kit 
as described in 2.2.7.5. Subsequently, HMEC-1 cells and HCAECs were treated with 
medium alone, TNF-a/IFN-y alone or with TNF-a/EFN-y and sodium acetate or 
propionate at 0.1, 1.0, 10 or lOOpM and the concentration of nitrite was determined.
Treatment of EA.hy926 cells with TNF-a/IFN-y did not cause a significant 
alteration in levels of nitrite over 0, 3, 6 or 12 hours when compared to cells treated with 
medium alone (figure 5.3). Treatment did significantly alter the levels of nitrite at 24 
hours (p<0.0105) and 48 hours (p<0.0237) as determined by an unpaired Students t-test. 
Although the levels detected in the supernatants from the treated cells were higher than 
the levels in the supernatants from the cells treated with medium alone, at 72 hours, this 
difference was not statistically significant. It was decided, therefore, that 24 hour 
incubations would be used for the purposes of these investigations.
EA.hy926
0 3 6 12 24 48 72
Incribation time (ninutes)
Figure 5.3: Time course of detection of nitrite in EA.hy926 supernatants. Cells were 
grown to confluency then treated with either medium alone (■) or lOOIU/ml TNF-a and 
50IU/ml IFN-y (■) for 0, 3, 6, 12, 24, 48 or 72 hours. The concentration of nitrite was 
determined by a Griess reagent kit. Data are displayed as mean + standard deviation of 3- 
4 experiments, where * denotes p<0.05 using a paired Student’s t-test.
HMEC-1
The concentration of nitrite was determined in the supernatants of HMEC-1 cells 
treated with medium alone, TNF-a/IFN-y alone and from cells activated with TNF-
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a/IFN-y and further treated with sodium acetate or sodium propionate (0.1, 1.0, 10 or 
lOOpM) or with a water control for 24 hours. Treatment with TNF-a/IFN-y increased the 
concentration of nitrite from 1.3 to 3.5pM, however, this increase was not statistically 
significant. The levels of nitrite in the supernatants of cells treated with the water control 
were significantly higher at 4.6pM compared to cells treated with media alone 
(p<0.0042). Treatment of TNF-a/IFN-y activated cells with acetate or propionate 
appeared to reduce the levels of nitrite to differing extents when compared to the water 
control, although this was not statistically significant (figure 5.4).
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Figure 5.4: Nitrite secreted by HMEC-1 cells. Cells were grown to confluency then 
treated with either medium (control, C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 
hours. TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or 
sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of 
nitrite in the supernatant was determined by a Griess reagent kit. Data are displayed as 
mean + standard deviation of 3 experiments, where *** denotes p<0.005 using a two way 
ANOVA test
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HCAEC
The concentration of nitrite secreted by HCAECs was determined on cells treated 
with medium alone, TNF-a/IFN-y alone and on cells activated with TNF-a/IFN-y and 
further treated with sodium acetate or sodium propionate (0.1, 1.0,10 or lOOgM) or with 
a water control All levels of nitrite, however, were below the level of detection (lpM) of 
the assay (data not shown).
5.3 Haemostatic secreted factors
vWF and tPA-1 carry out opposing functions in coagulation and fibrinolysis 
respectively, maintaining the balance associated with haemostasis. Both can be secreted 
by endothelial cells and increased levels have been associated with inflammation and 
vascular injury, supporting suggested links to CVD risk.
5.3.1 Tissue plasminogen activator-1
The concentration of tPA-1 secreted by HMEC-1 cells and primary HCAECs was 
determined as described in 2.2,5.1, after treatment with medium alone, TNF-a/IFN-y 
alone and by cells activated with TNF-a/IFN-y and further treated with sodium acetate or 
sodium propionate (at 0.1, 1.0,10 or lOOpM) or with a water control.
HMEC-1
Treatment of HMEC-1 with TNF-a/IFN-y did not significantly affect the levels of 
tPA-1 detected in the supernatants’ subsequent treatment with water also showed no 
significant effect on secretion level When treated with acetate or propionate (at the 
concentrations described above) no significant changes in the levels secreted when
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compared to the water control were observed, with levels remaining below 1 lng/ml 
(figure 5.5).
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Figure 5.5: tPA-I secreted by HMEC-1 cells. Cells were grown to confluency then 
treated with either medium (control, C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 
hours. TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or 
sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of 
tPA-1 expressed was determined by an in-house ELISA. Data are displayed as mean + 
standard deviation of 3 experiments. No significant differences were found using a two 
way ANOVA test.
HCAEC
Treatment of primary HCAECs with TNF-a/IFN-y did not significantly affect the 
levels of tPA-1 secreted, nor did subsequent treatment with water. Treatment with acetate 
or propionate at the levels indicated below also had no significant impact on secretion of 
tPA-1 by these cells (figure 5.6) with levels remaining below 4ng/ml.
198
/— \ 8"
Treatment
Figure 5.6: tPA-1 secreted by HCAECs. Cells were grown to confluency over 72 hours 
then treated with either medium (control, C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 
24 hours. TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or 
sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of 
tPA-1 secreted was determined by an in-house ELISA. Data is displayed as mean + 
standard deviation of 6 experiments. No significant differences were found using a two 
way ANOVA test.
5.3.2 von Willebrand factor
An in house ELISA, as described in 2.2.5.1, was used to determine the 
concentration of vWF secreted by HMEC-1 cells and HCAECs on treatment with 
medium alone, TNF-a/IFN-y alone and by cells activated with TNF-a/IFN-y and further 
treated with sodium acetate or sodium propionate (at 0.1, 1.0, 10 or lOOpM) or with a 
water control.
HMEC-1
Treatment of HMEC-1 cells with TNF-a/IFN-y and further treatment of TNF- 
a/IFN-y activated cells with water, acetate or propionate at the concentrations tested did
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not significantly alter the levels of vWF secreted (figure 5.7) which remained consistently 
below 0.0013IU/ml.
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Figure 5.7: vWF expressed by HMEC-1 cells. Cells were grown to confluency then 
treated with either medium (C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 hours. 
TNF-a/IFN-y cells were then treated with medium alone (M), water (W), or sodium 
acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of vWF 
expressed was determined by an in-house ELISA. Data are displayed as mean + standard 
deviation of 3 experiments. No significant differences were found using a two way 
ANOVA test.
HCAEC
A drop in the level of secreted vWF after treatment of the cells with TNF-a/IFN-y 
was observed, however, this was not significant. Treatment with water, acetate or 
propionate at the concentrations shown (figure 5.8) did not change the levels of secreted 
vWF, with levels continuously below 0.051IU/ml.
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Figure 5.8: vWF expressed by HCAECs. Cells were grown to confluency then treated 
with either medium (C) or lOOIU/ml TNF-a and 50IU/ml IFN-y for 24 hours. TNF- 
a/IFN-y cells were then treated with medium alone (M), water (W), or sodium acetate or 
propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. The concentration of vWF expressed 
was determined by an in-house ELISA. Data are displayed as mean + standard deviation 
of 4-5 experiments. No significant differences were found using a two way ANOVA test.
5.4 The effect of SCFA on endothelial cell surface markers
The cellular adhesion molecules ICAM-1, VCAM-1 and PEC AM-1 are active in 
the movement of cells through the endothelium and into the atherosclerotic plaques. The 
percentage of HMEC-1 and HCAEC cells expressing these surface adhesion molecules 
was determined after treatment with medium alone, TNF-a/IFN-y alone for 24 hours 
and on cells activated with TNF-a/IFN-y and further treated with sodium acetate or 
sodium propionate (0.1, 1.0, 10 or lOOpM) or with a water control for 24 hours by flow 
cytometry, as described in 2.2.7.4.
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Forty-two percent of cells treated with medium alone expressed ICAM-1 on their 
surface, which was significantly increased to 76% upon stimulation with TNF-a/IFN-y 
(p<0.005) and stimulation with TNF-a/IFN-y and further treatment with the water control 
(p<0.01). No significant difference was observed between cells treated with TNF-a/IFN-y 
alone or further treated with water. Treatment of the TNF-a/EFN-y activated cells with 
either acetate or propionate at any of the concentrations tested did not significantly alter 
the percentage of surface ICAM-1 expression. The mean fluorescence intensity of 
staining (MFI) of the cells treated with medium alone was 47.
On treatment with TNF-a/IFN-y this rose to 272 which was a significant increase 
(p<0.01, figure 5.9) and 316 following further treatment with water (p<0.005). The MFI 
of TNF-a/IFN-y activated cells, subsequently treated with any concentration used of 
either acetate or propionate, did not alter significantly from that of the water treated cells.
5.4.1 Intercellular adhesion molecule-1
HMEC-1
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Figure 5.9: ICAM-1 expression on HMEC-1 cells treated with SCFAs. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were then treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 
hours. The percentage of cells expressing (A) and the MFI of staining (B), were 
determined by flow cytometry. Values are displayed as mean + standard deviation of 3 
experiments, where** and *** denote p<0.01 and p<0.005 respectively, when compared 
to cells treated with medium alone, using a two way ANOVA test.
HCAEC
In HCAECs, treatment with TNF-a/IFN-y increased surface expression of ICAM- 
1 from 37% (medium treated) to 59% (TNF-a/IFN-y treated) although this was not 
statistically significantly. Further treatment of TNF-a/IFN-y activated cells with water, 
acetate or propionate showed no significant change in the expression of ICAM-1 
compared to the water control. No significant differences were observed in MFI between 
any groups (figure 5.10).
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Figure 5.10: Expression of ICAM-1 by HCAECs treated with SCFAs. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. 
The percentage of cells expressing ICAM-1 (A) and the MFI of staining (B), were 
determined by flow cytometry. Values displayed as mean + standard deviation (n = 3). 
No significant differences were found using a two way ANOVA test.
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HMEC-1 cells, treated with TNF-a/IFN-y increased their surface expression of 
VCAM-1 from 0.9% (medium treated) to 5.19% (TNF-a/EFN-y treated) although this was 
not statistically significant. Further treatment of TNF-a/IFN-y activated cells with water, 
acetate or propionate showed no significant change in the expression of VCAM-1 
compared to the water control. The MFI of cells treated with medium alone rose non- 
significantly on treatment with TNF-a/IFN-y (figure 5.11). No significant difference was 
observed when TNF-a/IFN-y activated cells were subsequently treated with water or with 
any concentration used of either acetate or propionate.
5.4.2 Vascular cell adhesion molecule-1
HMEC-1
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Figure 5.11: VCAM-1 expression by HMEC-I cells treated with SCFAs. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were then treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0, 10 or 100pM for 24 hours. 
The percentage of cells expressing VCAM-1 (A) and the MFI of staining (B) as 
determined by flow cytometry. Values displayed as mean + standard deviation of 3 
experiments. No significant differences were found using a two way ANOVA test.
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HCAEC
The expression of VCAM-1 by HCAECs varied slightly but remained below 2% 
following all treatments. Treatment with TNF-a/IFN-y and subsequent treatment with 
water, or the range of concentrations of acetate or propionate used, did not significantly 
alter the percentage of HCAECs expressing VCAM-1. The MFI of cells treated with 
medium alone was 4.6. This was not significantly altered by treatment with TNF-a/IFN-y 
(figure 5.12). No significant difference was observed when TNF-a/IFN-y activated cells 
were subsequently treated with water (MFI of 3.7), acetate or propionate.
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Figure 5.12: VCAM-1 and expression by HCAECs treated with SCFAs. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were then treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. 
The percentage of cells expressing VCAM-1 (A) and the MFI of staining (B) as 
determined by flow cytometry. Values displayed as mean + standard deviation of 3-5 
experiments. No significant differences were found using a two way ANOVA test.
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The percentage of HMEC-1 cells expressing PECAM-1 after treatment with 
medium alone was 11.4%. This was reduced to 8.1% on treatment with TNF-o/IFN-y but 
the change was not statistically significant. Subsequent treatment with water, or the 
various concentrations of acetate and propionate used, did not significantly affect the 
percentage of cells expressing PECAM-1 (figure 5.13). Treatment of HMEC-1 cells with 
TNF-aTFN-y did not alter the PECAM-1 MFI. Further treatment with water, acetate or 
propionate also had no impact on MFI.
5.4.3 Platelet endothelial cell adhesion molecule-1
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Figure 5.13: PECAM-1 expression by HMEC-1 cells treated with SCFAs. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were then treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0, 10 or lOOpM for 24 hours. 
The percentage of cells expressing PECAM-1 (A) and the MFI of staining (B) as 
determined by flow cytometry. Values displayed as mean + standard deviation of 3 
experiments. No significant differences were found using a two way ANOVA test.
HCAEC
Treatment with TNF-a/IFN-y, and subsequent treatment with water, reduced the 
percentage of cells expressing PECAM-1 from 27.0 to 18.0% and 22.4% respectively but 
not significantly. Further treatment with acetate or propionate did not significantly affect 
the percentage of cells expressing PECAM-1 when compared to the water control. The 
MFI of PECAM-1 staining of HCAECs was significantly reduced from 8.6 to 4.6 on 
treatment with TNF-a/IFN-y and to 4.3 on subsequent treatment with water (p<0.0046, 
figure 5.14). Treatment with acetate or propionate did not significantly alter PECAM-1 
MFI when compared to the water control.
212
A^  40-1
Treatment
B
20i
Treatment
Figure 5.14: PECAM-1 expression by HCAECs treated with SCFA. Cells were 
grown to confluency then treated with either medium (control, C) or 1 OOIU/ml TNF-a 
and 50IU/ml IFN-y for 24 hours. TNF-a/IFN-y cells were then treated with medium alone 
(M), water (W), or sodium acetate or propionate at 0.1, 1.0,10 or lOOpM for 24 hours. 
The percentage of cells expressing PECAM-1 (A) and the MFI of staining (B), were 
determined by flow cytometry. Values displayed as mean + standard deviation of 3 
experiments, where ** denotes p<0.01 using a two way ANOVA test.
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The aim of this study was to investigate the effects of the SCFAs sodium acetate 
and sodium propionate, the fermentation products of whole grains, on markers of 
vascular function at the cellular level.
Endothelial cell secreted inflammatory mediators
It was hypothesised that the SCFAs would have anti-inflammatory effects based 
on previous research looking at the effects of acetate, propionate and butyrate on cytokine 
release from human neutrophils. This showed a decrease in LPS-stimulated TNF-a as a 
result of incubation with 30mM of each SCFA independently (Tedelind S 2007). Indeed, 
HMEC-1 cells activated with TNF-a/IFN-y secreted higher levels of the inflammatory 
cytokine IL-8 than those not stimulated, although this was not significantly different. This 
enhanced secretion was maintained upon further incubation of the cells with the water 
control and levels remained high after treatment with low concentrations of acetate but 
was lower (non-signifxcantly) upon treatment with higher concentrations of acetate and 
all concentrations of propionate. As an inflammatory cytokine, levels of IL-8 secretion 
would have been expected to fall on treatment with protective factors and has been shown 
to do so by one group looking at the anti-inflammatory effect of the platelet activity 
inhibitor ticlopidine on the secretion of IL-8 by HUVECs (Hu C 2009).
This response was mirrored in HCAECs which significantly increased IL-8 
secretion on treatment with TNF-a/IFN-y and further treatment with water indicating 
activation of the cells. Subsequent treatment with the higher concentrations of acetate 
resulted in a reversal of this higher production (similar to the result in HMEC-1 cells)
5.5 Discussion
however, this was not statistically significant. To determine whether the treatments 
investigated (especially at the higher concentrations) were affecting cell viability and, 
therefore, function and production of relevant mediators, an MTT cell viability assay was 
carried out as outlined in 2.2.7.7. The results indicated no significant effects on cell 
viability of the compounds investigated suggesting the cells remained viable and in good 
functional health throughout the treatments and that any changes in IL-8 production 
might be due to an anti-inflammatory effect of SCFAs. Moon et al showed a significant 
reduction in IL-8 and MCP-1 on treatment of HUVECs with the anti-inflammatory 
phytochemical caffeic acid (Moon M 2009) showing that this powerful chemotactic 
cytokine can be modulated in vitro and, as such, may be responsive to beneficial effects 
of whole grains.
Levels of secreted nitric oxide reflect endothelial cell function and can be 
measured as the stable end product nitrite in cell culture supernatants. Preliminary work 
carried out in EA.hy926 cells confirmed an increase of nitrite production following 
activation with TNF-a and IFN-y which was apparent after 24 hours of incubation. This 
increase was mirrored in the cell culture supernatants of HMEC-1 cells following TNF- 
a/IFN-y activation. A trend towards a reduction on treatment with certain concentrations 
of SCFAs was observed as was hypothesised, although this was not significant or 
consistent, which could be due to the low levels detected. Cell culture supernatant levels 
of NO from HCAECs cultures all remained below the limit of detection.
Little is available in the literature to compare to this work. However, the small 
molecular weight lignan, Gomisin A, has been shown to increase NO production in both
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a time- and concentration-dependent manner, and increase eNOS activity, in un­
stimulated HCAECs (Park J 2009) reflecting a cardio-protective effect of increased vaso­
relaxation. The cardio-protective diets would be hypothesised to act via a reduction in the 
increased levels of NO production from eNOS. However, in this research it is likely that 
iNOS was stimulated to a greater proportional extent than would occur in vivo. Future 
work could investigate the mRNA of both eNOS and iNOS to determine the effects 
within the cell. This has been investigated in work by Park et al in researching the effect 
of Gomisin A in HCAECs (Park J 2009) supporting the need for further investigations.
Further potential markers of interest could include TNF- a or IL-1, or the 
inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1), the expression of 
which was also shown by Hu et al to increase significantly on treatment with TNF-a.
Haemostatic secreted factors
The fibrinolytic and pro-coagulant factors circulating in the blood work in a 
tightly controlled balance to maintain haemostasis. Damage to the endothelium can 
disturb this balance as many of the factors are produced by endothelial cells. As such, the 
secretion of these mediators is a good indicator of vascular dysfunction and, potentially, 
risk of CVD (Folsom A 2001; Jager A 2001).
In this study, no significant differences were seen in levels of tPA-1 secreted from 
either HMEC-1 cells or HCAECs on activation by TNF-a/IFN-y or further treatment with 
the test interventions. Levels would be expected to increase upon activation and possibly 
decrease after treatment with protective factors such as SCFAs. The reverse has been
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observed, however, in a study investigating the effects of the proposed inflammatory 
mediator CRP on bovine aortic endothelial cells. In their report, the authors demonstrated 
significantly increased expression of PAI-1, the tPA-1 inhibitor, by HCAECs after CRP 
incubation (Nakakuki T 2005). Decreases in tPA-1 gene expression were also observed in 
a study by Ulfhammer et al in which TNF-a suppressed tPA-1 gene expression by human 
umbilical vein endothelial cells after a 24 hour activation (Ulfhammer E 2006). These 
reports indicate that this factor can be modulated in vitro by inflammatory (and 
presumably anti-inflammatory mediators). However, its secretion in vitro in response to 
these factors is complicated and may rely on the secretion of other haemostatic factors 
such as vWF.
No change was detected in levels of vWF expressed from HMEC-1 cells on 
activation or on subsequent treatment with the test intervention and the level of secreted 
vWF was very low. HCAECs, however, secreted higher levels of vWF which decreased 
(albeit non-significantly) upon stimulation by TNF-a/IFN-y. This was unexpected, as pro- 
inflammatory cytokines activate endothelial cells usually resulting in the increased 
secretion of a variety of endothelial cell products.
More recently, however, several reports have been published using slightly 
different stimulators of a variety of endothelial cells to secrete haemostatic factors. Other 
activators such as histamine, ionomycin and interleukin-1(3 (IL-1 P) have been 
demonstrated to enhance the secretion and activity of vWF, tissue factor (TF), PAI-1 and 
tPA-1 (Disse J 2009; Lakota K 2009; Knipe L 2010) and may, therefore, be better 
activators for this type of research. Although no relevant research could be found
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investigating the effects of SCFAs in human endothelial cells, the above mentioned 
report by Lakota et al demonstrated a significant increase in the activity of TF (another 
pivotal factor in thrombosis, able to transform the endothelial cell membrane from an 
anticoagulant to a pro-coagulant surface following vascular injury) upon incubation with 
IL-1|3. This was subsequently down-regulated with the anti-inflammatory plant extracts 
in a method similar to that of the current research. This clearly demonstrates the potential 
for dietary constituents to impact on endothelial production of haemostatic factors 
involved in atherosclerosis and the effects of SCFAs, therefore, should be followed up to 
elucidate their mechanisms.
Suiface markers
The cellular adhesion molecules are key mediators of the extravasation of cells 
including monocytes and regulation of their expression is involved in the progression of 
atherosclerosis (Springer T 1994; Yang L 2005). As such, levels of expression of these 
were measured as described in 2.2.7,4.
The percentage of HMEC-1 cells expressing ICAM-1 and the mean fluorescence 
intensity (MFI) of ICAM-1 staining were both significantly increased upon activation 
with TNF-a/IFN-y when compared to those treated with medium alone. This increased 
level remained on further treatment with water, acetate or propionate showing no 
significant differences in activation as a result of the SCFA treatment. An increase in 
expression of ICAM-1 on activation was as expected, reflecting an inflammatory or 
activated state in an ‘at risk’ individual. Treatment with the SCFAs would have been 
expected to reduce these levels, post-activation, if any protective effects were afforded by
them The percentage of HCAECs expressing ICAM-1 mimicked this reaction although 
the change on activation by TNF-a/IFN-y was not significant. The MFI of ICAM-1 
staining of HCAECs showed no trends toward change on activation or further treatment, 
with levels were similar to those of the activated HMEC-1 cells. This might be due to 
maximal stimulation of cells with treatment of TNF-a/IFN-y levels of which, although 
widely used in the literature (approximately lOOIU/ml TNF-a and lOOIU/ml IFN-y 
(Lombardi A 2009; Zapolska-Downar D 2009)), were higher than circulating 
concentrations in vivo which are widely known to be in the range of 0.55 to 2.82pg/ml. 
These pleiotropic cytokines are known to interact synergistically to stimulate cells in 
vitro (Lombardi A 2009). Titration of TNF-a/IFN-y would be of benefit in future work to 
produce optimal stimulation. Future work may also benefit from stimulation of such 
physiologically relevant levels of TNF-a.
In agreement with this data, Miller et al exposed human umbilical vein 
endothelial cells (HUVECs) to 5mM propionate and showed no significant differences in 
the levels of ICAM-1 expressed, as determined by flow cytometry (Miller S 2005). They 
also treated HUVECs with the SCFA butyrate for 24 hours and assessed ICAM-1 
expression, interestingly showing a significant increase in expression on treatment with
2.5 and 5.0mM butyrate which was unexpected. Levels of ICAM-1 mRNA and E-selectin 
were also found to be significantly increased by treatment with butyrate. These cells, 
however, are not primary cells, were treated with a different SCFA and were not 
activated with TNF-a, which may account for the differences in results. Zapolska- 
Downar et al showed a significant increase in ICAM-1 and VCAM-1 production from 
HUVECs on treatment with lOOIU/ml TNF-a in agreement with the current research.
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Their investigation into the effects of propionate on HUVECs showed that pre-treatment 
with 0.1, 1.0 and lOmM propionate significantly reduced the TNF-a induced expression 
of ICAM-1 in a dose and time dependent manner (Zapolska-Downar D 2009). These 
results may differ to those of this research as the methodology was different, with 
HUVECs being treated first with the propionate and then with TNF-a. The umbilical vein 
origins of the HUVECs renders them less physiologically relevant with regard to CVD 
than the HMEC-1 cells or the HCAECs. Zapolska-Downar attributed the observed effects 
to propionate’s inhibition of NFk-B, a key transcription factor implicated in the 
regulation of genes during immune and inflammatory responses and in particular in 
responses to TNF-a. Other studies on the anti-inflammatory effects of dietary 
components include Moon et al, who showed a significant increase in ICAM-1 
expression by HUVECs on stimulation with TNF-a in agreement with this work. This 
group, however, also showed a significant reduction in ICAM-1 and E-selectin 
expression on treatment with caffeic acid (Moon M  2009).
The percentage of HMEC-1 cells and HCAECs expressing VCAM-1 remained 
below 5% throughout the experiment, without significant changes upon activation or 
treatment The VCAM-1 MFI of both cell types showed no significant changes due to 
activation or treatment, with levels continuously below 12 and lower on the HCAECs 
than the HMEC-1 cells. As VCAM-1 is directly active in the pathology of 
atherosclerosis, expression of VCAM-1 would be expected to rise on activation, to mimic 
an inflammatory state, as would be seen in high CVD risk individuals (O'Brien K 1993). 
Levels of VCAM-1 were, therefore, hypothesised to increase on activation and to 
decrease in response to protective compounds such as SCFAs, although this was not
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shown in the data. This may be due, however, to the overall low concentrations of 
VCAM-1 rendering any reductions undetectable or a potential overstimulation by 
stimulators TNF-a/IFN-y although this is unlikely as other similar concurrent work 
carried out in human abdominal aortic endothelial cells not pre-treated with the 
stimulators TNF-a/IFN-y also showed no significant effects of the SCFAs (data not 
shown).
Zapolska-Downar et al showed a significant reduction in TNF-a stimulated 
HUVEC expression of VCAM-1 on pre-treatment with several physiologically relevant 
concentrations of propionate (Zapolska-Downar D 2009), which may differ from this 
research for the reasons outlined above for ICAM-1. Treatment of HUVECs with the 
SCFA, butyrate, did not significantly alter expression of VC AM-1 as determined by flow 
cytometry (Miller S 2005). Interestingly, TNF-a induced increases in VCAM-1 
expression by HUVECs were significantly reduced to near baseline levels by the platelet 
activity inhibitor ticlopidine proving such a reversal of expression is possible although 
not reflected in the current research (Hu C 2009). This was also reflected in TNF-a 
treated HUVECs further treated with caffeic acid (Moon M 2009). VCAM-1 is not 
constitutively expressed by the endothelium so may not be the most appropriate marker 
for in vitro work, with other potential markers including E- or P-selectin.
As a mediator of various migration steps through distinct domains including 
trans-endothelial migration and migration through the extracellular matrix, levels of 
circulating PECAM-1 are inversely related to CVD risk as falling levels allow for 
increased extravasation, an important step in atherosclerosis (Liao F 1995). HMEC-1
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cells showed low levels of PECAM-1 expression when incubated with media alone. 
Although these levels would have been expected to fall on activation, this was not shown 
to occur and levels did not alter significantly in response to further treatment with 
SCFAs. Baseline levels of PECAM-1 were higher in HCAECs with a trend towards a 
reduction upon activation (which was mirrored by the MFI of staining). Neither, 
however, were significantly different. Levels were then slightly increased by further 
treatment with certain concentrations of SCFAs, as would be expected, although these 
changes were not significant when compared to those treated with media alone.
Treatment with SCFAs had no further impact on levels although a protective effect would 
have manifested itself rise to levels seen with media alone. This was reflected by Peng et 
al who observed that tumour conditioned medium induced the expression of PEC AM by 
HUVECs as assessed by flow cytometry (Peng Y 2010). The different cells and activators 
involved in the current research may account for the differences in findings and may 
suggest other activators for future research.
Increasing the number of repeats of each experiment carried out would have 
increased power and reduced the impact of the inter-cell variations associated with using 
primary cells, which can often grown differently between experiments.
Cells were activated first and then treated with the investigational components. 
This was to reproduce, as closely as possible, the situation in vivo in which the inflamed 
endothelium (represented by the activated endothelial cells) comes into contact with the 
SCFAs produced as a by product of the high levels of whole grains or fibres within the 
GI tract (or added to the media in vitro). An alternative method would have been to pre­
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treat the cells with the SCFAs and then activate, although this method was not thought to 
replicate the human intervention studies as well as the alternative and so was dismissed in 
favour of the ‘activate then treat’ method employed.
In summary, although treatment with TNF-a/IFN-y did, on occasion, significantly 
alter levels of markers investigated, the short chain fatty acids did not significantly affect 
any markers at the concentrations involved. Thus it was concluded that this work can not 
be used to prove a protective role for SCFAs on the cardiovascular endothelium although 
the model has been shown to be productive suggesting the potential for future work 
investigating different types or concentrations of activators and SCFAs.
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Chapter 6
G e n e r a l  d isc u ss io n
Cardiovascular disease (CVD) is the single largest cause of mortality and 
morbidity in the UK and several other Westernised countries (Truswell A 2002). It is a 
complex and multifactorial disease with both modifiable and non-modifiable causes and 
several co-morbidities including obesity, type II diabetes and hyperlipidaemia (Bogardus 
C 1985; Haffher S 1998; Turner R 1998). One popular, non-invasive pro- and re-active 
intervention method proposed to beneficially impact on risk CVD and of several of these 
co-morbidities is dietary modification. High whole grain diets, for example, have been 
shown to have beneficial effects on risk of CVD (Jacobs D 1998; Liu S 1999; Liu S 
2000; Liu S 2003; Steffen L 2003), cancer (Chatenoud L 1998; Jacobs D 1998; Williams 
M 2005), type II diabetes (Jensen M 2004; Halton T 2006), obesity (Slavin J 2005), 
appetite regulation or reduction (Koh-Banerjee P 2003), body composition (Nelson L 
1996), myocardial infarction prevention (Martinez-Ortiz J A 2006), insulin resistance 
(Esposito K 2004) and total mortality from all causes (Steffen L 2003). Unfortunately, 
the pathways behind this relationship are currently poorly understood, but one proposed 
mechanism of action is via their fermentation products, the short chain fatty acids, which 
have proven to be anti-inflammatory (Tedelind S 2007). The aim of this research, 
therefore, was to investigate the effects of high whole grain diets on a population 
displaying risk markers for CVD and to explore this proposed mechanism of action, at 
both the whole body and the cellular level.
6.1 Human intervention trials
It was hypothesised that the high whole grain or high fibre diets, via mechanisms 
including the actions of the SCFAs, would beneficially affect markers of CVD risk in a 
population group displaying increased risk profiles (determined by age, sex and BMI).
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The human studies used the novel delivery method of including the intervention 
compounds within a certain number of portions of bespoke bread roll-like products to 
promote compliance and thorough monitoring.
Approximately 9 to 17% of whole wheat by weight consists of fibre and it has 
been suggested that an anti-inflammatory protective effect of whole grains may be 
conferred by this fibre. Indigestible fibre proceeds through the human small intestine, 
resisting digestion and, on reaching the bowel, acts as a substrate for bacterial anaerobic 
fermentation to the short chain fatty acids (SCFAs), acetate, propionate and butyrate 
(Wong J 2006) in the molar ratio 60:20:20 (Cummings J 1979). The average production 
is 100 to 200mM/day (Cook S 1998) in the lumen of the colon, from where they are 
absorbed, by both passive and active transport, over the colonic epithelium (Cook S 
1998). The majority (70 to 90%) of the butyrate is metabolised as the primary fuel of the 
colonocytes but the acetate and propionate move into the circulation (Roediger W 1980).
Butyrate is known to have anti-inflammatory effects both in vivo and in vitro 
(Tedelind S 2007) but, unfortunately, the mechanisms of action are poorly understood. 
One proposed mechanism is via an inhibitory effect on NF-kB, a key transcription factor 
involved in the regulation of genes active in the innate immune system and cell cycle 
control (Luhrs H 2001). It may be hypothesised, therefore, that the similar SCFAs acetate 
and propionate can affect NF-kB in the same way, thus providing a possible mechanism 
of action for their inflammatory effects. Indeed, acetate and propionate have been shown 
to inhibit the TNF-a-mediated activation of the NF-kB pathway in cells of a human colon 
adenocarcinoma line (Tedelind S 2007). Further to this, SCFAs have been reported to
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promote the following in hepatocytes: increased glucose oxidation, decreased fatty acid 
release and increased insulin clearance, functions which would promote an enhancement 
in insulin sensitivity (Venter C 1990; Thorbum A 1993; Frayn K 1996). Interestingly, 
butyrate has also been reported to inhibit the hepatic synthesis of cholesterol (Jenkins D 
1989), which may contribute to the proposed cholesterol lowering effects of foods such 
as whole grains. As acetate and propionate are proposed to have anti-inflammatory 
effects similar to those of butyrate (Tedelind S 2007), it was further proposed that they 
may act on the vascular endothelium to reduce inflammation, thus, cardio-protective 
effects of whole grains may be due to the anti-inflammatory effects of the SCFAs 
produced by the fermentation of the fibres in the whole grains.
Further to this, different types of fibres are known to lead to differing amounts of 
SCFAs. Approximately 5 to 20% insoluble fibre is metabolised to SCFAs whereas this 
value is up to 90% for soluble fibre (Cook S 1998). As such, it was hypothesised that 
whole grains would have a protective effect on the endothelium via the actions of SCFAs 
and that this effect would be greater in response to equal quantities of soluble than 
insoluble fibres due to the increased production of SCFAs. These changes were not 
observed in the current research, with no changes being shown in total, HDL or LDL 
cholesterol, TAGs or NEFAs. As circulating levels of markers were not increased at 
baseline it is unlikely that such impacts would be reflected in the resultant levels. Clinical 
screening of participants to select a higher risk profile population group may allow for 
significant observations in these markers in future work.
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Whole grains are also rich in antioxidants including vitamins, trace minerals, non- 
nutrients (e.g. phenolic acids, lignans and phytoestrogens) and anti-nutrients such as 
phytic acid (Thompson L 1994). They are also a better source of selenium and the 
intracellular antioxidant vitamin E (especially tocotrienols) than are refined grains. 
Antioxidants delay the onset of or slow the rate of oxidation of oxidizable substrates 
and, therefore, the formation of harmful free radicals. Oxidative stress caused by these 
particles has been implicated in cancer (Klaunig J 1998) and CVD risk (Rush J 2005).
The antioxidant phenolic acids ( e.g. ferulic, canillic and caffeic acid) are found in the 
outer layers of whole grains and have also been associated with potential protection from 
CVD (Thompson L 1993), as have the phytoestrogens (e.g. isoflavones, lignans and 
coumestans) mediating effects on insulin and glucose responses. Impaired metabolism of 
these factors is, therefore, implicated in CVD risk.
Adipocytes are known to release inflammatory cytokines, including TNF-a and 
IL-6, which act on the liver to increase production of CRP and CRP has been shown to 
activate endothelial cells. Therefore, a reduction in either adipocyte number or activity 
may pose a potential method for reducing endothelial activation. Weight loss has been 
shown to reduce circulating levels of tPA-1, IL-6 and circulating lipid (Rave K 2007; 
Hermsdorff H 2010; Wycherley T 2010) and this reduction in adipocyte inflammatory 
cytokine release may be a possible causal pathway. No changes in inflammatory markers 
were observed after the intervention diets. None of the participants in the Pilot WISE or 
the FITMA trials, however, showed significant weight loss so such potential mechanisms 
would not have been invoked in the current research as was reflected in the stability of 
the markers pre- to post-intervention.
228
Whole grains and dietary fibre, predominantly soluble dietary fibre, has been 
shown to lower circulating cholesterol and lipid levels (Anderson J 1991) with part of the 
protective effects of whole grains being proposed as due to their fibre content (Truswell 
A 2002). This may be, in part, due to the slowing of nutrient absorption from the 
intestines associated with fibre, resulting in increased loss in the faeces, a function which 
is also greater for soluble fibres in agreement with their increased lipid lowering 
capacities (Jenkins D 1985). Although circulating levels of total and LDL cholesterol, 
TAGs and NEFAs were expected to fall in response to the increased whole grain intake, 
this was not observed in the Pilot WISE or FITMA trials. Although the population groups 
were at risk of CVD as determined by their sex, age and BMI, future work could involve 
clinical screening of participants to ensure a higher baseline risk profile as determined by, 
for example, hypercholesterolaemia.
Products manufactured predominantly from whole grains tend to have lower 
glycaemic indices than those produced from refined grains (Foster-Powell K 1995) and, 
as such, their ingestion attenuates the glucose response by inducing a slightly lower rise 
in blood glucose than those of higher GI products such as potatoes or refined grain pasta. 
This may be due to the associated increased fibre bulk, with the physical actions of fibre 
in the gastro-intestinal tract being a slowing of nutrient absorption, with these actions 
being greater for soluble than insoluble fibres (Jenkins D 1985). The insulin response is, 
thus, also attenuated which may result long term in an increase in insulin sensitivity, 
potentially via an increase in expression of insulin receptors, in insulin resistant 
individuals (Pereira M 2002). One recent study in healthy young males showed the non-
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viscous dietary fibre, resistant starch, not only significantly lowered energy intake 
following consumption when compared to a placebo but also significantly lowered post­
prandial insulin responses (Bodinham C 2010). As such, it was hypothesised that 
increased intake of dietary whole grains or the soluble or insoluble fibres would reduce 
fasting levels and attenuate post-prandial responses of both glucose and insulin. No 
significant changes, however, were observed in fasting levels or post-prandial responses 
of insulin or glucose in either the Pilot WISE or the FITMA trial which may be due in 
part to levels being only moderately raised at baseline. Alternatively, such benefits may 
manifest over a longer period of time than was allowed for in the current research, with 
the resultant beneficial changes taking longer to become established.
Limitations of research
Further investigations could benefit from including a more responsive population 
group with raised baseline levels of markers, which may include clinical screening before 
initiation. Longer intervention periods could also enable a longer term impact of the 
intervention products although this would have to be considered in conjunction with the 
possible detrimental impacts of an increased imposition on the participants and 
subsequent potential effects on compliance. The cross-over methodology used in the 
FITMA trial provides a more robust design and thus more powerful data although the 
number of participants used was still low.
Future work could include also measurement of other potential markers which 
may provide alternative or more comprehensive measurements. These could include 
VCAM-1, PECAM-1, E-selectin, P-selectin, the tPA-1/PAI-1 complex, fibrinogen,
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Hageman factor, MCP-1, TNF-a, IL-1, IL-6 or the activity of the vWF cofactor ristocetin 
(Meade T 1994; Bongers T 2006; Vuksan V 2007). When combined with physical 
activity, dietary interventions have been shown to reduce circulating CRP, IL-8, IL-6 and 
monocyte chemoattractant protein-1 and to increase insulin sensitivity (Bruun J 2005). 
Weight loss has also been shown to reduce circulating inflammatory markers (Wycherley 
T 2010) and as such, physical activity and weight loss may be considered for concurrent 
interventions in future work. Future work could use the other emerging technology of 
nutrigenomics to further investigate any potential nutrient-gene interactions associated 
with whole grains and their constituents or fermentation products.
Metabolomics
The current study is one of only a limited number of reports using metabolomics 
to investigate the impact of dietaiy modifications in human intervention studies and 
highlights the potential of metabolomic technology in nutritional research in defining 
alternative functions for nutrients and elucidating how diet influences metabolic 
pathways.
The Pilot WISE trial found no significant differences in any ion signals in, or 
between, the groups investigated, which may be due to the low numbers of participants 
involved or changes in ions not detected by the analysis platform The FITMA trial 
putitatively defined three ion species present in significantly different intensities between 
intervention groups as the lysophosphatidylcholines (LysoPCs 22:6) and (18:0) and 
(18:2), suggesting, in agreement with previous research, that diets high in wheat fibre or 
inulin can influence metabolite profiles. Although relevant interventions are very limited
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in the literature, these data concur with those of Lankinen et al, who also showed a diet 
including wheat bread significantly altered levels of several LysoPC species, including 
(18:0) and (18:2) (Lankinen M 2010). Future investigations could investigate for any 
correlations between these LysoPC species and the circulating markers found at the 
whole body level.
Other research provides evidence of the alkylresorcinols, the phenolic lipids 
present in the outer layers of wheat, rye and barley grains but few other foods (Ross A 
2003), as biomarkers of whole grain intake in blood (Landberg R 2008) and adipose 
tissue (Jansson E 2010). Their validated use as biomarkers would greatly benefit 
nutritional research as a method for monitoring dietary intake in the place of the less 
robust methods such as diet diaries. Unfortunately, although the whole intact and whole 
milled grain interventions of the Pilot WISE trial and the wheat fibre intervention of the 
FITMA trial would have been expected to show increased levels compared to baseline, 
no significant differences in the signals of any alkylresorcinols were observed so the 
current research can not add further support to this hypothesis. This may be due to 
analysis of the data on the HPLC/MS in positive mode, where alkylresorcinols are 
observed in negative mode. Alternatively, it may be due to the short half life of all 
homologues of alkysresorcinols in the blood (5 hours (van Dam R 2008)) which suggests 
that circulating concentrations reflect only recent intake. It is also possible that higher 
intakes of the dietary products may be necessary to induce a significant change in levels. 
Thus, future work could investigate the effects of shorter term, higher level intakes, 
analysed in negative mode on the HPLC/MS.
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A challenge common to all human metabolomic studies is the inter-individual 
variations in factors such as habitual dietary intake and metabolic rate, and in metabolite 
profiles themselves. Standardisation of both the experimental design at inception of the 
study (Scalbert A 2009) and the dietary intervention itself (Walsh M 2006) is, therefore, 
important if the impacts of such variations are to be controlled for. In the FITMA study, 
differences in baseline levels between dietary interventions were controlled for by 
implementing a cross-over design although this has no impact on inter-individual 
variation. As mentioned previously, increasing the numbers of participants in the research 
would have increased the power of the results. No restrictions were placed on the diet to 
impose standardisation, other than the inclusion of each intervention product, as this is 
not always practicable in human dietary intervention studies. The researchers felt this 
would be too much of an imposition on the life-styles of the free living participants and 
would lead to reduced levels of compliance.
6.2 Cell Work
The aim of this part of the current research was to investigate the effects of the 
fermentation products, the short chain fatty acids (SCFAs), on endothelial markers of 
cardiovascular risk expressed or secreted by endothelial cells in vitro. Levels of the 
markers investigated were hypothesised to increase on TNF-a/EFN- y activation to reflect 
the activated endothelium and to decrease towards their resting state on further treatment 
with the SCFAs. No significant impacts, however, were observed due to the SCFAs on 
the markers investigated.
233
The cell types investigated, HMEC-1 and HCAECs, were chosen to reflect the 
human vascular endothelium and initial work was carried out on the endothelial like cell 
line HMEC-1 (immortalised with simian virus, SV40). As such, any results from such 
work may not be directly reflective of those from primary cells or, indeed, the in vivo 
situation. Investigations were, therefore, also carried out in human abdominal artery 
endothelial cells, but were ceased in favour of the HCAECs, a more physiologically 
relevant cell type as atherosclerotic plaques are common in the coronary arteries. The 
cells used behaved as expected in culture and were within their recommended doubling 
numbers. No significant impacts were seen in any of the markers investigated and results 
from both cell types were similar, suggesting immortalisation had no impact on the 
processes involved in this investigation although other markers, not investigated in the 
current research, could be affected and reproducibility of results both within and between 
cell types. As such, future work would be more relevant if carried out solely in HCAECs.
Markers were chosen to cover a range of physiological functions of the 
endothelium and to reflect those measured in vivo in the Pilot WISE and FITMA trials in 
so far as was possible. However, the markers chosen could have been unrepresentative of 
the impacts under investigation. Other potential factors to measure could have included 
the inflammatory markers E-selectin, PAI-1, IL-6 and MCP-1. TNF-a could also have 
been measured if an alternative compound was used for cell activation. It is possible that 
markers could have broken down in the media before measurement, although this is 
unlikely as other investigations have noted significant changes in several of the markers 
used here (Moon M 2009; Sen U 2009; Zapolska-Downar D 2009; Peng Y 2010).
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The endothelial activators TNF-a and IFN-y were chosen as suggested by the 
literature (Hu C 2009; Moon M 2009) and preliminary investigations with EA,hy926 
cells supported the literature in showing significant activation of the cells upon TNF- 
a/IFN-y treatment. This research used lOOIU/ml TNF-a and 50IU/ml IFN-y to activate 
cells, thus modelling the stimulated endothelium associated with endothelial dysfunction 
and chronic inflammatory state associated with disorders such as CVD. Other research 
has shown significant increases in factors including ICAM-1 and VCAM-1 on 
stimulation with 100IU TNF-a (Zapolska-Downar D 2009) and various concentrations of 
TNF-a and IFN-y (Lombardi A 2009). The concentrations of TNF-a and IFN-y used were 
above those normally found in the circulation but were similar to those of previous 
research. As such, it is possible that the cells were over stimulated and that in future work 
this level should be reduced to more physiologically relevant levels. A further possible 
alternative research method could involve pre-treatment with SCFAs and subsequent 
activation with TNF-a and IFN-y.
Other potential activators could include fibrinogen, LPS or IL-L A single time 
point of 24 hours was chosen for these experiments as other in-house work into similar 
markers, as well as the EA.hy926 mentioned above, suggested 24 hours as optimum. This 
time point is also generally widely accepted in the literature. The incubation times with 
both the activators and the SCFAs may be further investigated to optimise the cells 
responses to them
The range of concentrations of the SCFAs were chosen as representative of those 
relevant physiologically. A broader range of concentrations of the investigational
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compounds may provide further evidence of an impact. Indeed, other in vitro work has 
investigated mM concentrations of SCFAs on endothelial cells, showing a significant 
reduction in the TNF-a induced increased expression of ICAM-1 (Zapolska-Downar D 
2009). The current research investigated pM concentrations as these are physiologically 
relevant (Cummings J 1987). As such, these higher concentrations could account for the 
differences in results.
Other potential breakdown products posed as influencing health include the 
lignins, such as enterolactone and enterodiol and other concurrent research has 
investigated these factors in endothelial cells although no significant alterations were 
seen in the markers investigated in this research (Kivela A 200). This work, however, 
was preliminary and involved cells treated with medium alone and treatment with the 
investigational factors, rather than pre-treatment to activate. Thus, cells represented the 
resting Tow risk’ endothelium so would not have been expected to show changes in 
response to enterolactone or enterodiol. Of course, the breakdown products of whole 
grain and fibre do not act on the endothelium in isolation and future work could 
investigate combinations of break down products.
Other similar work investigating the effects of the lignan gomisin A on HCAECs 
found significant enhancement of eNOS activity, thus, future work could involve iNOS 
and eNOS mRNA as markers, to further investigate cellular responses. Investigations 
could be extended to include combinations of such factors, at differing ratios to one 
another, thus providing a more physiologically relevant model and allowing for 
compounding effects of the treatments or interactions between them
Potentially, the treatment factors investigated could have been toxic to the cells 
chosen. Microscopic examination of the cells throughout the course of the treatments did 
not reveal a change in apparent confluency, with no significant changes in numbers of 
dead cells in the media. An investigation into the effects of the treatment interventions on 
cell viability using an MTT assay showed no significant impact, suggesting that the 
sodium acetate and propionate had no negative effects on viability of the cells.
Endothelial cells do not exist in isolation in vivo, there are a multitude of factors 
acting on them, thus limiting the relevance of such work to the whole body. The work 
must be modelled in vitro, however, as it is not viable to conduct this work in vivo, which 
is a limitation common to all cell culture models of whole body responses.
Future work could investigate these activators or alternative haemostatic secreted 
factors including Hageman factor, factor XIII and those of clotting/fibrinolytic pathways. 
Increased numbers of repeats would add significance to the results and investigation into 
other potential activators including CRP and/or fibrinogen may reveal interesting data.
6.3 Conclusions
This thesis addressed the impact of diets high in whole grains and their 
constituents on risk markers of endothelial function and, therefore, cardiovascular disease 
at both the whole body and the cellular level. The two whole body, randomised controlled 
human dietary intervention trials yielded interesting results suggesting that, although 
epidemiological evidence points to a clear correlation between diets high in whole grains,
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the links may not be as simple as cause and effect. Metabolomic analysis, indeed, 
reflected three significantly altered species of lysophosphatidylcholines, two of which 
were increased after the inulin treatments. LysoPCs are products of phospholipid 
metabolism often formed during oxidative modification. LysoPCs are pro-inflammatory 
with the capacity to activate cell lines and induce endothelial dysfunction, thus, a 
decrease in circulating levels, as was observed in one of the species, may be reflective of 
a cardio-protective effect, but the increase suggests that more work is required in this 
area. No significant changes, however, were observed in any of the inflammatory, 
haemostatic, lipid or insulin sensitivity end points investigated. The observations of the 
cell work were in agreement with the whole body work, in that no significant impacts of 
the investigational products were observed on the markers investigated.
Although this research shows no significant effects of whole grains or their 
constituents on whole body risk markers, observational evidence suggests a link between 
such diets and a reduced risk profile for CVD. Other research combining such diets with 
exercise or weight loss have shown cardio-protective results and, therefore, future work 
investigating the effects of the bespoke products with the inclusion of exercise or weight 
loss may warrant further work. Similarly, the short chain fatty acids showed no 
significant impacts on the markers investigated but there is a growing body of evidence to 
suggest their anti-inflammatory effects which requires further investigation.
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Appendix 1
A ) The nutritional com position o f  the w hole intact grain (3 6 .0 %  flour, 2 7 .0% %  w ater, 0 .6%  
salt and 0 .6%  yeast w ith  the addition o f 3 6 .0 %  w hole w heat grain kernels) and w hole m illed  
grain (3 4 .7 %  flo u r, 30 .0%  w ater, 0 .6%  salt and 0 .5%  yeast w ith  the addition o f 36 .0%  m illed  
w hole w heat grain kernels) products, and the control (6 3 .2 %  flour, 34 .8%  w ater, 1.0%  salt 
and 1 .0%  yeast) product, used in  the P ilo t W IS E  tria l.
Whole Intact Whole Milled Control
Energy (kcal) 293 283 258
Energy (kJ) 1243 1200 1093
Moisture 21.8 24.5 30.4
Carbohydrate (of 59.5 57.4 54.1
Sugar 1.5 1.5 1.1
Starch 58 56 53.1
Protein 10 9.7 7.6
Fat (of which) 1.7 1.6 1.2
Sats 0.22 0.22 0.16
Mono 0.18 0.17 0.08
Polys 0.76 0.74 0.55
Fibre 5.6 5.4 2.7
Sodium 0.288 0.278 0.505
Salt equivalent 0.733 0.708 1.284
B ) The nutritional com position o f  the w heat fib re  (5 1 .7 %  flou r, 40 .8%  w ater, 1.6%  yeast, 
0 .8%  salt and 0 .5%  ‘Z ip p y  P lus’ w ith  the addition o f  4 .6 %  W F  600 D V ), inu lin  (5 6 .4 %  flou r, 
36 .1%  w ater, 1.7%  yeast, 0 .9%  salt and 0 .6%  ‘Z ip p y  P lus’ w ith  the addition o f 4 .4%  O rafti 
H P X  In u lin ) and control (6 0 .4 %  flou r, 36 .2%  w ater, 1.8%  yeast, 1.0%  salt and 0 .6%  ‘Z ipp y  
Plus’)  products used in  the F IT M A  tria l.
Wheat Fibre Inulin Control
Energy (kcal) 220 239 256
Energy (kJ) 932 1015 1088
Moisture 37.4 32.2 33.1
Carbohydrate (of which) 43.4 47.4 50.7
Sugar 0.8 0.9 1
Starch 42.6 46,5 49.8
Protein 8.5 9.3 9.9
Fat (of which) 1.3 1.4 1.5
Sats 0.5 0.54 0.58
Mono 0.07 0.08 0.08
Polys 0.38 0.42 0.45
Fibre 7.7 7.6 2.5
Sodium 0.415 0.45 0.482
Salt equivalent 1.057 1.145 1.226
Appendix 2A
Product in form ation sheet 
WF 600 DV, VITACEL®
Wheat Fibre 
Characteristic
V IT A C E L ®  W heat F ib re  W F  600 D V  is a w h ite , fine-fib rous dietary fib re , produced by a 
special process, w hich stands out fo r its extrem ely lo w  dust building. The m ulti-functional 
and physiological properties o f  V IT A C E L ®  W heat F ib re  m ake it an excellent ingredient fo r a 
w ide range o f foodstuffs.
Standard Analysis
dietary fib re  content (acc. to  A O A C -m e th o d )* m in. 96.5 %  i. T r.
o f w hich: insoluble d ietary fib re  94 .0  %
soluble d ietary fib re  2 .5  %
loss on drying m ax. 8 %
ash max. 3 %
protein * 0 .4  %
trig lycerid e* 0 .5  %
fa t*  0 .2 %
phytic acid * negative  
g lu ten * negative
p H -value (1 0  %  suspension) 6 .5  + /-1 .5  
average fib re  length 80 pm  
average fib re  thickness 20  pm
Composition of Dietary Fibre* 
cellulose 74 % 
hem icellulose 26 % 
lig n in  m ax. 0.5 %
Microbiological Analysis
standard plate count m ax. 5 x  103 K B E /g  
yeasts and m oulds m ax. 2  x  102 K B E /g  
salm onella* in  25 g negative  
aflatoxines* not detectable 
( *  typ ical values)
Heavy Metals*
lead (P b) 0 .14  ppm
cadm ium  (C d ) m ax. 0.01 ppm  (detection lim it) 
m ercury (H g ) m ax. 0.01 ppm  (detection lim it) 
arsenic (A s ) 0 .01 ppm
Pesticides and Fungicides*
chlorinated hydrocarbons m ax. 0 .002  ppm  (detection lim it)
Physical Data
w ater binding capacity (A A C C -m eth o d ) m in. 4 .9  g H 2 0 /g  d. s. 
o il absorption m in. 3 .7  g o il/g  d. s. 
aw - va lu e* 0 .44
calo rific  va lu e /g * 0 .09  kcal resp. 0 .39  kJ
b u lk  density (in  accordance w ith  D IN  53 4 6 8 ) 200  g/1 -  240 g/1
fineness 90 %  <  70 pm
Sensory Properties
appearance w hite, fibrous 
fla v o r neutral 
odor neutral
Screen Analysis (in  accordance w ith  DIN 53 73 4 /a ir je t sieve)
>  200 pm  m ax. 5 %
>  100 pm m ax. 1 0 %
Declaration
V IT A C E L ®  W heat fib re  W F  600 D V  is a fo odstu ff w hich  can be added to  a ll other 
foodstuffs, provided that no other special instructions have to  be observed due to  the 
com position o f these foodstuffs.
W e recom m end a declaration as W heat F ibre o r W heat P lant Fibre.
Packaging and Storage
Paper bags a 20  kgs w ith  fo il in-betw een,
960 kg/pallet, m easurem ent (cm ): 130 x  90 x  215  
480 kg /pallet, m easurem ent (cm ): 130 x  90 x  120 
Store at room  tem perature in  dry condition. S h e lf life : 18 months.
( *  typ ical values)
J. R E T T E N M A IE R  &  S O H N E  G M B H  +  C O ,
Fibres designed by N atu re  
H olzm uhle  1 
D -7 3 4 9 4  Rosenberg
Appendix 2B
Product in form ation sheet 
Orafti®HPX
Description
Orafti®HPX is a H ig h  Perform ance In u lin . I t  is a food ingredient consisting o f chicory  
inu lin , from  w hich the sm aller m olecules w ere rem oved (patent pending). Com pared to  the 
standard O ra fti® H P , O ra fti® H P X  has a higher gel strength in  fa t substitution applications at 
higher tem peratures.
Chicory inulin is a m ixture o f o lig o - and polysaccharides w hich are composed o f fructose 
units
linked together by 13(2-l)linkages. A lm ost every m olecule is term inated by a glucose unit. The 
to ta l num ber o f fructose or glucose units (=  Degree o f Polym erisation or D P ) o f chicory inu lin  
ranges m ain ly betw een 2  and 60.
Compositional Specifications
A ll values expressed on dry m atter.
A naly tica l M ethods : see our Technical Brochures.
In u lin  >  99 .5  %
In u lin  D P  > 5  > 9 9 %
Glucose +  fructose +  sucrose <  0 .5  %
D ry  M a tte r (d .m .) 97  ±  1.5 %
Carbohydrate content >  99.5 %
Average D P  o f the inu lin  >  23 
Ash (sulphated) <  0 .2  %
C onductivity (15  B rix ) <  250  jiS  
H eavy M etals  Pb, A s each <  0.1 m g/kg  
Cd, H g  each <  O .O lm g/kg  
p H  (1 0 °B rix ) 5 .0  -  7 .0
Microbiological Specifications
A ll values expressed on dry m atter.
A nalytica l M ethods : see our Technical Brochures.
M esoph ilic  bacteria - to ta l count m ax. 1000/g  
Yeasts max. 20 /g  
M oulds max. 2 0 /g
Therm ophilic aerobic Spores m ax. 1000/g  
Anaerobic H 2S  producing therm ophilic spores m ax. 25 /g  
Enterobacteriaceae absent in  1 g 
B acillus cereus m ax. 100/g  
Staphilococcus aureus absent in  1 g 
Escherichia co li absent in  1 g  
C lostrid ium  perffingens absent in  1 g 
C lostrid ium  botulinum  absent in  1 g 
Salm onella absent in  100 g 
L isteria  Absent in  25 g  
H P X  A 4 -0 7 -0 1 -0 6 .d o c  2 /2  
T o  the best o f our know ledge, this in form ation  is re liab le  but should not be considered as a 
w arranty o f any kind. Specifications m ight be subject to  change w itho ut notice
L a b e lin g
A ll values are average values expressed per 100 g com m ercial product. 
Carbohydrates 0 (9 7 1 )) G luten absent 
Sugars 0 Lactose absent
D ie ta ry  F ib re2 ) 97 M ilk /m eat/fish /eg g  components absent
Protein absent Seed/soy components absent
Fat absent Insecticides, pesticides absent
V itam ins and M in era ls  N eg ligeab le  N uts, nut components absent
C aloric  value 3 ) 97  kcal/407 kJ C o lza absent
B roteinheiten 4 ) 0 O ther allergens absent
E nzym atic activ ity  absent
Fo late  absent
N .D . =  N o t D etectable N /A  =  N o t A pp licable
1) including d ietary fib re
2 ) measured by A O  A C  M ethod  997.08
3 ) based on a caloric value o f  1 kcal/g  fo r pure inu lin . T o  be adapted to local
regulations.
4 ) in  accordance w ith  G erm an regulations.
Other Information (see also our Technical Brochures)
Aspect F ine w h ite  pow der
B ehaviour Hygroscopic
Taste N eutral, not sweet, w ithout aftertaste
S o lub ility  in  w ater
W etta b ility  in  w ater
1 g/1 at 25 °C
fa irly  good
D ispersab ility  in  w ater Requires stirring.
Properties and A pplications See our Technical Brochures.
P artic le  Sizes See docum ent “ P artic le  Sizes” .
D ensity  Approx. 490  ±  40  g/1 
L ab e llin g  -  Ingredients L is t In u lin  
Safety Safe. N o t toxic. N o t dangerous.
Excessive consum ption m ay cause laxative effects.
Is , like  other fine powders, w hen m ixed w ith  a ir and ignited, 
capable o f causing an explosion.
Packaging Paper bags on pallets, see 'Packaging Sheet Powders’
O ptim al storage conditions C ool and dry, in  its orig inal a irtigh t packaging. 
M axim um  durab ility  See packaging (m in im um  18 months upon d e livery)
Transport conditions A ccording to  docum ent ‘Transport C onditions’
Irrad iation  N o t irradiated
G M O  N o t containing G M O s or G M O -d erived  components.
N o t produced using G M O -based technology.
K osher C ertified , O rthodox U n io n  Represented by :
H a la l C ertified , H a la l Feed and Food  
Inspection A uthority
P lant orig in  Suitable fo r vegetarians &  vegans
Produced by B E N E O -O ra fti, B elg ium
A )
B E N E F IT S  O F W H O L E  G R A IN S  O N  C A R D IO V A S C U L A R  D IS E A S E
The P ilo t W IS E  tria l
Appendix 3
IF  Y O U  A R E :
•  M a le , aged 3 0 - 6 0  years or a post-menopausal fem ale
•  W aist greater than 34inches (86cm ) fo r men or 3 1 ,5inches (80cm ) fo r wom en
•  W illin g  to alter your diet fo r 8 weeks
•  W illin g  to give a num ber o f blood samples
I f  you are interested in being involved in this study or w ould like  m ore inform ation, please 
contact:
Laura (bsp3lt a surrey.ac.uk) or Caroline (bsplcb dsurrey.ac.uk)
N u tritio n  Research G roup  
School o f B iom edical and L ife  Sciences, The U niversity  o f Surrey 
M o b ile: 07817 229246
B)
A  N utrition  Study: H o w  does Fibre affect our health? 
The F IT M A  tria l
IF  Y O U  A R E :
•  A n adult, aged 3 0 -6 0  years
•  W illin g  to alter your diet s lightly fo r 20 weeks
•  W illin g  to  give a num ber o f blood samples
Com pensation w ill be given fo r your tim e and inconvenience. I f  you are interested in being 
involved in  this study or w ould lik e  m ore inform ation, please contact:
Laura (bsp3Weisurrey, ac. uk) or Niky bsp2nm d\surrev. ac. uk)
N u tritio n  Research G roup  
School o f B iom edical and L ife  Sciences, The U n iversity  o f Surrey 
M o bile: 07817 22 92 46, O ffice: 01483 68 63 93 
This study has been given a favourable ethical opinion from  the U n iversity  o f Surrey Ethics
Com m ittee
A  P ilo t Study: The influence o f w hole grain in tervention on m arkers o f cardiovascular disease 
risk in  adult males. The P ilo t W IS E  tria l.
N a m e :___________________________________ D O B :___________________________________
A ddress:___________________________________________________________________________
Appendix 4
Health and Lifestyle Questionnaire
D aytim e T e l:______________________________ E vening Tel:
G P N a m e :________________________________
GP A ddress:____________________________________________
Please fin d  below  a short health and lifes ty le  questionnaire that w ill be used as part o f the 
screening process fo r th is study.
Please tic k  a ll that apply:
I  have no p rio r/ present history o f coronary heart disease, angina, heart attack or 
stroke
I  have no prior/present history o f Type 1 and Type 2  Diabetes.
I  have no prior/present history o f a gastrointestinal disorder, such as Crohns 
Disease, Coeliac Disease or Irrita b le  B o w el Syndrom e.
I  have no prior/present history o f liv e r o r kidney disease.
I  have no prior/present history o f, o r I  am not currently being treated fo r c lin ical 
depression or other psychological disorders.
I  have no prior/present history o f eating disorders.
I  have no prior/present history o f  drug o r alcohol abuse w ith in  the last 2  years.
I  am currently not taking any regular m edication prescribed by m y GP.
D o  you take any dietary supplements such as vitam ins, Y E S /N O
m inerals or fish oils?
I f  yes, please state w hich type and how  often.
A re  you currently on a w eight-reducing d iet or other dietary restrictions? Y E S /N O  
I f  yes, please g ive details.
D o  you regularly include w hole grain foods in  your norm al diet? Y E S /N O
I f  yes, how  m any tim es a w eek do you have w hole grain foods?
(Please see attached lis t)
D o  you exercise regularly?
I f  yes, w hat type o f  exercise and how  often?
Y E S / N O
H ave you been involved in  a c lin ical tria l in  the last 3 months? Y E S /N O
D o  you smoke? Y E S /N O
I f  yes, how  m any per day?
D o  you drink alcohol? Y E S /N O
I f  yes, how  m any units per week? (See below )
Thank you fo r your tim e in  com pleting this questionnaire. A ll in form ation w ill be kept strictly  
confidential at a ll tim es.
What is a unit of Alcohol?
The lis t below  shows the approxim ate num ber o f units o f alcohol in  com m on drinks:-
A lcoho l M easure U n it
O rdinary strength lager (4 % ) e.g. C arling, Fosters P int 2.3
Strong lager (5 .2 % ) e.g. S tella A rto is, Kronenburg P int 3
Strong lager e.g. Stella A rto is, Carlsberg E xport, Grolsch 440m l can 2 .2
B eer/ord inary strength A le  e.g. John S m ith ’ s, Guinness P in t 2.3
R ed /W h ite  W in e Std 175m l 2
R ed /W hite  W in e Lg . 250m l 3
Spirits Std 25m l 1
Spirits Lg . 35m l 1.4
A lcopop e.g. S m irn o ff Ice , Bacardi B reezer, R e e f 275m l 1.5
X
Dutch Eating Behaviour Questionnaire (DEBQ)
P articipant code__________________________ D a te /  /
Please answer the fo llo w in g  questions as carefu lly  and honestly as possible. 
Read each question and sim ply f i l l  in  the colum n w hich best applies to  you.
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1. I f  you have put on w eight, do you eat less than you  usually do?
2. D o  you have a desire to  eat w hen you are irritated?
3. I f  food tastes good to  you, do you eat m ore than you usually do?
4. D o  you try  and eat less at m eal tim es than you w ould lik e  to  eat?
5. D o  you have a desire to  eat w hen you have nothing to  do?
6. D o  you have a desire to  eat w hen you are fed up?
7. I f  food smells and looks good, do you eat m ore than you usually eat?
8. H o w  often do you refuse food or drink offered because you are w orried about 
your w eight?
9. D o  you have a desire to  eat w hen you are feeling  lonely?
10. I f  you see or sm ell som ething delicious, do you have a desire to  eat it?
11. D o  you w atch exactly w hat you eat?
12. D o  you have a desire to  eat w hen somebody disappoints you?
13. I f  you have som ething delicious to  eat, do you eat it  straight away?
14. D o  you deliberately eat foods that are slim m ing?
15 D o  you have a desire to  eat w hen you are cross?
16. D o  you have a desire to  eat w hen you are expecting som ething to  happen?
17. I f  you w a lk  past the baker do you have a desire to  buy something delicious?
18. W hen you have eaten too m uch, do you eat less than usual on the fo llo w in g  
days?
19. D o  you get a desire to  eat w hen you are anxious, w orried  or tense?
20. I f  you w a lk  past a snack bar o r cafe, do you have a desire to  buy som ething 
delicious?
21. D o  you deliberately eat less in  order not to  become heavier?
22. D o  you have a desire to  eat w hen things are going against you, o r things 
have gone wrong?
23. I f  you see others eating, do you have a desire to  eat?
24. H o w  often do you try  not to  eat betw een m eals because you are w atching  
your w eight?
25. D o  you have a desire to  eat w hen you are frightened?
26. Can you resist eating delicious food?
27. H o w  often in  the evening do you try  not to  eat because you are w atching  
your w eight?
28. D o  you have a desire to  eat w hen you are disappointed?
29. D o  you eat m ore than usual w hen you see other eating?
30. D o  you take your w eight in to  account w hen you eat?
31. D o  you have a desire to  eat w hen you are em otionally upset?
32. W hen preparing a m eal are you inclined to  eat something?
33. D o  you have a desire to  eat w hen you are bored or restless?
Participant Information Sheet -  The Pilot WISE trial 
The Pilot Whole grain Study in England
T itle : A  P ilo t Study: The influence o f w hole grain intervention on m arkers o f cardiovascular 
disease risk in  adult m ales and post-m enopausal w om en.
Investigators: P rof. G ary Frost (Professor o f N u tritio n , P rincip le Investigator), D r
K athryn H a rt (L ectu rer in  N u tritio n ), D r  John Lodge (L ectu rer in  N u tritio n a l 
B iochem istry), D r  D enise Robertson (Lecturer in  N u tritio n a l Physio logy), 
C aroline B odinham  (P h D  student), N ico la  M u irhead (P h D  student), Laura  
T ripkovic  (P hD  student). N u tritio n  Research G roup, School o f B iom edical 
and M o lecu lar Sciences, U n ivers ity  o f  Surrey.
Contact Names: Prof. G ary Frost on 01483 689384, N ic o la  M uirhead, Laura  
T rip ko vic  or C aroline Bodinham  on 07817 229246.
Introduction:
C ardiovascular disease is a serious condition, w hich is affecting  an increasing num ber o f  
people in  the U n ited  K ingdom . I t  is a com plex disease that has m any causes including  
dietary, social and genetic factors. Changes to  diet and lifesty le  factors are im plicated in  the 
treatm ent and prevention o f cardiovascular disease.
Evidence from  population studies have suggested that diets that are rich  in  w hole grains (> 3  
servings/day) m ay help to  reduce the risk  o f cardiovascular disease. This is thought to be due 
to  im provem ents in  blood pressure, glycaem ic control (sugar and insulin  levels in  the blood), 
blood lip ids (includ ing cholesterol), and reductions in  in flam m atory m arkers. W hole  grains 
com prise 3 m ain parts, bran, endosperm  and germ , a ll o f  w hich  need to  be present in  the same 
amounts as w hen the grain is intact in  a product fo r it to  be term ed ‘w hole g ra in ’ .
There are currently no intervention studies th at d irectly  com pare w hole grains versus refined  
grain in  re lation  to  cardiovascular disease. Therefore  th is study aim s to  determ ine w hether a 
diet high in  w hole grains w ill b en efic ia lly  a ffec t m arkers o f cardiovascular disease and 
appetite, com pared to  a d iet h igh in  an equivalent am ount o f m illed  w hole grain o r refined  
grain. This w ill ascertain w hether it is the am ount o r the structure o f the grain that is the 
determ ining factor fo r reducing cardiovascular disease risk.
Who is suitable to participate?
•  A d u lt m ales (aged betw een 3 0 - 6 0  years)
•  Post-m enopausal fem ales
•  O verw eight (B ody M ass Index 25 -  35kg/m 2 * )
•  W aist circum ference greater than 86cm  (34inches) fo r m en and 80cm  (31.5inches) fo r 
w om en
•  Fasting Insu lin  > 60p m o l/L
•  N o t taking any prescription m edicines or supplements w ith in  the past 6m onths
•  Those w ho drink no m ore than 21 units o f alcohol per w eek
•  Those w ho do not regularly  undertake vigorous exercise o r fitness train ing  (no m ore 
than 3 x  30m inute aerobic sessions per w eek)
*T o  calculate B M I: body w eight in  kg d ivided by height in  m2
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What is the screening process?
The screening involves you attending the C lin ic a l Investigation U n it, in  the School o f  
B iom edical and M o lecu lar Sciences (U n ivers ity  o f Surrey) one m orning, having fasted 
overnight, fo r a sm all blood sam ple (~ 2 0 m l), w h ich  w ill be used to  test fo r anaem ia and 
fasting insulin  levels. The presence o f anaem ia w ill exclude you from  the study, fo r health  
reasons. H eig h t, w eight, w aist circum ference and blood pressure w ill also be taken. Y o u  w ill 
also be requested to  com plete the questionnaires (H ealth  and L ifes ty le , D utch  E ating  
B ehaviour and Food Frequency) accom panying this P articipant In fo rm ation  Sheet. 
Ind ividuals w ith  certain m edical conditions such as heart disease, diabetes, gastro-intestinal 
problem s (fo r exam ple coeliac disease, irritab le  bow el syndrom e), liv e r disease, w ill be 
unable to  take part in  the study. Once the questionnaires are com pleted and you are happy 
that the study has been fu lly  explained to  you, please com plete the consent form .
I f  you m eet a ll o f  the screening criteria  you w ill then be invited  to  take part in  the study and 
requested to  com plete a 7 day food diary.
What will the study involve?
Y o u  w ill be requested to  attend the C lin ica l Investigation  U n it (C IU ) fo r an in itia l study day, 
the day p rio r to  the start o f the study. Y o u  w ill be requested to  attend the C IU  having  
consumed a standardised m eal the previous evening and having fasted fo r 12 hours overnight. 
I t  w ill also be advised that you re fra in  from  strenuous exercise the day before the study. O n  
arriva l you w ill be cannulated w hich  involves inserting a sm all tube in to  your vein , th is w ill 
be gently secured and used to obtain blood samples, safely and painlessly, throughout the 
duration o f the study day. A  fasting blood sample (3 0 m l) w ill be taken along w ith  a 
questionnaire regarding your appetite and body measurements (e.g . height and w eigh t). Y o u r 
blood pressure and blood flo w  (Pulse W ave  V e lo c ity  -  see below ) w ill also be measured. Y o u  
w ill then consume a standard breakfast test m eal. Fo llow ing  this, h a lf hourly blood samples 
(10m l) w ill be taken v ia  the cannula and appetite questionnaires w ill be com pleted fo r three  
hours a fte r the m eal. A fte r tw o  hours the Pulse W ave V e lo c ity  w ill be repeated. A fte r the  
three hours, you w ill be offered a pre-w eighed m eal to  consume freely. Y o u  w ill then be free  
to  leave and provided w ith  a food diary to  be com pleted fo r the rest o f  the day.
The fo llo w in g  day, the 8 w eek study w ill begin. Y o u  w ill be required to  consume a 
standardised m eal (s im ila r to  the previous standardised m eal) the evening p rio r to  the study 
day and then fast fo r 12 hours overnight. Y o u  w ill also be advised to  refra in  from  strenuous 
exercise the day before the study. O n arriva l in  the m orning, you w ill be cannulated and an 
in itia l 30m l blood sample, body m easurements and a questionnaire regarding your appetite 
w ill be taken. Y o u  w ill then be required to  consume a test m eal containing either w hole  
grains o r an equivalent am ount o f m illed  w hole grain o r refined grain. B lood samples (1 0 m l) 
w ill be obtained v ia  the cannula and questionnaires on appetite w ill be com pleted every  
30m inutes fo r 3hours, fo llo w in g  the m eal. A fte r tw o  hours the Pulse W ave V e lo c ity  w ill be 
repeated. A fte r 3 hours you w ill be provided w ith  a pre-w eighed m eal (pasta based w ith  
sauce) and asked to  consume as m uch as you w ish. Before leaving the unit you will be 
provided with a 24 hour ambulatory blood pressure monitor, which you will be shown 
how to fit and be asked to wear for 24 hours following the study day. A fte r w hich you are 
free to  leave and w ill be provided w ith  a food diary to  be com pleted fo r the rem ainder o f  that 
day.
As part o f the study you w ill be random ly assigned to  the diet rich in  W ho le  In tac t, W hole  
M ille d  grains or refined grain (C o n tro l) products, therefore, you need to  be prepared to  
consume these products fo r the entire 8 w eeks o f the study. T w o  servings o f the products w ill 
be supplied fo r you to  have fo r each day o f  the study. Y o u  w ill not need to  alter your diet in  
any other w ay, please continue to  eat your norm al diet. Y ou  w ill be contacted regularly by  
the D ie titia n  during the study to  answer any questions you m ay have, to  reiterate previous 
advice and obtain a 24 hour recall o f  your diet.
A t the beginning o f the eighth w eek, you w ill be posted a food diary w hich  you w ill need to  
com plete fo r 7 consecutive days. O n the last day o f  the study you w ill return to  C IU  fo r a 
repeat o f the firs t study day w ith  the addition o f the 24 hour am bulatory blood pressure 
m onitor.
Initial
Screening Study Test Test
Day Day Day 1 Day 2
8 week study time
Diet Diary* 7 Day Diary
D ay 0 D ay  1 D ay  49  D ay  56
*7  D a y  D ie t D ia ry  to  be com pleted at some point betw een screening and In itia l Study D ay
What will be measured in the collected samples?
A ll o f  the collected blood samples w ill be analysed fo r plasm a glucose, insulin , trig lyceride, 
to tal cholesterol, high-density lipopro tein  (H D L ) and low -density lipoprotein (L D L )  
cholesterol. The samples w ill also be analysed fo r in flam m atory/clo tting  m arkers, m arkers o f  
adipocyte m etabolism , gut hormones invo lved in  appetite and fo r m etabolic breakdow n  
products.
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What is Pulse Wave Velocity?
H ealthy arteries have elastic properties and evidence shows that as the elastic ity  o f  the arteries 
reduces the risk o f developing cardiovascular disease increases. Pulse W ave V e lo c ity  (P W V ) 
is a specialised technique designed to measure how  the blood flow s around the body and 
therefore can g ive an indication o f the elastic properties o f arteries. The m ethod involves a 
sm all m etal probe being gently placed upon your pulse points on your w ris t, neck and the top  
o f your leg (g ro in  area) fo r a short am ount o f tim e (approxim ately 30 seconds at each poin t). 
M easurem ents w ill be taken before and after the study to  see i f  the inclusion o f w hole grains 
affects the elastic properties o f  arteries.
How confidential are the results?
The results are strictly confidential to  the investigators and each volunteer. Y o u r G eneral 
Practitioner (G P ) w ill be inform ed o f your participation in  the study. I f  you do not w ish us to  
contact your G P, please indicate th is on the consent fo rm  you w ill be asked to  com plete.
A ll o f  the collected data w ill be kept anonym ous and a ll participants w ill be allocated a 
confidential num ber at the start o f the study, w hich  w ill be used to  id en tify  a ll collected blood  
samples and subsequent results.
Are you free to withdraw from the study once you have agreed to take part?
Participants are free to  w ithdraw  from  the study at any tim e w ithout having to  give a reason.
Do you need to modify your diet or activities in any way?
Y o u  w ill be asked to  exercise and carry out activities as norm al, apart fro m  the evening prio r 
to  the study day w here you w ill be asked not to  carry out excessive exercise. Y o u  w ill only  
be required to  consume the test foods provided as part o f your norm al d iet and no other 
dietary changes are required and therefore there should be no additional cost involved fo r you. 
The ambulatory blood pressure monitor will be work for 24 hours following the second 
and third study days. All normal daily activities can be carried out, with care, and the 
monitor should not restrict movement or function. W e do ask that you in form  us i f  you  
are ill or start/stop taking any prescription m edicines during the study period.
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As a result of being involved in this study are there any adverse consequences to my 
health?
B lood samples w ill be taken v ia  cannula by experienced investigators (trained in  
venepuncture and firs t a id ) w ith  on-call m edical cover throughout the study days. The  
volum e o f blood collected over the course o f the study is approxim ately 300m l fo r the w hole  
study, w hich is less than a typ ica l blood donation.
A s w ith  any increase in  fib re  intake there m aybe an increase in  stool frequency.
A lthough w hole grains are beneficial to  health no adverse effects should be seen in  the refined  
grain group. I f  beneficial effects are seen any o f  the groups, then those w ho had not 
consumed that product w ill be offered it, in  equal amounts to  those used, a fter com pletion o f  
the study.
Will you get payment for taking part in the study?
Y o u  w ill be reim bursed £50 fo r any inconvenience caused due to  the study. A n y  additional 
travel costs incurred d irectly  relating  to  the study w ill also be reim bursed, on provision o f a 
valid  receipt.
What if I have a complaint or concern?
A n y com plaint o r concerns about any aspect o f the w ay you have been dealt w ith  during the  
course o f the study w ill be addressed. Please contact Prof. G ary Frost (P rincipal Investigator) 
on 01483 689384 (em ail: g.frost@ surrey.ac.uk).
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A Pilot Study: The influence of whole grain intervention on markers of cardiovascular 
disease risk in adult males and post-menopausal women.
Appendix 7
The Pilot WISE trial
Consent Form
I  have read and understood the inform ation sheet provided relating to  the study on the benefits 
o f w hole grains on cardiovascular disease. I  have been given a fu ll explanation by the 
investigators o f the nature, purpose, location and lik e ly  duration o f the study, and o f w hat I  
w ill be expected to  do. I  have been advised about any discom fort and possible ill-e ffe c ts  on 
m y health and w ell-be ing  w hich m ay result. I  am  aw are o f the procedure involved regarding  
Pulse W ave V e lo c ity  tests. I  have been g iven  the opportunity to  ask questions on a ll aspects 
o f the study and have understood the advice and inform ation given as a result.
I  agree to  com ply w ith  any instruction given to  m e during the study and to  co-operate fu lly  
w ith  the investigators. I  shall in fo rm  them  im m ediately i f  I  suffer any deterioration o f any 
kind in  m y health o r w ell-being , or experience any unexpected or unusual symptoms.
I  understand that a ll personal data relating to  volunteers is held and processed in  the strictest 
confidence, and in  accordance w ith  the D a ta  Protection A ct (1 9 9 8 ). I  agree that I  w ill not seek 
to  restrict the use o f the results o f the study on the understanding that m y anonym ity is 
preserved.
I  understand that I  am free to  w ithdraw  from  the study at any tim e w itho u t needing to  ju s tify  
m y decision and w itho u t prejudice.
I  acknow ledge that in  consideration fo r com pleting the study I  shall receive the sum o f £50  
and w ill be reim bursed fo r any costs incurred d irectly  re lating  to the study (e.g . travel and 
extra food costs) on provision o f  a t ill receipt.
P T O
I  confirm  that I  have read and understood the above and freely  consent to  participating in  this  
study. I  have been g iven adequate tim e to  consider m y participation and agree to  com ply w ith  
the instructions and restrictions o f the study.
Signatures.
Participant Principal Investigator
N am e ........................................... N am e ...........................................
Signed................ ...........................................  Signed ...........................................
D ate  ........................................... D ate  ...........................................
Witness
N am e ...........................................
Signed................ ...........................................
D ate  ...........................................
I  have no objection to  m y general practitioner (G P ) being inform ed o f m y participation in  the 
study.
Signed................ ......................................................................
xviii
Date:
Appendix 8
D r ______
Address 1 
Address 2  
Surrey 
Post code
D ear D r _________
Re: M r. Sm ith  
D O B :
Address:
The ind iv idual stated above has agreed to  participate in  the study ‘A pilot study: The influence 
of whole grain intervention on markers of cardiovascular disease risk in adult males and 
post-menopausal women
M r  Sm ith has been selected after the appropriate screening mechanisms. H ealth , lifesty le  and 
behaviour questionnaires have been com pleted, o f  w hich M r. Sm ith indicated that he does not 
have any significant m edical h isto iy  nor is he currently taking  any prescription m edications 
that m ay unduly influence the outcom e o f the study.
D u rin g  the course o f the 8 w eek study, blood lip ids, fasting and post-prandial glucose and 
insulin  w ill be m onitored, as w e ll as other anthropom etric, m etabolic and vascular outcome 
measures.
I f  you have any queries regarding the above inform ation, or have additional in form ation  
regarding M r. Sm ith that you feel is relevant to  the study, please feel free to  contact The  
N u tritio n  Research G roup on the contact details above.
Yours Sincerely
Laura Tripkovic  BSc (hons) RD
(O n  b eh a lf o f The N u tritio n  Research G roup, U n ivers ity  o f Surrey)
4?  UNIVERSITY OF
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Appendix 9
Pilot WISE trial test breakfast nutritional information
Ingredient Weight (g) Protein (g) Carbohydrate (g) F a tM
Skimmed milk 200 6 .6 10 0.2
Marvel dried milk 31 11.2 16.4 0 .2
Olive oil 20 0 0 20
Glucose 20 0 20 0
Cadbury's drinking 
chocolate 18 1.1 13 1
Total 289 18.9 59 .4 21 .4
To ta l kcal in  250m l serving: 505.8kcal (75 .6kca l from  protein, 237.6kcal from  carbohydrates 
and 192.6kcal from  fa t).
XX
Participant Information Sheet -  FITMA 
The Fibre and Inulin Trial in Male Adults
Title: The acute effects o f the soluble and insoluble fibres found w ith in  w hole grain on the  
m arkers o f cardiovascular disease risk  in  adult m en and wom en.
Investigators: Prof. G ary Frost (Professor o f N u tritio n , P rincip le Investigator), D r
K athryn  H a rt (L ectu rer in  N u tritio n ), D r  John Lodge (L ectu rer in  N u tritio n a l 
B iochem istry), Laura T rip ko v ic  (P h D  student), N ic o la  M uirhead (P hD  
student). N u tritio n  Research G roup, School o f  B iom edical and M o lecu lar 
Sciences, U n ivers ity  o f  Surrey.
Contact Names: P rof. G ary Frost on 01483 689384 , Laura T rip ko v ic  or N ic o la  M u irhead on 
07817 229246  o r 01483 68 63 93.
Introduction:
Cardiovascular disease is a serious condition, w hich is affecting an increasing num ber o f  
people in  the U n ited  K ingdom . I t  is a com plex disease that has m any causes including dietary, 
social and genetic factors. Changes to  diet and lifes ty le  factors can have a m ajor im pact on the 
treatm ent and prevention o f cardiovascular disease.
W hen carbohydrates are eaten sugars are released as energy. I f  an ind iv idual is in  good health  
then the body produces a horm one called insulin  to  help the body use the sugar e ffective ly. 
H ow ever, i f  an ind ividual is overw eight, has a poor diet, and/or exercises infrequently, then  
the insulin can lose its effectiveness in  helping the body use the sugar released from  food. The  
extra sugar then stays in  the bloodstream  fo r longer w hich can lead to  m any health problem s.
C urrently, the latest evidence shows that the m ore soluble fib re  (p -g lucan -  com m only found  
in  barley and oats) and insoluble fib re  (cereal fib re  -  e.g. bran) that is eaten, the m ore 
effective  insulin  becomes in  assisting the body to  use energy from  food. H ow ever, questions 
rem ain as to  how  the fib re  w orks and how  m uch w e need to  eat each day to  help keep us 
healthy.
There are currently no dietary studies th at d irectly  com pare ind ividual fib re  components o f  
w hole grains to  see the effect they have on the risk  o f developing cardiovascular disease. 
Therefore, th is study aims to  determ ine w hether a d iet high in  soluble fib re  or insoluble fib re  
w ill benefic ia lly  affect m arkers o f cardiovascular disease, compared to  a control d iet (i.e . no 
active ingredient present.) This w ill ascertain w hich  part o f  the w hole grain (i.e . soluble or 
insoluble fib re ) is responsible fo r im proving particu lar markers o f C V D  risk.
Who is suitable to participate?
•  A d u lt males
•  Aged 30 to  60  years
•  N o t taking any prescription m edicines or supplements w ith in  the past 6months
•  Those w ho drink no m ore than 21 units o f alcohol per w eek
•  Those w ho do not regularly undertake vigorous exercise or fitness train ing  (no m ore 
than 3 x 3 0  m inute aerobic sessions per w eek)
Appendix 10
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What Is the screening process?
The screening involves you attending the C lin ic a l Investigation U n it, in  the School o f  
B iom edical and M o lecu lar Sciences (U n ivers ity  o f Surrey) one m orning, having fasted 
overnight, fo r a sm all blood sample (1 0 m l) w hich  w ill be tested fo r anaem ia and certain  
glucose m arkers. H e igh t, w eight, w aist circum ference and blood pressure w ill also be taken. 
Y o u  w ill also be requested to  com plete tw o  questionnaires (H ea lth  and L ifes ty le  and Food  
Frequency). Ind ividuals w ith  certain m edical conditions such as heart disease, diabetes, 
gastro-intestinal problem s (fo r exam ple coeliac disease, irritab le  bow el syndrom e), liv e r 
disease or anaem ia w ill be unable to  take part in  the study
I f  you m eet a ll o f  the screening criteria  you w ill be invited  to  take part in  the study. I f  you are 
happy th at the study has been fu lly  explained to  you (includ ing risks and benefits), you w ill 
then be requested to  com plete the consent fo rm  fo r your involvem ent in  the study.
What will the study involve?
O nce the screening phase has been com pleted successfully and before the study commences 
you w ill be required to  com plete a 2  w eek w ash-out diet at the beginning o f the study, during  
w hich tim e you w ill be asked to  refra in  from  eating any w hole grain products. D uring  this  
tim e you w ill also be asked to  com plete a 3 day diet diary. D ie ta ry  advice w ill be provided  
throughout th is tim e by the Registered D ie titia n  v ia  a prelim inary one-to-one in terview  and 
regular telephone conversations as required.
A t the end o f th is run-in  period you w ill be asked to  attend the C lin ica l Investigation U n it 
(C IU ) fo r an in itia l study m orning to  provide baseline data. H aving  consumed a standardised 
meal the previous evening (guidance w ill be g iven ) you w ill need to  be fasted fo r 12 hours 
overnight. W e w ill also ask that you re fra in  from  strenuous exercise, caffeine and alcohol the  
day before the study. The purpose o f  each study day is to  test your body’ s ab ility  to  handle 
sugars (g lucose). This w ill be determ ined using an O ra l G lucose Tolerance Test w hich  is 
described in  detail below .
O n arriva l at the C IU , measurements o f  blood pressure, Pulse W ave V e lo c ity , height, w eight, 
body fa t percentage and w aist circum ference w ill be taken. Y o u  w ill then be cannulated. This  
involves inserting a sm all tube into  your vein, w hich  w ill be gently secured and used to  obtain  
blood samples, safely and painlessly, throughout the duration o f  the study m orning. A  fasting  
blood sam ple o f  50m l w ill then be taken. Y o u  w ill then consume a high glucose d rink  
(contain ing 75g glucose). F o llo w in g  th is, blood samples o f  5m l w ill be taken every 15m inutes 
v ia  the cannula fo r tw o  hours after the drink. A fte r the tw o  hours, the pulse w ave velo city  w ill 
be repeated and a further tw o  5m l samples w ill be taken in  the fo llo w in g  hour at h a lf hourly  
intervals. O nce the blood samples have been com pleted you w ill be offered  refreshm ents and 
an opportunity to  rest. Each study day should last no longer than 4hours 30m inutes. A  blood  
pressure m onitor w ill then be fitted  w hich  is a sm all, lig h t-w e ig h t m achine and w ill be 
required to  be w orn fo r 24hrs a fter the study m orning.
Starting the fo llo w in g  day you w ill be required to  consume the food products provided as 
directed fo r 28 days. These are to  be included in  your norm al d iet in  the place o f  other grain  
products such as bread or cereals. A t regular intervals during this intervention period the 
Registered D ie titia n  w ill contact you by telephone (a t a pre-arranged tim e ) to  com plete a 
recall o f  your d ietary intake over the last 24  hours. Y o u  are free to  fo llo w  your norm al 
lifes ty le  and d iet during th is tim e. A t the end o f  the 28 days, you w ill attend the C IU  fo r a 
repeat o f the in itia l study m orning.
On day 3 and day 7 o f each intervention period you w ill be invited to  attend the C IU  fo r a 
fasting blood sample to  assess the short-term  effects o f the fibre you are consum ing. These 
appointm ents w ill be fitted  around your w ork  schedule and tim e-com m itm ents and should 
take no longer than 15 m inutes each.
There are three stages to  the study, each stage testing a d ifferent food product (soluble fibre, 
insoluble fib re  and a contro l.) Y o u  w ill be provided w ith  the required am ounts o f  food  
product fo r 28 days and you w ill not be to ld  w h ich  product you are testing at any particu lar 
tim e as th is m ay inadvertently in fluence the results. Each stage lasts 28 days, w ith  a study 
m orning at the end, after w hich there is a break o f  another 28 days. Th is is a w ash-out period  
during w hich  you w ill continue to  eat your norm al d iet but be required to  refrain  from  
consum ing any w hole grain products w ith  ongoing support from  a Registered D ie titian . This  
is an im portant part o f  the study, as w e need to  be sure that each food product does not 
in terfere w ith  the next.
A fte r the in itia l baseline study m orning, you w ill not be required to  attend the C IU  at the 
beginning o f the intervention period, on ly at the end. Therefore, the second and th ird  
in tervention legs w ill only invo lve tw o  very short visits and one longer one each. Please see 
study diagram  fo r fu rther inform ation.
The study should take no m ore than a to ta l o f  20  w eeks to  com plete and no m ore than 530m l 
(equal to  19fl o z) blood, including screening, w ill be taken over the 15weeks. This is ju s t 
under a p in t (5 7 0 m l), w hich is the average am ount taken at one tim e in  a blood donation. The  
average adult body contains 10 to  12 pints o f blood. Please see below  fo r the outline o f  the 
study design.
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What will be measured in the collected samples?
A ll o f the collected blood samples w ill be analysed fo r plasm a glucose, insulin, 
triglyceride, to tal cholesterol, high-density lipoprotein (H D L ) and iow -density lipoprotein  
(L D L ) cholesterol. The samples w ill also be analysed fo r inflam m atory/clotting markers, 
markers o f fa t cell m etabolism  and fo r m etabolic breakdown products.
Lym phocytes and monocytes w ill be isolated from  blood in  order to test lym phocyte 
proliferation and monocyte production o f EL-2 and T N F -a . These are both reliable  
markers o f inflam m ation.
What is Pulse Wave Velocity?
H ealthy arteries have elastic properties and evidence shows that as the elasticity o f the 
arteries reduces the risk o f developing cardiovascular disease increases. Pulse W ave  
V elo city  (P W V ) is a specialised technique designed to measure the speed o f blood flo w  
around the body and therefore can give an indication o f the elastic properties o f arteries. 
The method involves a sm all m etal probe being gently placed upon your pulse points on 
your w rist, neck and the top o f your leg (gro in area) fo r a short amount o f tim e  
(approxim ately 30 seconds at each po int). Measurements w ill be taken at the beginning 
o f the study to see i f  the inclusion o f the components o f whole grains affects the elastic 
properties o f arteries.
How confidential are the results?
The results are strictly confidential to  the investigators and each volunteer. Y o u r General 
Practitioner (G P ) w ill be inform ed o f your participation in the study. I f  you do not wish 
us to contact your G P, please indicate this on the consent form  you w ill be asked to  
complete.
A ll o f the collected data w ill be kept anonymous and all participants w ill be allocated a 
confidential num ber at the start o f the study, w hich w ill be used to identify a ll collected  
blood samples and subsequent results.
Are you free to withdraw from the study once you have agreed to take part?
Participants are free to w ithdraw  from  the study at any tim e w ithout having to give a 
reason.
Do you need to modify your diet or activities in any way?
Y o u  w ill be asked to exercise and carry out activities as norm al, apart from  the evening 
prior to the study day where you w ill be asked not to carry out excessive exercise and to  
eat a standardised meal (w hich w ill be arranged w ith  you closer to the tim e). Y o u  w ill 
only be required to consume the test foods provided as part o f your norm al diet and no 
other dietary changes are required and therefore there should be no additional cost 
involved fo r you. W e do ask that you inform  us i f  you are ill or start/stop taking any 
prescription medicines during the study period or wish to donate blood.
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As a result of being involved in this study are there any adverse consequences to my 
health?
B lood samples w ill be taken v ia  cannula by the experienced investigators D r Shelagh 
Ham pton, Laura Tripkovic and N ico la  M uirhead (trained in venepuncture by Yvonne  
Vogt, a registered nurse, and first aid). Cannulas w ill be positioned by D r Shelagh 
Ham pton w ith  on-call m edical cover throughout the study days provided by D r. John 
W right. The volum e o f blood collected over the course o f the study w ill be no more than 
530m l fo r the w hole study (including screening).
A ny increase in dietary fibre m ay cause an increase in  stool frequency.
F ibre and its constituents are beneficial to health and therefore no adverse effects are 
anticipated. B y the end o f the study a ll participants w ould have received identical 
amounts o f  a ll the food products tested. H ow ever, i f  one food product appears to provide 
significant health benefits, a ll participants w ill be advised at the end o f the study.
Will you get payment for taking part in the study?
Y o u  w ill be reim bursed £120 fo r any inconvenience caused due to  the study. A ny  
additional travel costs incurred directly re lating to the study w ill also be reimbursed, on 
provision o f a valid  receipt.
Ethical study approval:
This study has been given a favourable ethical approval by the U niversity o f Surrey 
Ethics Com m ittee.
What if I have a complaint or concern?
Any com plaint or concerns about any aspect o f the w ay you have been dealt w ith  during 
the course o f the study w ill be addressed. Please contact Prof. Gary Frost (Principal 
Investigator) on 01483 689384 (em ail: g.frost@ surrey.ac.uk).
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C onsent F o rm SURREYU N IV E R S IT Y  O F
I  the undersigned voluntarily agree to take part in  the study: The acute effects o f the
soluble and insoluble fibres found w ith in  whole grain on the markers o f cardiovascular
disease risk in adult men and women.
•  I  have read and understood the Inform ation Sheet provided. I  have been given a fu ll 
explanation by the investigators o f the nature, purpose, location and lik e ly  duration o f  
the study, and o f w hat I  w ill be expected to do. I  have been advised about any 
discom fort and possible ill-e ffects  on m y health and w ell-being w hich m ay result. I  
am aware o f the procedure involved regarding Pulse W ave V elo city  tests. I  have been 
given the opportunity to  ask questions on a ll aspects o f the study and have understood 
the advice and inform ation given as a result.
•  I  agree to comply w ith  any instruction given to  me during the study and to co-operate 
fu lly  w ith  the investigators. I  shall in form  them  im m ediately i f  I  suffer any 
deterioration o f any kind in  m y health o r w ell-being, or experience any unexpected or 
unusual symptoms.
•  I  agree to the investigators contacting m y general practitioner about my participation  
in  the study, and I  authorise m y G P to disclose details o f m y relevant m edical or drug 
history, in confidence.
•  I  understand that a ll personal data relating to volunteers is held and processed in the 
strictest confidence, and in  accordance w ith  the D ata  Protection A ct (1998). I  agree 
that I  w ill not seek to restrict the use o f the results o f the study on the understanding 
that m y anonym ity is preserved.
•  I  understand that I  am free to w ithdraw  from  the study at any tim e w ithout needing to 
ju s tify  m y decision and w ithout prejudice.
•  I  acknowledge that in  consideration fo r com pleting the study I  shall receive the sum  
o f £120. I  recognise that the sum w ould be less, and at the discretion o f the Principal 
Investigator, i f  I  w ithdraw  before com pletion o f the study.
•  I  understand that in the event o f m y suffering a significant and enduring in jury  
(including illness or disease) as a direct result o f my participation in  the study, 
compensation w ill be paid to me by the U niversity subject to certain provisos and 
lim itations. The amount o f compensation w ill be appropriate to the nature, severity 
and persistence o f the in jury and w ill, in  general terms, be consistent w ith  the amount 
o f damages com m only awarded for sim ilar in jury by an English court in  cases where 
the lia b ility  has been adm itted
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I  confirm  that I  have read and understood the above and freely consent to 
participating in this study. I  have been given adequate tim e to consider my 
participation and agree to com ply w ith  the instructions and restrictions o f the study.
Nam e o f volunteer (B L O C K  C A P IT A L S ) ...........................................
Signed...................................................................................................... .............................................
D ate .............................................
Nam e o f researcher/person taking consent (B L O C K  C A P IT A L S )..................................
Signed...................................................................................................... ..............................................
D ate ...............................................
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Appendix 12
Date:
D r ______
Address 1 
Address 2 
Surrey 
Post code
D ear D r _________
Re: M r/M s . Smith 
D O B :
Address:
The individual stated above has agreed to participate in the study ‘The acute effects of the 
soluble and insoluble fibres found within whole grain on the markers of cardiovascular 
disease risk in adult men and women \
M r/M s  Sm ith has been selected after the appropriate screening mechanisms. Health, 
lifestyle and dietary behaviour questionnaires have been completed, o f w hich M r. Sm ith  
indicated that he does not have any significant m edical history nor is he currently taking  
any prescription medications that may unduly influence the outcome o f the study.
D uring the course o f the 20 week study, blood lipids, fasting and post-prandial glucose 
and insulin w ill be m onitored, as w ell as other anthropometric, m etabolic and vascular 
outcome measures.
The protocol fo r this study has been given a favourable opinion from  the U niversity o f 
Surrey Ethics Com m ittee. I f  you have any queries regarding the above inform ation, or 
have additional inform ation regarding M r. Sm ith that you feel is relevant to the study, 
please feel free to contact The N utrition  Research Group on the contact details above.
Yours Sincerely
Laura Tripkovic BSc (hons) RD
(O n behalf o f Carbohydrate M etabolism  Research Group, University o f Surrey)
